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Background: Catheter-associated urinary tract infection (CAUTI) is a major preventable 
cause of harm for patients in hospital and incurs significant costs for health-care providers 
such as the UK NHS. Many preventative strategies and measures have been introduced to 
minimise CAUTI risk, including the use of antimicrobial catheters. However, there is 
considerable uncertainty regarding their usefulness in terms of reducing symptomatic 
CAUTI, and whether or not they are cost-effective.
Objectives: Do antimicrobial catheters reduce the rate of symptomatic urinary tract 
infection (UTI) during short-term hospital use and is their use cost-effective for the 
UK NHS?
Design: A pragmatic multicentre UK randomised controlled trial comparing three catheters 
as they would be used in the UK NHS: antimicrobial-impregnated (nitrofurazone) and 
antiseptic-coated (silver alloy) catheters with the standard polytetrafluoroethylene (PTFE)-
coated catheters. Economic evaluation used a decision model populated with data from 
the trial. Sensitivity analysis was used to explore uncertainty.
Setting: Relevant clinical departments in 24 NHS hospitals throughout the UK.
Participants: Adults requiring temporary urethral catheterisation for a period of between 1 
and 14 days as part of their care, predominantly as a result of elective surgery.
Interventions: Eligible participants were randomised 1 : 1 : 1 to one of three types of 
urethral catheter in order to make the following pragmatic comparisons: nitrofurazone-
impregnated silicone catheter compared with standard PTFE-coated latex catheter; and 
silver alloy-coated hydrogel latex catheter compared with standard PTFE-coated 
latex catheter.viii Abstract
Main outcome measures: The primary outcome for clinical effectiveness was the 
incidence of UTI at any time up to 6 weeks post randomisation. This was defined as any 
symptom reported during catheterisation, up to 3 days or 1 or 2 weeks post catheter 
removal or 6 weeks post randomisation combined with a prescription of antibiotics, at any 
of these times, for presumed symptomatic UTI. The primary economic outcome was 
incremental cost per quality-adjusted life-year (QALY). Health-care costs were estimated 
from NHS sources with QALYs calculated from participant completion of the European 
Quality of Life-5 Dimensions (EQ-5D).
Results: Outcome analyses encompassed 6394 (90%) of 7102 participants randomised. 
The rate of symptomatic UTI within 6 weeks of randomisation was 10.6% in the 
nitrofurazone group (n = 2153; –2.1% absolute risk difference), 12.5% in the silver alloy 
group (n = 2097; –0.1% absolute risk difference) and 12.6% in the PTFE group (n = 2144). 
The effect size {odds ratio (OR) [97.5% confidence interval (CI)]} was 0.82 (97.5% CI 0.66 
to 1.01) for nitrofurazone (p = 0.037) and 0.99 (97.5% CI 0.81 to 1.22) for silver alloy 
(p = 0.92) catheters. The nitrofurazone catheters were more likely to cause discomfort 
during use and on removal. The primary economic analysis suggested that nitrofurazone-
impregnated catheters would be, on average, the least costly (> £7 less than PTFE) and 
most effective option at current NHS prices. There was a 73% chance that nitrofurazone 
would be cost saving and an 84% chance that the incremental cost per QALY would be 
< £30,000. At the trial price (£6.46), silver alloy catheters were very unlikely to be cost-
effective. These results were unchanged in sensitivity analyses, although when the length 
of stay cost was excluded the incremental cost per QALY for nitrofurazone against PTFE 
was £28,602.
Conclusions: The trial estimate of clinical effectiveness for nitrofurazone-impregnated 
catheters was less than the pre-specified minimum absolute risk difference that we 
considered important (−3.3%), and the surrounding CI included zero, indicating that any 
reduction in catheter-associated UTI was uncertain. Economic analysis, although 
associated with uncertainty, suggested that nitrofurazone-impregnated catheters may be 
cost-effective for the NHS. The trial ruled out the possibility that silver alloy-coated 
catheters might reach the pre-set degree of clinical effectiveness and that their use was 
unlikely to be cost-effective. These findings should be considered by patients, clinicians 
and health-care policy-makers to determine whether or not a change in practice is 
worthwhile. Future research should be aimed at determining the minimum clinically 
important difference in terms of CAUTI prevention in comparative trials, and to identify 
reliable methods which can detect the impact of the intervention on quality of life and other 
drivers of cost, when the intervention is a subsidiary part of overall treatment plans.
Trial registration: Current Controlled Trials ISRCTN75198618.
Funding: This project was funded by the NIHR Health Technology Assessment programme 
and will be published in full in Health Technology Assessment; Vol. 16, No. 47. See the HTA 
programme website for further project information.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Pickard et al. under the terms of a commissioning contract issued by the Secretary of State for Health. 
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Executive summary
Background
Minimisation of health-care-associated infections, particularly within hospitals, is a key aspect 
of patient safety initiatives in many countries with well-developed health systems such as the 
UK. Catheter-associated urinary tract infection (CAUTI) is the second most common cause of 
hospital-acquired infection, and its prevention is therefore an important part of these initiatives. 
Urethral catheterisation remains a highly prevalent intervention in the care of patients admitted 
to hospital, particularly for elective surgical procedures, with approximately 15–25% of the 14.5 
million patients admitted to NHS England hospitals being catheterised at some point during their 
stay. The risk of CAUTI is mainly related to the duration of catheterisation, occurring at a rate 
of 5% per day. This means that, assuming an average duration of catheterisation of 3 days, about 
435,000 patients are likely to be affected in the English NHS each year, although most episodes 
are symptomless. One putative method of reducing CAUTI risk is to use catheters containing 
antimicrobial agents that inhibit bacterial contamination of the urethra and bladder. Two such 
devices are available to the NHS: a silver alloy-coated latex (natural rubber) catheter utilising 
the antiseptic properties of silver ions and a nitrofurazone-impregnated silicone plastic catheter 
utilising the antimicrobial action of nitrofurazone. This research was commissioned by the UK 
government National Institute for Health Research Health Technology Assessment programme to 
investigate whether either of these two devices would be clinically effective and cost-effective in 
reducing CAUTI risk in the UK NHS.
Objectives
The research set out to determine whether or not the use of antimicrobial catheters in people who 
undergo short-term urethral catheterisation as part of their routine care in UK NHS hospitals 
would result in a lower rate of symptomatic UTI compared with standard urethral catheters, and 
whether or not they would be cost-effective for use in the UK NHS.
Our initial hypothesis was that use of either antimicrobial catheter would result in a 30% relative 
reduction in the rate of antibiotic-treated symptomatic CAUTI occurring at up to 6 weeks 
following catheter insertion compared with the control of standard catheter use.
Two pragmatic comparisons of equal importance were made:
  ■ antimicrobial-impregnated silicone catheter (nitrofurazone) compared with standard 
polytetrafluoroethylene (PTFE)-coated latex catheter
  ■ antiseptic-coated hydrogel latex catheter (silver alloy) compared with standard PTFE-coated 
latex catheter.
Methods
Adults undergoing urethral catheterisation with an anticipated duration of between 1 and 
14 days were identified in 24 UK NHS hospitals. Exclusion criteria were an expected duration of 
catheterisation of > 14 days or < 1 day, having undergone a urethral procedure in the last 7 days, 
the need for catheterisation by a non-urethral route, allergy to catheter materials, the presence xiv Executive summary
of a microbiologically confirmed symptomatic urinary tract infection (UTI) and inability to 
give informed consent. Those fulfilling the relevant criteria were invited to participate by local 
clinical research staff and consented for randomisation. Eligible and consented participants were 
randomised to one of the three trial interventions: silver alloy-coated catheter, nitrofurazone-
impregnated catheter or standard PTFE catheter.
Baseline data were collected from each participant by completion of a case report form, patient-
completed questionnaire and microbiological examination of a urine sample. The primary 
clinical effectiveness outcome was the occurrence of at least one UTI, defined as the presence 
of participant-reported symptoms and clinician prescription of antibiotic drug for a UTI at any 
point up to 6 weeks after randomisation. The primary economic outcome was the incremental 
cost per UTI avoided. Outcome data were collected by local trial staff during hospital stay; 
participant questionnaire and case report form at 3 days following catheter removal; participant 
diary at 1 and 2 weeks after catheter removal; and participant questionnaire at 6 weeks after 
randomisation. Collection of primary outcome data was completed when necessary by telephone 
contact with the participants or communication with their general practitioner. Microbiological 
examination of a urine sample was performed at baseline and at 3 days after catheter removal. 
Data collected included UTI symptom questionnaire, European Quality of Life-5 Dimensions 
(EQ-5D), antibiotic use, use of health service resources over the 6-week trial period, and 
microbiological report of urine specimens at baseline and 3 days after catheter removal. The 
primary economic analysis was based on a decision-analytical model, which compared the three 
catheters in terms of both NHS costs and quality-adjusted life-years (QALYs), based on responses 
to the EQ-5D. A within-trial cost-effectiveness analysis and cost–utility analysis were also 
performed. For both economic evaluations, stochastic and deterministic sensitivity analyses were 
performed to address uncertainty caused by heterogeneity in the patient population.
Results
We randomised a total of 7102 participants recruited from 24 sites over a 40-month period, 
from July 2007 to September 2010. The main reason for catheterisation was perioperative 
monitoring. About 74% of participants in all of the three groups received antibiotics at the time 
of catheterisation, principally to prevent infection relating to the surgical procedure. The median 
(interquartile range) duration of catheterisation was 2 (1–3) days in all three groups. Data from 
a total of 6394 (90%) participants were included in the final analysis: 2153 participants were 
randomised to nitrofurazone, 2097 to silver alloy and 2144 to control. Over 90% of participants 
received the allocated catheter, with most errors resulting from insertion of a standard-type 
catheter rather than a silver alloy or nitrofurazone one. Baseline characteristics were well 
matched across the three groups. For the intention-to-treat analysis, we were successful in 
confirming participant-reported antibiotic prescription for UTI through participants’ clinical 
records and in obtaining primary outcome data on all except one non-responder (in whom we 
assumed no UTI occurred).
In terms of the primary outcome, 228/2153 (10.6%) participants in the nitrofurazone group, 
263/2097 (12.5%) of those randomised to silver alloy and 271/2144 (12.6%) in the control group 
experienced at least one symptomatic UTI in the 6 weeks after randomisation. Absolute risk 
differences [mean (97.5% confidence interval (CI)] were –2.1% (97.5% CI –4.2 to 0.1) in the 
nitrofurazone group and –0.1% (97.5% CI –2.4 to 2.2) in the silver alloy group. These proportions 
resulted in an odds ratio (OR) (97.5% CI) for benefit of nitrofurazone catheters in reducing 
CAUTI of 0.82 (97.5% CI 0.66 to 1.01; p = 0.037) and for silver alloy of 0.99 (97.5% CI 0.81 to 
1.22; p = 0.92). The direction and size of effect were not changed by adjustment for age, sex, © Queen’s Printer and Controller of HMSO 2012. This work was produced by Pickard et al. under the terms of a commissioning contract issued by the Secretary of State for Health. 
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comorbidity or antibiotic use prior to catheterisation. There was no evidence of interaction with 
the variables of participant age, duration of catheterisation or centre.
For secondary outcomes of benefit, the rate of symptomatic antibiotic-treated CAUTI associated 
with a positive urine culture at 6 weeks was 69/2153 (3.2%) in the nitrofurazone group, 
105/2097 (5.0%) in the silver alloy group and 99/2144 (4.6%) in the control group. Absolute risk 
differences (97.5% CI) were –1.4% (97.5% CI –2.7% to –0.1%) in the nitrofurazone group and 
0.4% (97.5% CI –1.2% to 1.9%) in the silver alloy group. The OR (97.5% CI) for risk was 0.68 
(97.5% CI 0.48 to 0.99; p = 0.017) in the nitrofurazone group and 1.02 (97.5% CI 0.78 to 1.52; 
p = 0.55) in the silver alloy group.
In terms of harms [OR (97.5% CI)], nitrofurazone-impregnated catheters were associated with 
greater participant-reported discomfort during catheter use [1.34 (97.5% CI 1.13 to 1.60)] and 
catheter removal [1.77 (97.5% CI 1.51 to 22.07)].
The planned within-trial cost-effectiveness analysis was limited by implausible estimates from 
trial data for the likely differences in length of stay, the main driver of costs and cost-effectiveness. 
Therefore, the pre-planned decision model-based analysis was taken as the primary economic 
analysis. The price of the catheters used in the trial was £0.86, £5.29 and £6.46 for standard PTFE, 
nitrofurazone and silver alloy types, respectively. In the base-case analysis, use of nitrofurazone 
catheters was least costly to the NHS, with PTFE and silver alloy catheters costing, on average 
£7.00 and £12.00 more, respectively. On average, the nitrofurazone catheter was also slightly 
more effective so an incremental cost per QALY [incremental cost-effectiveness ratio (ICER)] was 
not calculated. Nitrofurazone catheters had an approximately 70% chance of being cost saving 
and an 84% chance of having an ICER of < £30,000, the willingness-to-pay threshold typically 
suggested by the UK National Institute for Health and Clinical Excellence. Silver alloy catheters 
had an approximately 0% chance of being cost-effective at all threshold values between £0 and 
£50,000. As the trial population was heterogeneous in terms of underlying health condition, 
alternative analyses were performed considering more homogeneous subgroups. The results of 
these analyses were similar to those of the base case. The main driver of the difference in cost and 
cost-effectiveness was potential differences in length of stay between the trial arms. A further 
analysis excluding length of stay data resulted in PTFE being the least costly option, with the 
ICER against nitrofurazone being £28,600. It should be noted that this result was driven by small 
differences in QALYs, which may not be important clinically or appreciable by patients.
Conclusions
Silver alloy-coated catheters are unlikely to be effective at reducing CAUTI risk in terms of the 
pre-set minimum clinically important difference, with the best estimate of clinical effectiveness 
being close to no difference and the surrounding CI not including the hypothesised relative 
risk reduction in comparison with standard catheters. Silver alloy-coated catheters were also 
not considered to be cost-effective at the unit price considered in the analysis for short-term 
use in the UK NHS. The best estimate for reduction in CAUTI achieved by nitrofurazone-
impregnated catheters was less than the prespecified minimum clinically important difference, 
and the surrounding CI included zero. The trial results therefore give no evidence that use 
of this catheter could achieve this level of clinical effectiveness. Participants reported greater 
discomfort of use with nitrofurazone catheters. Model-based health economic analysis suggested 
that nitrofurazone-impregnated catheters might possibly be cost-effective for use in the UK 
NHS, although there was a high degree of uncertainty surrounding this finding related to the 
plausibility of parameter estimates regarding length of stay and change in health-related quality 
of life.xvi Executive summary
In summary, in this trial the lack of evidence found to support the use of silver alloy catheters 
for short-term catheterisation at their current unit price will influence decisions regarding 
their continued use for this indication. Nitrofurazone catheters were also ineffective against 
symptomatic CAUTI but did show some antimicrobial activity for secondary bacteriological 
outcomes. Any benefit may be offset by increased discomfort from their use and concerns 
regarding indiscriminate antimicrobial use. Clinicians and managers will have to weigh up these 
factors to plan any change in practice in terms of use of nitrofurazone-impregnated catheters.
Implications for research
Research is required to determine the minimum clinically important difference in terms of 
CAUTI prevention so that the benefit of antimicrobial catheter devices can be judged against 
alternative interventions.
Methods are required to detect within-trial quality-of-life benefits and associated changes in 
length of stay when the intervention under test is a subsidiary part of overall treatment plans.
The short duration of catheterisation for many patients means that further research is required to 
identify alternative methods of bladder drainage.
Alternative antimicrobial additives, catheter designs and mechanisms of release of agents from 
catheter materials should be explored to maximise benefit of such interventions.
Trial registration
This trial is registered as ISRCTN75198618.
Funding
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Chapter 1  
Introduction
I
n 2005, the UK government National Institute for Health Research Health Technology 
Assessment (NIHR HTA) programme called for a randomised controlled trial (RCT) to give 
a definitive answer to the question ‘Is there a benefit to using antimicrobial-coated urethral 
catheters over catheters without antimicrobial coatings in adults requiring catheterisation 
expected to be of limited duration, and what are the costs?’ This report describes the research 
(the CATHETER trial) that was subsequently commissioned.
The CATHETER trial was a large pragmatic UK-based multicentre RCT. It aimed to establish 
whether or not the short-term use of either of two commercially available antimicrobial catheters 
– an antimicrobial-impregnated urethral catheter (nitrofurazone) or an antiseptic-coated urethral 
catheter (silver alloy) – in comparison with the use of a standard urethral catheter reduced the 
incidence of symptomatic catheter-associated urinary tract infection (CAUTI) up to 6 weeks 
after catheter insertion, and whether or not these catheters are cost-effective in the context of the 
UK NHS.
Background
Urethral catheter design
Tubes that can be inserted through the urethra to drain the urinary bladder have been used 
for centuries. The current standard single-use indwelling catheter design was developed by a 
urologist, Frederic Foley, in the mid-1930s and marketed by the American company CR Bard 
Inc. The catheter consists of a drainage channel, open both at the tip positioned in the bladder 
and at the other end outside the body, which can be connected to a drainage bag.1 A second 
channel allows inflation, through a port with a non-return valve next to the drainage outlet, of 
a 10-ml retention balloon, which is positioned in the bladder and prevents the catheter coming 
out (Figure 1). The catheter is inserted into the urethra by a trained health professional, using an 
aseptic technique and lubricating anaesthetic gel, and is left indwelling for as long as is necessary; 
removal requires deflation of the balloon and simple withdrawal of the catheter.2
Catheter in bladder
Male and female lower urinary tract
FIGURE 1  A urethral catheter positioned in the female and male bladder.2 Introduction
The calibre, length, number of channels and material of manufacture of the catheter can all 
be varied.3 Natural extruded rubber (latex) continues to be used as the standard material of 
manufacture, although usually with an added internal and external water-resistant coating 
of polytetrafluoroethylene (PTFE) to ensure that smoother surfaces are in contact with the 
urethral mucosa and urine. In 2011, these standard catheters in the UK NHS cost approximately 
£0.914 (US$1.48; €1.03) each. More recently, catheters made out of moulded plastics, such as 
silicone, have become available. These have the advantage of consistent smooth surfaces and 
hypoallergenicity but with higher costs of material and manufacture with a unit cost to the UK 
NHS in 2011 of £2.074 (US$3.41; €2.37).
Use of urethral catheters in hospitals
Urethral catheters are one of the most commonly applied medical devices, with an estimated 
96 million used worldwide in 1999.5 Within the UK, approximately 15–25% of the 14.5 million 
patients admitted to NHS hospitals each year will receive catheterisation at some stage during 
their stay.6–9 The most common usage is for short term (which we have arbitrarily defined as up 
to and including 14 days) perioperative bladder drainage during and immediately after surgical 
or other interventional procedures. This patient group is the primary focus for our trial.10 
Other reasons for urethral catheterisation include prolonged unconsciousness or immobility, 
monitoring of urine output for management of fluid balance in critically ill patients, acute urinary 
retention and longer-term care of urinary incontinence. For patients undergoing interventions 
that require temporary catheterisation, the catheter is generally inserted just prior to starting the 
procedure and is removed when the patient is sufficiently recovered in terms of bladder function 
and mobility to safely re-establish normal micturition. The duration of catheterisation for these 
purposes is highly variable, with a recent study recording a mean [standard deviation (SD)/
median] of 3.5 (4.8/2) days.11 The type of catheter used depends on local purchasing policies and 
indication for use; for example, a recent audit in a large north-east England acute care hospital, 
which is likely to be typical of current NHS practice, showed that of the 15% of inpatients with 
an indwelling catheter, 50% were fitted with a silicone catheter and 36% a PTFE-coated latex 
catheter; in 14% the catheter type was unknown.12
Definition of catheter-associated urinary tract infection
Normally, the urethral antimicrobial barrier is closed, preventing infection. The presence of 
an indwelling urinary catheter disrupts this barrier and allows colonisation of the urethra and 
subsequently the bladder with commensal and externally acquired organisms. These may result 
in bacteriuria, symptomatic urinary tract infection (UTI), and, rarely, bloodstream infection; 
these are collectively referred to as CAUTI.13,14 For epidemiological and health protection 
purposes, CAUTI continues to be predominantly defined worldwide through consensus policy 
documents produced by the US government Centers for Disease Control and Prevention (CDC).
The CDC definition of symptomatic UTI associated with urethral catheterisation at the time 
of trial inception (2007)15 required the presence of appropriate symptoms together with either 
microbiological confirmation of significant bacteriuria or that a clinical diagnosis of UTI had 
been made and treatment instituted (Box 1).
The CDC definitions were updated in 2009 while our trial was in progress.16 The 2009 
specification states that symptomatic infection can be deemed catheter-related only if an 
indwelling urinary catheter had been present within 48 hours of diagnosis. In addition, 
there must be evidence of concurrent symptoms and urinary abnormality – either pyuria or 
bacteriuria. Criteria 2f and 2g concerning physician diagnosis and treatment initiation have 
been removed in the updated 2009 version. This more restricted definition was designed for 
reporting of CAUTI from US hospitals as part of national surveillance of health-care-associated 
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capture the community impact of CAUTI following discharge from hospital and avoid reliance 
on submission and microbiological analysis of urine specimens. For the primary outcome of the 
trial we therefore based definition of CAUTI on criterion 2g of the 2004 CDC definition. We 
do recognise, however, that other definitions of CAUTI have been used in previous trials. We 
therefore defined microbiologically proven antibiotic-treated UTI and the presence of bacteriuria 
irrespective of symptoms or treatment as tertiary outcomes.
The impact of catheter-associated urinary tract infection on hospital-based care
It is estimated that individuals with an indwelling catheter are faced with a daily risk of 5% 
of developing bacteriuria,6 with the proportion affected after 7 and 14 days of indwelling 
catheterisation being approximately 35% and 70%, respectively. It has been estimated that 
symptomatic UTI occurs in 20% of patients with bacteriuria,17,18 and while bloodstream infection 
occurs in < 1%,19,20 it is associated with a high (30%) mortality rate. An important possible 
consequence of development of CAUTI in an individual is the prolonging of hospital stay. 
A diagnosis of symptomatic UTI associated with urethral catheterisation should fulfil at least 
one of the following criteria:
Criterion 1
Patient has an indwelling urethral catheter or has had one in the last 7 days before the urine culture
and
patient has at least one of the following signs or symptoms with no other recognised cause: fever (> 38°C), 
urgency, frequency, dysuria, or suprapubic tenderness
and
patient has a positive urine culture, that is, ≥ 105 microorganisms per cm3 of urine with no more than two 
species of microorganisms
Criterion 2
Patient has an indwelling urethral catheter or has had one in the last 7 days before the urine culture
and
patient has at least two of the following signs or symptoms with no other recognised cause: fever (> 38 °C), 
urgency, frequency, dysuria or suprapubic tenderness
and
at least one of the following:
(a) positive dipstick for leucocyte esterase and/or nitrite
(b) pyuria (urine specimen with ≥ 10 WBC/mm3 or ≥ 3 WBC/high-power field of unspun urine)
(c) organisms seen on Gram stain of unspun urine
(d) at least two urine cultures with repeated isolation of the same uropathogen (Gram-negative bacteria or 
Staphylococcus saprophyticus) with ≥ 102 colonies/ml in non-voided specimens
(e) < 105 colonies/ml of a single uropathogen (Gram-negative bacteria or S. saprophyticus) in a patient being 
treated with an effective antimicrobial agent for a urinary tract infection
(f)  physician diagnosis of a urinary tract infection
(g) physician institutes appropriate therapy for a urinary tract infection
WBC, white blood cell.
BOX 1  Centers for Disease Control and Prevention definition of symptomatic UTI associated with indwelling 
catheterisation154 Introduction
Estimates of the average duration of this extra stay vary from 0.55 to 5 days.21 CAUTI can also 
adversely affect health-related quality of life (QoL).5,22 Both of these factors are important in 
health economic terms, as they impact on both QoL reduction and additional treatment costs, 
which, for the UK in 1995, were estimated to amount to a mean [95% confidence interval (CI)] of 
£1327 (£1140–1465) per episode, which extrapolates to a cost of £125M per annum to the NHS.21 
The presence of bacteriuria in hospital patients with an indwelling catheter is also a potential 
source of cross-infection, particularly in critical care units, with an estimated risk per episode of 
15%.23 In addition to CAUTI risk, short-term indwelling urethral catheters, although useful to 
avoid the need for voluntary bladder emptying, also contribute to postoperative discomfort, loss 
of dignity and delayed discharge from hospital.
The increasing realisation that hospital-acquired infections account for significant morbidity 
and mortality, together with associated financial and personal costs, led health-care providers 
to develop strategies to reduce the burden of these events. UTI, in general, is one of the two 
most common hospital-acquired infections, accounting for between 20% and 40% of cases.24–26 
Between 56% and 80% of these cases can be attributed to the use of indwelling urethral 
catheters.20,26,27 CAUTI is therefore a major focus of these preventative strategies. The UK 
government Department of Health set up the Saving Lives initiative in 2007 and, subsequently, 
the High Impact Actions for Nursing and Midwifery initiative in 2009, which made reduction 
in CAUTI a key aim for the NHS through High Impact Action number 6.28 This was based on 
guidelines for urethral catheter insertion and subsequent care developed from a systematic 
review of the evidence.29
Pathogenesis of catheter-associated urinary tract infections
The development of bacteriuria associated with an indwelling catheter is thought to occur in 
stages. Microbes gain entry to the normally sterile upper urethra and bladder either by physical 
introduction during catheter insertion or by migration along the interface between the outer 
catheter surface and the urethral mucosa, or by upward migration through the internal catheter 
channel lumen following colonisation of the drainage system.30 The disruption of the normal 
filling and emptying cycle of the bladder, and the position of the catheter drainage channel inlet 
above the catheter balloon resulting in a urine residue in the bladder, prevent physical removal 
of invading bacteria and so facilitate urinary colonisation.31 Bacteria then adhere to the urinary 
tract epithelium or the catheter surface and excite an inflammatory reaction resulting in local 
and systemic symptoms.32–34 Bacteria expressing more aggressive virulence factors can migrate 
further into the upper urinary tract or bloodstream, resulting in worsening sepsis.35 As the 
duration of catheterisation increases, bacteria begin to attach to the catheter surfaces, where they 
multiply and produce polysaccharides, forming a biofilm.36 Subsequently, mineral precipitation 
due to increased urinary pH causes catheter blockage and urinary stagnation, further facilitating 
bacterial growth.37
Microbiology
Urinary tract infection associated with short-term catheterisation typically involves a single 
organism, in contrast with long-term catheterisation, where polymicrobial infection is frequent 
(Table 1).38 Although a variety of microorganisms may be associated with CAUTI, enteric Gram-
negative bacilli are the most frequently isolated.40 Escherichia coli is the most frequently isolated 
single species, but other species such as Klebsiella spp., Proteus spp. and Enterobacter spp. are also 
commonly identified. Enterococci, Pseudomonas aeruginosa and Candida spp. are also important 
causes of CAUTI, particularly in patients within critical care settings.40 Staphylococci and other 
Gram-negative bacilli are isolated less frequently.38
Risk factors for catheter-associated urinary tract infection
A number of patient characteristics are associated with increased risk of CAUTI, including 
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of antibiotic use, longer duration of catheterisation, insertion by poorly trained personnel, and 
deviation from catheter care protocols.38
Measures and strategies aimed at reducing catheter-associated urinary 
tract infections
There are a number of existing recommendations that can reduce the risk of CAUTI (Box 2) and 
the evidence for each of these has been summarised in recent reviews.29,38,41–44
A range of UK guideline and best practice documents have encouraged implementation of some 
of these measures into the NHS with performance monitoring of individual NHS organisations 
to ensure compliance. These can be broadly divided into eight distinct actions.29,45–48
  ■ education of patients, their care-givers and health-care personnel, in terms of hand hygiene 
and steps in preventing spread of infection
  ■ assessing the need for catheterisation – to avoid or consider alternatives
  ■ selection of appropriate type of catheter for individual and clinical context
  ■ use of strict aseptic technique for catheter insertion
  ■ use of antibiotic prophylaxis in selected high-risk groups at insertion
  ■ use of a closed drainage system or catheter valve
  ■ maintenance of a sterile closed drainage system by obtaining urine specimens from the 
sampling port, positioning of drainage bag above floor level and below bladder level; frequent 
emptying of drainage bag to maintain urine flow and prevent reflux; daily washing of meatus
  ■ reduction in duration of catheterisation: regular review of need for catheterisation and aim 
for early removal of catheter.
Development of urethral catheters containing antimicrobials
The most researched technical innovation in catheter design over the past 10 years has been 
the introduction of antimicrobial coatings applied to catheter surfaces or impregnated into 
the catheter material. Several manufactures have marketed either antimicrobial-impregnated 
or silver-coated catheters as representing a technology to reduce CAUTI risk and it is this 
development that is the focus of this trial.23
Silver
Silver has long been recognised as an antimicrobial agent with demonstrated activity against 
uropathogens through multiple mechanisms of action.49 Silver exposure results in limited toxicity 
to mammalian cells50 and does not appear to induce microbial resistance.51 Two silver-containing 
compounds have been used for urethral catheters: silver oxide and silver alloy. Silver oxide-
coated catheters showed lack of clinical efficacy in early clinical studies and were superseded 
by silver alloy-coated urethral catheters, which showed more promise in reducing bacteriuria 
during catheterisation.42 The current most widely used device is a hydrogel silver alloy-coated 
latex catheter marketed by CR Bard Inc., New Jersey, USA, with a 2007 UK NHS cost of £6.46.52 
This catheter has metallic silver in a gold and platinum coating, linked to a latex base on the 
TABLE 1  Bacterial isolates from 105 cases of CAUTI during short-term urethral catheterisation39
Pathogen % CAUTI
E. coli 13
Other Gram-negative bacilli, such as Proteus spp. 26
Enterococcus spp. and Streptococcus spp. 26
Candida spp. 30
Polymicrobial 56 Introduction
external surface of the catheter and on the inner luminal surfaces. Silver ions are released into 
the periurethral space to exert antibacterial activity. The outer hydrogel layer gives the catheter its 
self-lubricating properties.53
Antimicrobials
A potentially more direct method of inhibiting CAUTI is to coat or impregnate catheters with 
antimicrobials active against expected uropathogens. Two antimicrobial agents have been used 
in clinical studies. Initially, a minocycline/rifampicin mixture was used.54 Despite promising 
preliminary results, this specific catheter was not pursued by the development company (Cook 
Urological). The second antimicrobial agent used for catheter impregnation was nitrofurazone, 
a topical nitrofuran related to nitrofurantoin, which has a spectrum of activity against many 
potential uropathogens. Nitrofurazone-impregnated urethral catheters are commercially available 
and marketed by Rochester Medical Corp in 2007 at a UK NHS cost of £5.29.4 For this catheter 
design, nitrofurazone is impregnated into the external and internal luminal surfaces to give an 
effective concentration of 10.2 µg/mm3. The drug then elutes over time into the external surface–
urethral mucosa and internal lumen–urinary boundaries.55
Evidence for clinical and bacteriological effectiveness
Several systematic reviews have investigated the effectiveness of antimicrobial catheters 
in reducing CAUTI, including pooled data from up to 13,000 patients. The results of five 
systematic reviews23,42,56–58 suggest that silver alloy-coated catheters reduce the incidence of 
bacteriuria in hospitalised patients catheterised for < 2 weeks in comparison with standard 
catheters. The magnitude of relative risk reduction varied in each of the analyses due to 
different inclusion criteria, ranging from 16% (95% CI 6% to 47%; absolute risk reduction of 
2.0%)58 to 46% (95% CI 33% to 57%; absolute risk reduction of 11.3%).42 The pooled results 
for nitrofurazone-impregnated catheters showed a relative risk reduction of up to 48% (95% 
CI 32% to 66%; absolute risk reduction 8.6%);42 however, the benefit of this type of catheter 
appeared to be limited to the initial 7 days of catheterisation. It should be noted that these event 
rates and associated risk reductions apply to CAUTI diagnosis based solely on microbiological 
identification of bacteriuria without any patient-driven or clinician-defined contribution to 
the primary outcomes used. Overall, the methodological quality of these reviews was poor to 
moderate according to the AMSTAR quality assessment tool,59 with the exception of that by 
Schumm et al.,42 which was methodologically more robust. [K Schumm (now K Gillies) and 
Catheter care policies
  ■ Reduction in prevalence of catheterisation
  ■ Reduction in duration of catheterisation
  ■ Maintenance of closed drainage system
Administration of antibiotics
  ■ On insertion
  ■ Throughout duration of catheterisation
  ■ On removal
Technical developments
  ■ Closed drainage systems
  ■ Antimicrobial catheters
  ■ Sealed catheter and drainage systems
  ■ Catheter valves
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T Lam, authors of the updated Cochrane review, were both members of the trial steering and 
project management groups and are named authors of this monograph.]
In summary, these systematic reviews have concluded that silver alloy-coated and nitrofurazone-
impregnated catheters do show promise for the reduction of CAUTI. The reviews did, however, 
highlight a number of uncertainties regarding the evidence base, in particular the clinical and 
health economic relevance of the outcome measures used.
Problems with current evidence
Clinical effectiveness
The majority of studies used the presence of bacteriuria on microbiological examination as 
the outcome measure for a diagnosis of CAUTI without specifying as to whether or not it was 
symptomatic and without linking to clinical decision to treat with antibiotics.23,42,58 The lack of 
use of an outcome explicitly measuring patient benefit hampers interpretation of these data to 
guide change in practice. In addition, the majority of the individual trials were small and of poor 
to moderate methodological quality, with wide variations in study design, population studied, 
and outcome definitions, together with failure to account for confounding factors.23,42 These 
aspects may account for the heterogeneity in effect size between individual studies and between 
meta-analyses. Given these uncertainties, the authors of systematic reviews and clinical practice 
guidelines emphasised the urgent need for well-designed, adequately powered RCTs using 
outcome measures of relevance to patients and health-care systems to determine the clinical 
effectiveness of antimicrobial-coated catheters.42
Cost-effectiveness
For the background to our planned economic evaluation we performed a systematic literature 
search that identified 400 economic studies, of which six reports5,60–64 and two systematic 
reviews65,66 were deemed relevant, although only one was from the perspective of the UK NHS.61 
All reports concerned the comparison between silver alloy-coated and standard catheters, with 
no data on nitrofurazone-impregnated catheters. The design of the studies varied with two being 
model-based,5,61 two trial-based,60,62 and two surveillance-based studies.63,64 These studies were 
summarised and critically evaluated (see Appendix 1).
A study using a decision model based on a simulated cohort of 1000 hospitalised patients from 
various specialties in the USA5 found that, based on an assumption that silver alloy-coated 
catheter use would result in a 47% relative reduction in CAUTI rate, there was a probability of 
0.84 that cost savings would accrue with change in practice. A UK NHS-based study61 reported 
that if routine use of silver alloy-coated catheters was adopted, and assuming an additional cost 
of £9 per catheter, lower costs of extra hospital stay in medical patients, and a baseline risk for 
CAUTI of 7.3%, relative risk reductions in CAUTI of 14.6% in catheterised medical patients, and 
of 11.4% in catheterised surgical patients were required before cost savings could be made.
An economic analysis performed within a large cluster randomised trial involving 28,000 
patients62 reported that use of silver alloy-coated catheters could lead to cost reduction of 
between 3.3% (US$14,456) and 35.5% (US$537,293) in annual institutional CAUTI costs, 
depending on whether low (US$840) or high (US$4693) estimates of the cost of an individual 
episode of CAUTI were used. A masked prospective study from a single institution calculated 
that the annual cost saving from the 41 episodes of CAUTI saved by routine use of silver alloy-
coated catheters was US$98,021.60 A study using surveillance data estimated that use of silver 
alloy-coated catheters resulted in a decrease in CAUTI incidence from 6.13/1000 catheter-days 
to 2.16/1000 catheter-days.63 It was calculated that this would result in annual cost savings for 
the institution of either US$5811 or US$484,070, depending on whether low (US$700) or high 
(US$5682) estimates of the cost of an individual episode of CAUTI were used. Finally, estimates 8 Introduction
of annual, single institutional cost savings associated with routine use of silver alloy-coated 
catheters ranged from US$12,564 to US$142,315 based on mean (median) cost of a single episode 
of CAUTI of US$1214 (US$614).64
The methodological quality of the studies varied and it is difficult to draw general conclusions 
from them. For example, in the model-based analyses, assumptions concerning baseline rate 
of CAUTI, the relative risk reduction associated with the intervention, and calculation of cost 
of CAUTI varied. Overall, these results do illustrate the high degree of uncertainty regarding 
the cost implications following introduction of antimicrobial catheters, and this predominantly 
reflects imprecision of the parameter estimates included in the specific models.
Need for a trial
The current frequency of indwelling urethral catheterisation in UK NHS acute hospitals suggests 
that more than 2 million people are at risk of CAUTI each year. The subsequent costs in terms 
of patient morbidity and extra care mean that CAUTI continues to be an important health-care 
problem. Current evidence from meta-analyses of predominantly small explanatory trials shows 
that antimicrobial catheters do reduce the risk of developing bacteriuria during periods of 
short-term urethral catheterisation. The logical next step is to demonstrate that this antimicrobial 
effect translates into clinical benefit for patients in terms of reducing the risk of symptomatic 
UTI requiring antibiotic treatment, and that it achieves this at an acceptable cost to the NHS. 
The current evidence base suggested that a pragmatic trial design was required which would 
be able to provide a definitive result generalisable across the population at risk. From a clinical 
effectiveness perspective, any trial would also need to measure discomfort and urinary symptom 
burden suffered by individuals within a specific health-care system, the UK NHS in this instance.
Trial objectives
The following questions were addressed: in hospitalised adults requiring short-term 
catheterisation what is the clinical benefit and cost-effectiveness of using antimicrobial-
impregnated or antiseptic-coated urethral catheters over standard urethral catheters? Two 
pragmatic comparisons of equal importance were made:
  ■ antimicrobial-impregnated silicone catheter (nitrofurazone) compared with standard PTFE-
coated latex catheter
  ■ antiseptic-coated hydrogel latex catheter (silver alloy) compared with standard PTFE-coated 
latex catheter.
The systematic review and meta-analysis of available randomised studies current at the time of 
inception of the trial suggested that the use of silver alloy catheters resulted in a 40% reduction in 
risk of catheter-associated symptomatic UTI against standard comparators [RR 0.60 (95% CI 0.50 
to 0.73)].41 A previous epidemiological review estimated that for people catheterised for up to 
10 days the absolute risk (95% CI) of developing bacteriuria was 26% (95% CI 23% to 29%) and 
of these, around a quarter (6.5% of the total) would develop a symptomatic infection.67
These summarised data were used to generate the hypothesis to be tested by this trial: use of 
either silver alloy-coated or nitrofurazone-impregnated catheters reduces the incidence of CAUTI 
during short-term use by 40% relative to the standard catheter, with an absolute reduction of at 
least 2.8% (from 7.0% to 4.2%).© Queen’s Printer and Controller of HMSO 2012. This work was produced by Pickard et al. under the terms of a commissioning contract issued by the Secretary of State for Health. 
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Chapter 2  
Trial design
T
he CATHETER trial was a RCT testing three types of short-term urinary catheters in a range 
of clinical settings in the UK.
Participants
Potential participants were identified according to the inclusion and exclusion criteria 
detailed below.
Inclusion criteria
Adults (≥ 16 years of age) requiring urethral catheterisation (which was expected to be 
required for a maximum of 14 days), from selected hospital wards with a high volume of 
short-term catheterisation.
Exclusion criteria
  ■ Patients for whom urinary catheterisation was expected to be longer-term (defined as 
> 14 days).
  ■ Patients who had urological intervention or instrumentation within the 7 days preceding 
recruitment (e.g. catheterisation, cystoscopy, prostatic biopsy and nephrostomy insertion).
  ■ Patients who required non-urethral catheterisation (e.g. suprapubic catheterisation).
  ■ Patients who had a known allergy to any of the following: latex, silver salts, hydrogel, silicone 
or nitrofurazone.
  ■ Any patient who had a microbiologically confirmed symptomatic UTI, at time 
of randomisation.
  ■ Patients who were unable to give informed consent or retrospective informed consent.
Participants were equally allocated to one of the three trial interventions using a web- or 
telephone-based system managed by the Centre for Healthcare Randomised Trials (CHaRT), 
University of Aberdeen. The inclusion criterion for participation of centres was a high volume of 
short-term catheterisations, principally as part of elective surgical activity. Twenty-four centres 
took part in the trial: Aberdeen Royal Infirmary; Royal Blackburn Hospital & Burnley General 
Hospital; Blackpool Victoria Hospital; Bristol Royal Infirmary; Edinburgh Royal Infirmary; Guy’s 
Hospital; Harrogate District Hospital; Hillingdon Hospital; Hinchingbrooke Hospital; Raigmore 
Hospital, Inverness; Liverpool Women’s Hospital; Newcastle upon Tyne Hospitals (Newcastle 
General Hospital, Freeman Hospital, and Royal Victoria Infirmary); Norfolk and Norwich 
University Hospital; North Tyneside General Hospital; Nottingham City Hospital; Royal Preston 
Hospital; Queen Alexandra Hospital, Portsmouth; Southampton General Hospital; Sunderland 
Royal Hospital; Musgrove Park Hospital, Taunton; Torbay Hospital and Yeovil District Hospital. 
The trial recruited from a wide range of clinical settings including cardiovascular, obstetrics and 
gynaecology, orthopaedics and neurosurgery as detailed in Chapter 4.10 Trial design
Planned trial interventions
There were two experimental groups of equal importance:
  ■ nitrofurazone-impregnated silicone urethral catheter (N), sourced from Rochester Medical, 
UK (product reference number 95214)
  ■ silver alloy-coated latex hydrogel urethral catheter (S), sourced from CR Bard Ltd, UK 
(product reference number 236514UKS).
The control group was managed with a PTFE-coated latex urethral catheter (P), sourced from CR 
Bard Ltd, UK (product reference number 1254S14UK).
All catheters used in the trial had an external circumference of 14 mm, termed 14 French (Fr) 
or 14 Charrière (Ch), with equivalent luminal calibre, length, recommended balloon volume 
(10 ml), drainage ports and external connection fittings. The silver alloy-coated and control 
catheters were manufactured from latex, whereas the nitrofurazone catheters were made from 
silicone. The choice of a PTFE catheter as the ‘standard’ control was based on the results of an 
audit of short-term catheter use in all secondary care wards in Newcastle upon Tyne Hospitals 
and Aberdeen Royal Infirmary, which confirmed that the PTFE-coated latex urethral catheter 
was the most commonly used in both hospitals (> 70%).
Proposed duration of intervention
The period of urethral catheterisation was expected to be between 1 and 14 days.
Comparisons
The outcomes were compared with:
  ■ nitrofurazone-impregnated catheters and standard PTFE catheters
  ■ silver alloy-coated catheters and standard PTFE catheters.
Outcome measures
Primary outcome measure
Incidence of symptomatic UTI treated with antibiotics at any time up to 6 weeks post 
randomisation (number of participants with at least one occurrence). This was defined as any 
symptom reported up to 3 days after catheter removal, at 1 or 2 weeks post catheter removal, or 
at 6 weeks post randomisation combined with a prescription of antibiotics, at any of these times 
(see Table 4).
Subgroup analyses of the primary outcome examined possible interaction with participant age, 
sex, comorbidity, duration of catheterisation, indication for catheterisation and antibiotic use 
prior to trial enrolment.
Details of which data contributed to the primary outcome are shown later in this chapter (see 
Table 4), and Chapter 3 (see Important changes to methods after trial commencement) details how 
the attributes of the primary outcome were strengthened during the course of the trial.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Pickard et al. under the terms of a commissioning contract issued by the Secretary of State for Health. 
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Secondary outcome measures
Clinical
Microbiological confirmation of bacteriuria in addition to primary outcome: this was 
defined as those who fulfilled the criteria for the primary outcome and in addition had any 
microbiologically positive result where there were ≥ 104 colony-forming units (CFUs)/ml of no 
more than two different species of uropathogen. This was assessed by a protocol-mandated urine 
sample at 3 days after catheter removal.
Economic
  ■ Incremental cost per infection averted and quality-adjusted life-years (QALYs) gained.
  ■ QALYs estimated from European Quality of Life-5 Dimensions (EQ-5D) responses.
  ■ Cost to the NHS and patient of the different catheters.
Tertiary outcome measures
Individual analysis of the components of the definition of the primary and secondary outcomes is 
shown below.
Patient self-reported symptoms
  ■ Bacteriuria: any microbiologically positive result (≥ 104 CFU/ml of no more than two 
different species of uropathogen 3 days after catheter removal).
Other significant clinical events: septicaemia and mortality
  ■ Adverse effects of catheterisation apart from symptomatic UTI (e.g. urethral discomfort and 
pain on removal).
  ■ Antibiotic use following randomisation and indication.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Pickard et al. under the terms of a commissioning contract issued by the Secretary of State for Health. 
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Chapter 3  
Methods
Ethics and regulatory approvals
The CATHETER trial and subsequent amendments were reviewed and given a favourable 
opinion by the North of Scotland Research Ethics Service, Grampian Research Ethics Committee 
1 (reference 06/S0801/110) and local Research and Development Departments as appropriate 
prior to commencement. The trial was conducted according to the principles of Good Clinical 
Practice (GCP) and was registered and assigned an International Standard Randomised Clinical 
Trial Number (ISRCTN75198618). The CATHETER trial was not classed as a trial involving an 
Investigational Medicinal Product or Medical Device and therefore did not come under the EU 
Clinical Trials Directive.
Participants
Trial flow
The trial process is detailed in Figure 2.
Identification of patients
Patients were identified either by a member of the local research team or by ward staff. In order 
to publicise the trial to ward staff and patients, laminated recruitment posters were placed at 
prominent locations at each site as appropriate.
Recruitment process
Once a patient was identified as being eligible for the trial, he/she was approached by a member 
of the local research team and given the trial patient information sheet (see Appendix 2). Once 
the patient had been given time to consider and understand the implications and requirements 
of the trial, and was happy to take part, he/she was asked to sign the trial consent form (see 
Appendix 2).
The only exception to this was for patients in unplanned situations (e.g. non-elective admissions 
and catheterisations). The local research team was made aware of this and, once the patient’s 
condition had stabilised, he/she was provided with the patient information sheet and given an 
opportunity to consent retrospectively to take part in the trial; this methodology for recruitment 
was approved as part of our ethics submission. The decision to catheterise such patients was 
based solely on clinical need by the local clinical care team. As the antiseptic/antimicrobial-
impregnated catheters have previously been reported to lessen the risk of infection compared 
with the usual standard catheter, the inclusion of these patients in the trial prior to informed 
consent did not pose a clinical risk, did not lessen their standard of care and was not thought 
to be otherwise disadvantageous to the participant. Patients who subsequently gave informed 
consent then completed the normal trial processes. Patients who declined to give informed 
consent retained the trial catheter as appropriate but no trial data were collected.14 Methods
Randomisation and allocation to intervention
Eligible participants were randomly allocated 1 : 1 : 1 to one of the three interventions using a 
computer-generated system that was concealed and remote from the users. The local research 
team or ward staff performed randomisation using either the automated interactive voice 
recognition (IVR) telephone randomisation application or the CATHETER trial website 
(www.charttrials.abdn.ac.uk/catheter), both managed by CHaRT, University of Aberdeen. Both 
methods of randomisation were available 24 hours a day, 7 days a week. Compliance with the 
allocated intervention was recorded. No stratification or minimisation was used.
Blinding of trial interventions
The nitrofurazone catheter was easily identifiable because of its bright-yellow colour. To guard 
against bias in this respect, although the recruiter knew the allocated intervention, as far as was 
practicable participants and clinicians making decisions regarding the participant’s catheter care 
were not told. General practitioners (GPs) were also not informed by trial staff of the catheter 
type the participant received and therefore were unlikely to be influenced by knowledge of the 
catheter type. Urine samples taken at baseline and 3 days after catheterisation were analysed by 
staff at a local laboratory, who were blind to the intervention.
Elective patients
Intervention
Eligible participants identified by
local research team or medical staff
Unplanned catheterisations
Eligible participants identified by
local research team or medical staff
Information provided and consent
sought when condition stabilised
Information provided and
consent sought
3-day post-catheter-removal
urine sample
Baseline questionnaire
Pre-catheterisation urine sample
Pre-catheterisation urine sample
Participant data form
PTFE (P)
Nitrofurazone (N)
Silver alloy (S)
3-day post-catheter-removal questionnaire
1- and 2-week post-catheter-removal diaries
6-week post-randomisation follow-up
questionnaire
Catheterisation
Baseline questionnaire
Randomisation Randomisation
Data patient
reported
Data local research
team reported
Process local
research team
completed
Catheterisation
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Interventions
The calibre of urinary catheters is measured as the external circumference in millimetres, Fr or 
Ch gauge, and they can be supplied in differing lengths to suit the male (38–46 cm) or female 
(24–28 cm) urethra. The uniform calibre and length of the three catheters tested in this trial 
was specified as 14 Fr and 40 cm, respectively.68 This was chosen as 14 Fr is the standard calibre 
for short-term monitoring use. A longer urethral catheter does not cause problems when used 
in women, but it is not possible to use a shorter catheter in men. They were purchased direct 
from the manufacturers (CR Bard Ltd UK, Rochester Medical, UK) by the trial office at a unit 
price fixed in 2007 for the duration of the trial and distributed by the trial office in Aberdeen 
to the sites as needed. Each catheter had a detachable sticker attached to the outer packaging. 
This sticker displayed the ‘CATHETER’ logo and either ‘N’, ‘S’ or ‘P’ to denote catheter type 
(N = nitrofurazone, S = silver, P = PTFE). These stickers were then placed directly on to the 
participants’ consent forms to permit verification that they were given the catheter to which they 
were randomised.
Data collection
Questionnaires and diaries were designed to obtain information on symptomatic UTIs as well 
as other catheter-associated problems (e.g. urethral discomfort), QoL, and any health economic 
implications, such as costs to the participants and the NHS (see Appendix 3). Clinical data at 
baseline and throughout the participant’s hospital stay were collected by the local research team 
(see Appendix 4). An amended version of the UTI Symptom Assessment Questionnaire69 was 
used to assess UTI symptoms 3 days post catheterisation.
Following informed consent, the participants were asked to complete a baseline questionnaire 
before randomisation (for participants undergoing unplanned catheterisation, randomisation 
occurred before informed consent and the baseline questionnaire was then collected after consent 
was obtained). At baseline, a sterile mid-stream specimen of urine (MSSU) was collected and 
sent for microbiological analysis, in an accredited laboratory [Clinical Pathology Accreditation 
UK (CPA)] according to local diagnostic protocols, immediately prior to catheterisation (if one 
had not been sent within the preceding 48 hours). In situations where this was not possible, a 
specimen of urine was obtained during the process of catheter insertion, i.e. catheter specimen of 
urine (CSU) using standard aseptic techniques.
Three days post catheter removal, participant-reported outcome data were recorded by a 
questionnaire given to the participant by the local research team. When possible, these data 
were collected while the participant was hospitalised, but in situations where the participant was 
discharged before this time point, they were asked to complete this at home and return it to the 
trial office. An MSSU was collected for culture within or at 3 days of catheter removal (analysed 
in CPA-accredited laboratories according to local diagnostic protocols). For the purposes of the 
trial we defined a positive urine culture as the presence of at least 104 (CFUs)/ml.
If a clinical diagnosis of symptomatic UTI was made at any stage, including during the period of 
catheterisation, either a CSU or MSSU was obtained according to normal clinical practice.
Participants were asked to complete diaries at 1 and 2 weeks post catheter removal and at 6 weeks 
post randomisation. Table 2 describes the outcome data collected.
Diaries and questionnaires completed prior to hospital discharge were collected by the local 
recruitment co-ordinator. On discharge, patients were supplied with a pack containing the 
relevant 1- and 2-week diaries and pre-paid addressed envelopes to return the diaries to the trial 
office. At 6 weeks post catheterisation, participants were sent the follow-up questionnaire from 
the trial office and asked to return it using the pre-paid addressed envelope provided. Where 16 Methods
necessary, participants who did not return their diaries or questionnaires were telephoned 
either by the local research co-ordinator or a member of the trial office and asked to return their 
paperwork. If possible, primary outcome data were collected by phone at this point.
Where the period of catheterisation was longer than initially anticipated (i.e. the catheter was 
still in place after day 14), trial data were collected as if the catheter had been removed on day 
14 (e.g. the 3-day post removal questionnaire was completed 17 days post catheterisation). The 
date of catheter removal was subsequently recorded. The rationale for this was that it would 
not be appropriate to exclude data from these participants but it also would not be justified to 
prolong follow-up for any participant beyond the planned 6 weeks after randomisation. Given 
the likely small numbers of participants affected, we chose to use the same documentation but we 
instructed local trial staff to aid participant completion, as the majority of patients affected were 
likely to remain in hospital during the extended period of catheterisation. This ensured that we 
captured any UTI event during the 6-week period and ensured effective use of limited resources.
Collection of information to describe urinary tract infections
The primary outcome was derived using information collected from the sources at the time 
points described in Table 3 and was determined using the algorithm described in Appendix 5.
Participants met the definition of the primary outcome if they fulfilled the criteria described in 
Table 4. This is expanded in Appendix 5.
General practitioner confirmation of antibiotic prescription
Where participants reported antibiotic use at 1, 2 or 6 weeks or failed to return any trial 
paperwork at these time points, confirmation of these details, or a request for this information, 
was sent to the participant’s GP. This included a brief letter explaining the need for this 
information and a table for the GP to complete asking whether or not the participant had 
presented to them with a UTI during the period of their participation in the trial, and if 
so whether or not they had given the participant a prescription for antibiotics for UTI (see 
Appendix 4).
Change of status/withdrawal
The status of some participants changed during the trial for a number of reasons. These included 
post-randomisation exclusions; participants deciding they no longer wished to be a part of the 
trial; and decisions by medical staff that it was not appropriate for the participant to remain in 
the trial.
TABLE 2  Time points at which outcome data were collected
Outcome data Collected by Baseline
Time post catheter removal Time post randomisation
3 days 1 week 2 week 6 weeks
Urinary tract symptoms Participant P P P P P
EQ-5D Participant P P P P P
Antibiotic use Clinical P P
Antibiotic use Participant P P P
Antibiotic use GP P P P
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Participants were free to decline further follow-up from the trial at any point without giving 
a reason. Participants could also be withdrawn for medical reasons. In such cases, primary 
outcome data were still collected if the participant consented to the use of their relevant hospital 
and general practice records.
In addition, some patients were classed as post-randomisation exclusions for one of the 
following reasons:
  ■ patients who were randomised but received a suprapubic catheter
  ■ patients who were randomised but did not have any catheter inserted
  ■ emergency patients who were randomised but subsequently declined to participate in 
the trial.
The justification for excluding participants who did not receive a urethral catheter from the 
analysis was that they did not fulfil intention-to-treat criteria, as the ultimate decision-maker, the 
responsible clinician in the operating suite, determined that an alternative urine drainage option 
was preferred.
Data management
Data collected at site were input into the electronic CATHETER database through the trial web 
portal (www.charttrials.abdn.ac.uk/catheter) by the local research team; those received by the 
trial office were entered by the trial office staff.
At the end of the trial, a random 10% sample of all of the trial data were re-entered by the 
trial office to verify correct data input. Any discrepancies between originally entered data and 
re-entered data were reviewed and checked against the original paper copy by an individual who 
was not involved in entering either data set. Incorrectly entered data were corrected at the time of 
checking. An initial data entry error rate of > 5% would have triggered a requirement to re-enter 
the entire data set from that questionnaire. This was not found to be necessary.
TABLE 3  Collection of UTI data
1. During catheterisation Ward-based diagnosis from symptoms and observations (supported by microbiology where appropriate) and 
clinician-directed use of antibiotics for UTI. Data recorded by local research team
2. Three days post catheter 
removal
Ward-based diagnosis from symptoms and observations and clinician directed use of antibiotics for UTI. Urine 
specimen for microbiological confirmation of bacteriuria
Data recorded by local research team and participant
3. One and two weeks post 
catheter removal
Participant diary collected data on symptoms, clinician contact and antibiotic usage for UTI. Where antibiotic use was 
documented this was confirmed as being for UTI by the participant’s GP
4. Six weeks post 
randomisation
Symptoms, clinician contact, antibiotic usage for UTI and hospital readmissions were reported by the participants. 
Where antibiotic use was documented this was confirmed as being for UTI by the participant’s GP
TABLE 4  Collection of primary outcome data
Outcome measurement Method of collection 
Received antibiotics for UTI during catheterisation with associated symptoms Recorded from clinical records
Participants given an antibiotic for a symptomatic UTI Recorded at 3 days post catheterisation from clinical records 
and participant report
Participant-reported symptomatic UTI at 1 or 2 weeks post catheter removal or 
6 weeks post randomisation with GP confirmation of antibiotic prescription for UTI
Recorded up to 6 weeks post randomisation from participant 
diaries and questionnaires and GP records18 Methods
Trial oversight committees
A Trial Steering Committee (TSC), consisting of an independent chairperson, two further 
independent members and the grant holders, provided oversight of the trial. The TSC met six 
times over the course of the trial (at least annually).
The independent Data Monitoring Committee (DMC) met early in the trial and agreed its terms 
of reference and other procedures. They then met six times over the course of the trial (at least 
annually). The DMC reported any recommendations to the chairperson of the TSC.
Important changes to methods after trial commencement
Primary outcome
In response to recommendations from the DMC in June 2008, the TSC reviewed the method of 
recording the definition of the primary outcome to ensure that the trial was reliably capturing 
all events that determined catheter-associated symptomatic UTI. Over the course of the third 
and fourth meetings (dates 8 June 2009 and 23 November 2009) the DMC commented on a 
higher than anticipated proportion of trial participants with a positive primary outcome. Further 
investigation showed that this was due to high levels of urinary tract symptoms reported by the 
trial participants at 3 days, perhaps due to irritation from the recently removed urethral catheter, 
together with uncertainty regarding the purpose of prescribed antibiotics. As a result, at this time 
point (3 days post catheter removal) description and recording of the events needed to qualify 
as symptomatic UTI were strengthened in the case report form to explicitly include a record of 
appropriate antibiotic treatment for patient reported symptomatic UTI. Although it was felt that 
this had been implicit in the original wording, an amendment was made stating this to clearly 
qualify which events define the primary outcome.
Sample size calculation
The original sample size calculation for the trial was revised upwards. Given that the primary 
outcome for the trial was patient-reported symptomatic UTI supported by antibiotic treatment 
rather than bacteriuria or microbiology confirmed UTI, it became evident during the trial that 
the actual incidence of symptomatic UTIs without the requirement for microbiologically proven 
bacteriuria was greater than originally anticipated. This prompted a reassessment of the initial 
sample size calculation. Both the original and revised calculations are outlined below.
Original proposed size of the trial
Based on the Cochrane review and other data,5,41,67 the anticipated incidence of UTI in the 
standard control group was 7.0% and a reasonable estimate of the effect of the intervention 
catheters would reduce this to 4.2% [absolute risk reduction 2.8%, relative risk (RR) 0.60, odds 
ratio (OR) 0.58]. We estimated that based on a stricter alpha error rate of 0.025 (to correct for 
the two principal comparisons) and 90% power, 1750 participants were required for each arm 
of the trial. We inflated this to adjust for an anticipated 8.0% post-randomisation exclusion rate 
resulting in 1900 per arm, or 5700 total randomised.
Revised sample size calculation
Ongoing monitoring of the overall rate of the primary outcome in the trial indicated that the 
original estimate of the incidence of symptomatic UTI supported by antibiotic treatment was an 
underestimate and consequently this was revised upwards from 7% to 11% in the PTFE control 
group. The effect size was revised in light of this to reduce the primary outcome to 7.7% in the 
primary catheter groups (absolute risk reduction 3.3%, RR 0.7, OR 0.67). Recalculating the 
sample size based on these new parameters resulted in approximately 2000 required for each arm 
of the trial. Furthermore, the empirical rate of post-randomisation exclusion was also higher 
than originally estimated and therefore the final number required was inflated to compensate for 
an estimated 15% post-randomisation exclusion rate, resulting in a total required sample size of 
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Recruitment from specific clinical areas
As described in the trial protocol, we originally intended to have a wider recruitment area 
encompassing patients admitted to hospital for both elective and emergency reasons, including 
those admitted to or transferred to critical care areas who required unplanned catheterisation. 
Early in the trial it was established that recruitment and pre-consent randomisation of 
participants undergoing unplanned catheterisation was resource intensive in terms of NHS 
clinical and research staff activity, and that there was a high rate of subsequent refusal of consent, 
which raised ethical concerns. In discussion with the trial management committees, it was 
decided to concentrate our finite resources on recruitment of patients admitted for elective 
interventions associated with planned urethral catheterisation. To ensure generalisability we 
proceeded to establish a large number of sites including all of the relevant clinical specialties.
Statistical methods/trial analysis
All analyses were carried out using SAS software version 9.2 for Windows (SAS Institute, Cary, 
NC, USA), unless otherwise stated. The principal comparisons within the trial were between 
those allocated to (1) the nitrofurazone and PTFE catheters and (2) silver alloy and PTFE 
catheters. All UTI outcomes were also summarised as the absolute risk difference expressed as a 
percentage. The primary and secondary outcomes were analysed using generalised linear models. 
All estimates are presented with 97.5% CIs (to reflect the stricter level of alpha due to multiple 
comparisons used in sample size calculations). Estimates from marginal models (unadjusted) and 
conditional models are presented adjusted for:
  ■ age (< 60 years, ≥ 60 years)
  ■ sex
  ■ comorbidity (pre-existing urological disease, diabetes, immune suppression)
  ■ indication for catheterisation (incontinence, urinary retention and monitoring purpose)
  ■ antibiotic use prior to enrolment.
All outcomes related to UTI were based on the intention-to-treat principle, with all included 
participants analysed as randomised, regardless of the catheter received. All participants were 
assumed to have not had a UTI unless indicated otherwise (see algorithm for primary outcome).
Quality-of-life data were analysed in a repeated measures framework using SAS PROC MIXED. 
An AR(1) autoregressive correlation structure was used. QoL data are presented as means and 
SDs at each time point, and presented in a graph for ease of comparison over time. Analysis was 
by complete case intention to treat; sensitivity to missing data was explored using PROC MI 
under the missing-at-random assumption.
All outcomes related to symptoms and catheter-associated discomfort were analysed using 
ordered logit models (also called proportional odds or ordered logistic regression) that were 
suitable for ordinal outcome data implemented in Stata 11.2 (StataCorp LP, College Station, 
TX, USA). Results are presented as ORs (and 97.5% CIs). To aid interpretation the difference in 
predicted probabilities (and 97.5% CIs) of being in a particular category between intervention 
and control catheters are also presented.70 Analysis was complete case intention-to-treat and a 
sensitivity analysis using multiple imputations (under the assumption of missing at random) was 
carried out for each of these outcomes.
Timing and frequency of analyses
The data monitoring committee considered confidential interim inspection of the data on five 
occasions. At the first meeting, the DMC recommended refining the definition of algorithm used 20 Methods
to define the primary outcome; this was due to a higher than anticipated rate of UTI (for further 
details, see Chapter 3, Important changes to methods after trial commencement).
Planned secondary subgroup analyses and sensitivity analyses
Subgroup analyses of the primary outcome examined possible effect modification of 
the following:
  ■ age (< 60 years, ≥ 60 years)
  ■ sex
  ■ comorbidity (pre-existing urological disease, diabetes, immune suppression)
  ■ indication for catheterisation (incontinence, urine retention and monitoring purpose)
  ■ antibiotic use prior to randomisation
  ■ duration of catheterisation.
Modification of the treatment effect was explored using tests for interaction (all at stricter 
levels of significance; p < 0.01), and results are presented as forest plots with 99% CIs to reflect 
the exploratory nature of these analyses. Two further post hoc effect modification sensitivity 
analyses were carried out treating (1) age and (2) duration of catheterisation as continuous 
variable interactions with treatment allocation to explore any potential differential effects across 
catheters. All subgroup and treatment effect modification analyses were analysed using the same 
generalised linear modelling framework as the main analyses. A further sensitivity analysis was 
carried out to assess any potential impact of centre on the precision of estimates of treatment 
effects by including a random effect for centre in the model for the primary outcome.
Economics methods
Introduction
Two types of economic analyses were planned. The first was a ‘within-trial’, economic evaluation 
undertaken using data collected as part of the trial, and the second was based on a modelling 
exercise aiming to address the uncertainty (background noise) introduced by the heterogeneity 
in terms of underlying illness and type of operative procedure undergone by trial participants. 
The question addressed by both economic evaluations was: what is the cost-effectiveness of 
antimicrobial-impregnated (nitrofurazone) or antiseptic-coated (silver alloy) catheter versus 
standard PTFE-coated catheter? The methods and analysis for both the within-trial analysis and 
the modelling analysis are described below. The perspective of study was that of the UK’s NHS.
Within-trial analysis
Measurement of resource utilisation
The use of health services was recorded prospectively for each participant. Resource utilisation 
data were collected using the questionnaires at baseline, 3 days after catheter removal, 1 week 
and 2 weeks after catheter removal, and at 6 weeks post randomisation. As noted earlier the 
questionnaires were targeted at identifying symptomatic antibiotic-treated UTI as well as 
other catheter-associated problems (e.g. urethral discomfort), QoL, and any health economic 
implications such as costs to the NHS. The areas of resource considered are outlined in Table 5 
and are grouped into four broad areas:
  ■ intervention resource use
  ■ other secondary care resource use
  ■ primary care resource use
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The number and type of catheter used were collected from the case report form. Use of secondary 
care services following the period of catheterisation was collected using the 6-week participant 
follow-up questionnaire. This recorded information on outpatient visits and readmissions 
to hospital for a UTI during the 6-week period after randomisation. The use of primary care 
services including contacts with primary care practitioners (e.g. GPs and practice nurses) 
and prescription medications were collected using the health-care utilisation questionnaires 
administered at 1 and 2 weeks after catheter removal and at 6 weeks after randomisation.
Derivation of costs
Unit costs were based on study-specific estimates and data from standard sources. A summary 
of unit costs is presented in Table 6. Unit costs for the interventions were obtained from the 
manufacturers of the products through personal communication or from published price lists. 
The unit cost per day in hospital for each level of care was obtained from Information Services 
Division (ISD) of NHS Scotland.71 This source does not give a cost per inpatient-day for all 
hospital services but rather presents data as a total cost per average case for each clinical specialty 
along with an average length of stay. We used these data to calculate ‘cost per day’ for each level 
of care. The total cost per case for each specialty provided by ISD includes both theatre costs and 
allocated costs (representing the costs of running the hospital). The former were omitted from 
our analyses, as we were not concerned with the costs of surgery undergone by trial participants 
(apart from the catheter unit cost) and we omitted the infrastructure costs, as they represent a 
fixed cost that will not vary with length of stay. The unit cost per case with these two elements 
removed was divided by the trial estimate of average length of stay for each specialty to give a 
cost per day. For example, the total gross cost per case in urology given by ISD was £2019 and 
TABLE 5  Resource use
Area of resource use Source Reported outcome
Intervention
Antimicrobial impregnated 
(nitrofurazone)
CRF No. used
Antiseptic coated (silver alloy) CRF No. used
PTFE CRF No. used
Days in hospital (by level of care)
Medical ward CRF No. of days
Urology CRF No. of days
Cardiothoracic CRF No. of days
General surgery CRF No. of days
Obstetrics and gynaecology CRF No. of days
Ear, nose and throat CRF No. of days
Orthopaedics CRF No. of days
Vascular CRF No. of days
Gastroenterology CRF No. of days
Other costs
Antibiotics prescribed after discharge PQ No. and type
Outpatient visits PQ No.
Practice nurse home and surgery visits PQ No.
Practice doctor home and surgery visits PQ No.
Other health-care professional visits PQ No. and type
CRF, study case report form; PQ, patient questionnaire.22 Methods
the direct theatre cost per case was £479 (22%). We estimated the unit cost per stay by taking 
the theatre cost per case away from the unit cost per stay and then removing the allocated costs. 
This figure was then divided by the trial estimate of average length of stay for this specialty 
(3.3 days) to give the trial estimate of cost per day of £321 for participants treated under this 
specialty group.
Total patient NHS costs were derived by combining information on resource use with 
information on the unit costs of those resources. For each area of resource use, estimates of 
resource utilisation were combined with unit costs to derive total costs for each item of resource 
use for each patient. Averages were then calculated to give estimates for each item of resource use. 
The patient-level costs for each item of resource were summed to produce a total cost for each 
patient and allow an estimate of average total cost per patient to be calculated.
Effectiveness outcomes for cost-effectiveness analysis
Effectiveness was measured in terms of number of catheter-associated symptomatic UTIs treated 
with antibiotics up to 6 weeks after randomisation (trial primary outcome) and QALYs at 
6 weeks.
Quality-adjusted life-years were derived using data from participant completion of the EQ-5D, 
a generic health status measurement tool, at baseline, 3 days after catheter removal, 1 and 
2 weeks after catheter removal and at 6 weeks post randomisation as part of the main study 
questionnaires. The EQ-5D measure divides health status into five dimensions (mobility, 
self-care, usual activities, pain/discomfort and anxiety/depression). Each of these dimensions 
can have three levels, giving 243 possible health states.72 These responses were converted into 
health–state utilities using UK population tariffs.73 The utility scores were used to estimate the 
mean QALY score for each of the three trial groups. The estimation of QALYs took into account 
the death of any study participants with allocation of a utility score of zero from date of death to 
the date of 6 weeks after randomisation for participants who died during their involvement in the 
trial. QALYs were estimated using linear extrapolation between the QALY scores at baseline and 
all available EQ-5D data.
Incremental cost per infection avoided and quality-adjusted 
life-year gained
Average costs per patient for each intervention were calculated and the described comparisons 
were made. Similarly, the average number of QALYs were calculated for each intervention 
and compared with the control. Data collected on costs and effects of the interventions were 
combined to obtain an incremental cost-effectiveness ratio (ICER). This was performed by 
dividing the mean difference in costs by the difference in effect between the interventions 
and control group. This provides the incremental cost per infection avoided or incremental 
cost per additional QALY gained for the new interventions relative to standard practice, i.e. 
∆C/∆E = ICER (where C = cumulative costs at 6 weeks and E = cumulative effects over 6 weeks).
Measures of variance for these costs, infections and QALYs were derived using bootstrapping.74 
From the results of the bootstrapping, cost-effectiveness acceptability curves (CEACs) were 
created. CEACs are used to represent whether or not the two novel interventions are cost-
effective at various threshold values for society’s willingness to pay for an infection avoided or 
additional QALY. CEACs present results when the analysis follows a net benefit approach. This 
approach utilises a straightforward rearrangement of the cost-effectiveness decision rule used 
when calculating ICERs (see below) to create the net monetary benefit (NMB). The NMB of the 
interventions in question is as shown below:
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where λ represents the decision-maker’s willingness to pay for an infection avoided or for a 
QALY gained. If the above expression holds true, the intervention is considered cost-effective. 
As society’s willingness to pay is unknown, the NMB will be calculated for a number of possible 
λ values, including the threshold value of £20,000–30,000 for a QALY that is often adopted by 
policy-makers within the NHS.75 The estimates of NMB at various threshold values for society’s 
willingness to pay for a unit of outcome are used to produce graphical and tabular representations 
of the CEAC.
TABLE 6  Average NHS unit costs
Area of resource use
Unit cost  
(£ sterling) Notes
Intervention
Antimicrobial impregnated 
(nitrofurazone)
5.29 Personal communication with manufacturer (cost includes VAT). This was the price to the 
NHS of the catheter at trial commencement (2007)
Antiseptic impregnated (silver alloy) 6.46 Personal communication with manufacturer (cost includes VAT). This was the price to the 
NHS of the catheter at trial commencement (2007)
PTFE 0.86 This was the price to the NHS of the catheter at trial commencement (2007)
Cost per day in hospital (by level of care)
Medical ward 265 Based on specialty group costs, inpatients in medical ward (excluding long stay) (ISD)
Neurology 498 Based on specialty group costs, inpatients in neurology department (excluding long stay) 
(ISD)
Urology 321 Based on specialty group costs, inpatients in urology department (excluding long stay) 
(ISD)
Cardiothoracic department 530 Based on specialty group costs, inpatients in cardiothoracic department (excluding long 
stay) (ISD)
General surgery 331 Based on specialty group costs, inpatients in general surgery department (excluding long 
stay) (ISD)
Obstetrics and gynaecology 337 Based on specialty group costs, inpatients in obstetrics and gynaecology department 
(excluding long stay) (ISD)
ENT 492 Based on specialty group costs, inpatients in ENT department (excluding long stay) (ISD)
Orthopaedics department 321 Based on specialty group costs, inpatients in orthopaedics department (excluding long 
stay) (ISD)
Vascular 305 Based on specialty group costs, inpatients in vascular department (excluding long stay) 
(ISD)
Gastroenterology 341 Based on specialty group costs, inpatients in gastroenterology department (excluding 
long stay) (ISD)
Other costs
Antibiotics 5.41 Cost of antibiotic based on the average cost of UTI prescriptions in Scotland (ISD)
Outpatient visit 94 Based on the total average total direct cost per attendance of all specialties outpatient 
consultant-led clinics (ISD)
Practice nurse visit 10 Based on cost per consultation (PSSRU)
GP visit 36 Based on per surgery consultation lasting average of 11.7 minutes (PSSRU)
Personal costs incurred by 
participants for visits to other health-
care professionals
Various As provided by the participants
ENT, ear, nose and throat; PSSRU, Personal Social Services Research Unit.24 Methods
Data analysis
As trial data were collected over a 6-week period no discounting was carried out. The number 
of missing data for variables used in the cost analysis was low, and data that were missing were 
therefore considered to be missing completely at random.
Subgroup analyses
Subgroup analyses similar to those described in Statistical methods/trial analysis examined 
possible modification of the cost-effectiveness results by the following characteristics:
  ■ age (< 60 years, ≥ 60 years)
  ■ sex
  ■ comorbidity (pre-existing urological disease, diabetes, immunosuppression)
  ■ duration of catheterisation (< 4 days, ≥ 4 days)
  ■ indication for catheterisation (incontinence, urine retention and monitoring purpose)
  ■ use of antibiotics in the last 7 days
  ■ use of antibiotics at catheterisation.
Effect modification was explored using tests for interaction (all at stricter levels of significance; 
p < 0.01), and results are cost differences with 99% CIs to reflect the exploratory nature of 
these analyses.
Sensitivity analysis
Sensitivity analysis was performed to gauge the impact of varying key assumptions and/or 
parameter values in the base-case analysis.
  ■ Sensitivity analysis around cost per day of hospital treatment. This analysis explored the 
impact of using an alternative source of unit cost data for the cost per day in hospital. 
Sensitivity analysis was performed using unit costs from other published sources, for 
example NHS reference costs.76
  ■ The base-case analysis was conducted using data that were adjusted for the characteristics 
mentioned above for the subgroup analyses. To indicate the importance of adjusting for these 
baseline factors a further analysis has been conducted using cost data that were not adjusted 
for any potential imbalance at baseline.
Model-based analysis
A decision-analytic model was developed to compare the different catheters in terms of the 
loss of QoL (based on the responses to the EQ-5D collected as part of the trial) and change in 
cost caused by a symptomatic catheter-associated UTI (Figure 3). In this modelling exercise, a 
comparison was drawn between the three different types of catheter (as shown in Figure 3). The 
trial-based analysis was expected to be characterised by considerable variation between patients 
in terms of both costs and QALYs. This was because, as noted above, participants within the 
trial were being treated for a variety of different conditions and the effect of these underlying 
conditions may have obscured or distorted the effect of the different catheters. Therefore, a 
modelling exercise was conducted which made the assumption that differences between the 
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Model-based analysis was performed from the perspective of the UK NHS. In this analysis it was 
assumed that the only difference in QoL was caused only by a symptomatic UTI and that the 
type of catheter did not affect QoL except by changing the risk of a symptomatic UTI occurring. 
Parameters used in the model included the costs of participants’ care, QALYs and the probability 
of having a symptomatic UTI. The costs and QALYs data required were derived from the within-
trial analysis and were estimated based on whether or not a participant had a symptomatic UTI.
Regression methods were used to estimate the QALYs for those with and without a symptomatic 
UTI. A similar approach was used to estimate costs associated with developing a symptomatic 
UTI compared with costs for those without an infection. The parameters required for the 
model were the risk of infection, the utilities associated with participants experiencing or not 
experiencing an infection, and management costs. Data to inform the model were derived from 
the within-trial analysis.
Data collected on costs and effects of the interventions were combined to obtain an ICER. This 
was performed by calculating the mean difference in costs between each intervention group and 
control, and dividing by the difference in effect between each intervention group and control. 
This generated the cost per QALY gained for the new interventions relative to standard practice, 
i.e. ∆C/∆E = incremental cost-effectiveness ratio (where C = cumulative costs at 6 weeks and 
E = cumulative effects over the same period). Measures of variance for these outcomes were 
estimated by bootstrapping estimates of costs and QALYs, and incremental cost per participant 
with UTI and per QALY. Incremental cost-effectiveness data are presented in terms of CEACs.
Sensitivity analysis
Parameter uncertainty was integrated by the incorporation of probability distributions into the 
model and using the Monte Carlo simulation. Other forms of uncertainty, such as that associated 
with cost estimates detailed in the within-trial analysis, were addressed by using the cost results 
of different samples from the study population, such as those who had an EQ-5D score of ‘1’ (full 
health) at 3 days and those participants treated on the obstetrics and gynaecology ward who were 
hypothesised to have experienced a homogeneous pathway of care. Other analyses considered 
the impact of basing costs and QALYs on whether or not a participant had experienced a 
symptomatic UTI at 3 days after catheter removal together with the impact of excluding 
inpatient costs.
PTFE
UTI
#
No UTI
PTFE_UTI
UTI
#
No UTI
Nitro_UTI
UTI
#
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Silver_UTI
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Chapter 4  
Participant baseline characteristics
Trial recruitment
In total, 7102 patients anticipated to require short-term catheterisation as part of their standard 
care were randomised from 24 hospitals over 40 months between July 2007 and October 2010. 
Figure 4 shows total recruitment from all sites over time and Table 7 shows the numbers recruited 
at each site and the number of months over which that site recruited.
Patient flow
The flow of participants through the trial is summarised in Figure 5, in line with 
recommendations of the Consolidated Standards of Reporting Trials (CONSORT) statement.77 
Included in the total of 7102 randomised participants were 905 participants randomised 
following unplanned catheterisations, of whom 385 subsequently refused consent to be involved 
in the trial and were thereby excluded. A further 45 participants withdrew consent before 
catheterisation and were excluded from the trial. In total, there were 708 post-randomisation 
exclusions, equally distributed throughout the groups, for reasons such as use of a suprapubic 
catheter or no catheterisation (e.g. due to cancellation of procedures or catheterisation not being 
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FIGURE 4  The CATHETER trial: recruitment over time.28 Participant baseline characteristics
deemed necessary by treating clinical staff), as well as the 385 who refused consent following 
unplanned catheterisation (Table 8); this reduced the number of participants included in the trial 
to 6394 – 90% of those randomised.
Baseline characteristics
As one would expect with a large sample size, the randomised groups were well balanced at 
baseline across all measured covariates (Table 9). Participants were drawn from a wide age range 
(17–92 years) with a median of 61 years. Women accounted for 62% of the trial population. 
Subgroups were pre-specified to identify those at a greater risk of developing a UTI. A total 
of 10% of participants had pre-existing urological disease or diabetes and 7% were receiving 
immunosuppressive therapy. In the baseline urine sample taken prior to catheterisation (MSSU 
84%) or at the time of catheterisation (CSU 16%), 8% of participants had ≥ 104 CFU/ml and 
27% had a pyuria with white blood cell (WBC) count of > 10/mm3 but were asymptomatic; 18% 
of participants had received antibiotics in the 7 days prior to randomisation for a variety of 
indications (Table 10).
TABLE 7  The CATHETER trial: recruitment by centre
Site  Ward specialties recruited
No. 
randomised
Percentage of total 
recruitment (7102)
Months 
recruiting
Aberdeen Royal Infirmary Cardiothoracic, general surgery, vascular, 
obstetrics and gynaecology
1421 20.0 40
Royal Blackburn Hospital & Burnley 
General Hospital
Obstetrics and gynaecology 109 1.5 7
Blackpool Victoria Hospital Cardiothoracic, obstetrics and gynaecology 203 2.9 16
Bristol Royal Infirmary Cardiothoracic, general surgery 6 0.1 5
Edinburgh Royal Infirmary Obstetrics and gynaecology 114 1.6 25
Guy’s Hospital, London Renal transplant 234 3.3 17
Harrogate District Hospital Obstetrics and gynaecology 4 0.1 5
Hillingdon Hospital General surgery, obstetrics and gynaecology 201 2.8 29
Hinchingbrooke Hospital Orthopaedics 64 0.9 10
Raigmore Hospital, Inverness Orthopaedics, general surgery 971 13.7 34
Liverpool Women’s Hospital Obstetrics and gynaecology 149 2.1 8
Newcastle General Hospital Neurosurgery, general surgery 869 12.2 29
Freeman Hospital, Newcastle Cardiothoracic 486 6.8 17
Royal Victoria Infirmary, Newcastle Obstetrics and gynaecology 312 4.4 10
Norfolk and Norwich University 
Hospital
Orthopaedics, obstetrics and gynaecology 42 0.6 8
North Tyneside General Hospital General surgery, urology, obstetrics and 
gynaecology, medical ward, orthopaedics
619 8.7 20
Nottingham City Hospital Orthopaedics, obstetrics and gynaecology 158 2.2 12
Queen Alexandra Hospital, 
Portsmouth
Obstetrics and gynaecology 151 2.1 7
Royal Preston Hospital Obstetrics and gynaecology 109 1.5 16
Southampton General Hospital Cardiothoracic 575 8.1 26
Sunderland Royal Hospital Obstetrics and gynaecology 64 0.9 24
Musgrove Park Hospital, Taunton General surgery, orthopaedics 33 0.5 14
Torbay Hospital General surgery, medical ward 90 1.3 9
Yeovil District Hospital General surgery, obstetrics and gynaecology 118 1.7 11
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Intervention received and descriptors of care
Table 10 contains details on the intervention received and aspects of in-hospital care. The main 
reason for catheterisation was for monitoring purposes during and after surgery. Duration 
of catheterisation and length of hospital stay were similar across all three groups, as was the 
proportion of participants receiving antibiotics for surgical prophylaxis.
Response 1815 1765 1807
Non-response 218 237 241
Declined further follow-up 78 65 68
Death 42 30 28
Completion of 6-week post-randomisation follow-up
Included in primary outcome analysisb
Did not receive allocated cathetera
Received allocated catheter 2008 1994 2120
Median (IQR) participants per centre
Number of centres 23 24 24
Included 2153 2097 2144
Post-randomisation exclusion 258 225 225
Number allocated 2411 2322 2369
Nitrofurazone
Total randomised n = 7102
PTFE Silver alloy
48 (27,134) 45 (21,120) 50 (27,135)
24 103 145
2144 2097 2153
FIGURE 5  Consort diagram. a, Generally participants underwent catheterisation in the operating suite. In 272 (4.3%) of 
cases an alternative catheter to that allocated by randomisation was inserted mainly due to error by clinical staff. b, We 
achieved verification of the primary outcome for all participants. A total of 907 (14%) participants did not complete the 
planned 6-week post-randomisation follow-up (see Table 12).
TABLE 8  Reasons for post-randomisation exclusions
Reason for post-randomisation exclusion (n) Nitrofurazone (n = 258) Silver alloy (n = 225) PTFE (n = 225)
Consent not givena or withdrawn 160 138 132
Suprapubic catheter 10 15 9
Not catheterised 77 60 72
Missed 1 4 1
Other reason 5 1 4
Patient died 1 0 0
No reason 4 7 7
a  Participants undergoing unplanned catheterisation who were randomised but subsequently refused consent to trial participation.30 Participant baseline characteristics
Over 93% of participants in each arm received the catheter to which they were allocated. In the 
majority of cases where the allocated catheter was not used, this was due to theatre staff inserting 
a standard PTFE catheter in error. Analyses were by catheter allocated (intention to treat).
Descriptive data for duration of catheterisation showed a mean of 2.78 days in the nitrofurazone 
group, 2.95 days in the silver alloy group and 2.85 days in the PTFE control group, whereas the 
median was the same in all groups at 2 days. A total of 219 (3.43%) participants experienced a 
duration of catheterisation of > 14 days with 79 (3.67%) in the nitrofurazone group, 73 (3.48%) 
in the silver alloy group and 67 (3.13%) in the control group. Hospital stay varied widely, with a 
TABLE 9  Baseline characteristics
Nitrofurazone (n = 2153) Silver alloy (n = 2097) PTFE (n = 2144)
Age (n) 2152 2096 2143
  Mean (SD) 58.46 (16.15) 58.95 (15.82) 58.84 (15.97)
  Median (IQR) 61 (47 to 71) 61 (47 to 72) 61 (47 to 72)
  (min., max.) (17, 91) (17, 92) (18, 91)
Sex (n) 2152 2097 2143
 Female 1333 (61.9) 1319 (62.9) 1325 (61.8)
Pre-existing urological disease (n) 2138 2084 2136
 Yes 214 (10.0) 196 (9.4) 214 (10.0)
Diabetes (n) 2138 2083 2136
 Yes 197 (9.2) 207 (9.9) 216 (10.1)
Immune suppression (n) 2137 2079 2132
 Yes 135 (6.3) 144 (6.9) 151 (7.1)
Urine sample: n 2074 2002 2057
 MSSU 1735 (83.7) 1709 (85.4) 1721 (83.7)
 CSU 339 (16.3) 293 (14.6) 336 (16.3)
No. of CFU/ml: n 2071 1998 2054
  < 104 1923 (92.9) 1830 (91.6) 1901 (92.6)
 104 64 (3.1) 71 (3.6) 69 (3.4)
  ≥ 105 84 (4.1) 97 (4.9) 84 (4.1)
Pyuria (n) 2074 2002 2057
  < 10 WBC/mm 1521 (73.3) 1446 (72.2) 1499 (72.9)
  > 10 WBC/mm 553 (26.7) 556 (27.8) 558 (27.1)
EQ-5D (n) 2127 2076 2123
  Mean (SD) 0.717 (0.292) 0.723 (0.291) 0.722 (0.299)
  Median (IQR) 0.796 (0.689 to 0.883) 0.796 (0.656 to 1) 0.812 (0.689 to 1.00)
  (min., max.) (–0.594, 1) (–0.594, 1) (–0.594, 1)
EQ-5D VAS (n) 2132 2076 2118
  Mean (SD) 70.4 (21.1) 71.0 (20.2) 70.6 (21.4)
  Median (IQR) 75 (60 to 88) 75.00 (60 to 90) 75.00 (55 to 90)
  (min., max.) (0, 100) (0, 100) (0, 100)
Symptom severity (n) 2143 2088 2136
  Mean (SD) 1.98 (2.64) 1.88 (2.50) 1.83 (2.49)
  Median (IQR) 1 (0 to 3) 1.00 (0 to 3) 1.00 (0 to 3)
  (min., max.) (0, 16) (0, 21) (0, 16)
IQR, interquartile range; max., maximum; min., minimum; VAS, visual analogue scale.
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markedly skewed distribution; the median was 6 days in each group, but the upper extreme of the 
range varied, with the longest stay being 159 days (see Table 10).
Allocation of participants to the three trial groups was equal across all centres (Table 11).
Response rates
Participant response rates are shown in Table 12. Response rates were similar across the three 
trial arms, with overall response rates of 88% for the 3 days post catheter removal questionnaire, 
72% and 71% for the 1 and 2 weeks post catheter removal diaries and 84% for the questionnaire 
at 6 weeks post randomisation.
Denominators reflect the number of participants that were included in the analysis for specific 
aspects of the data and reflect the response to the individual question.
TABLE 10  Intervention received and in-hospital care
Nitrofurazone (n = 2153) Silver alloy (n = 2097) PTFE (n = 2144)
Reason for catheterisation (n) 2095 2057 2091
  Unplanned emergency 94 (4.5) 94 (4.6) 89 (4.3)
  Elective monitoring 2001 (95.5) 1963 (95.4) 2002 (95.7)
Antibiotics in 7 days prior to randomisation (n) 2153 2097 2144
 Yes 396 (18.4) 370 (17.6) 385 (18.0)
Antibiotic at the time of catheterisation (n) 2153 2097 2144
 Yes 1537 (71.4) 1529 (72.9) 1547 (72.2)
Type of catheter used (n) 2153 2097 2144
 Nitrofurazone 2008 (93.3) 11 (0.5) 8 (0.4)
  Silver alloy 22 (1.0) 1994 (95.1) 16 (0.7)
 PTFE 123 (5.7) 92 (4.4) 2120 (98.9)
Duration of catheterisation (days) (n) 2100 2048 2100
  Mean (SD) 2.78 (3.3) 2.95 (3.6) 2.85 (3.3)
  Median (IQR) 2 (1 to 3) 2 (1 to 3) 2 (1 to 3)
  (min., max.) (1, 42) (1, 65) (1, 45)
Duration of hospitalisation (days) (n) 2105 2046 2102
  Mean (SD) 7.43 (8.0) 8.03 (9.3) 7.76 (8.3)
  Median (IQR) 6 (3 to 8) 6 (3 to 9) 6 (3 to 9)
  (min., max.) (1, 159) (1, 154) (1, 105)
IQR, interquartile range; max., maximum; min., minimum. 
Numbers in cells are n (%) unless otherwise stated.32 Participant baseline characteristics
TABLE 11  Participants randomised and included by centre
Centre Nitrofurazone (n = 2153) Silver alloy (n = 2097) PTFE (n = 2144)
Aberdeen Royal Infirmary 430 (20.0) 459 (21.9) 434 (20.2)
Royal Blackburn Hospital & Burnley General Hospital 40 (1.9) 33 (1.6) 36 (1.7)
Blackpool Victoria Hospital 64 (3.0) 69 (3.3) 69 (3.2)
Bristol Royal Infirmary 3 (0.1) 1 (0.0) 2 (0.1)
Edinburgh Royal Infirmary 42 (2.0) 36 (1.7) 28 (1.3)
Guy’s Hospital, London 75 (3.5) 72 (3.4) 81 (3.8)
Harrogate District Hospital 0 (0.0) 3 (0.1) 1 (0.0)
Hillingdon Hospital 72 (3.3) 60 (2.9) 66 (3.1)
Hinchingbrooke Hospital 22 (1.0) 20 (1.0) 14 (0.7)
Raigmore Hospital, Inverness 270 (12.5) 269 (12.8) 243 (11.3)
Liverpool Women’s Hospital 57 (2.6) 46 (2.2) 45 (2.1)
Newcastle General Hospital 250 (11.6) 240 (11.4) 264 (12.3)
Freeman Hospital, Newcastle 155 (7.2) 147 (7.0) 165 (7.7)
Royal Victoria Infirmary, Newcastle 95 (4.4) 95 (4.5) 113 (5.3)
Norfolk and Norwich University Hospital 14 (0.7) 5 (0.2) 9 (0.4)
North Tyneside General Hospital 156 (7.2) 144 (6.9) 155 (7.2)
Nottingham City Hospital 46 (2.1) 47 (2.2) 51 (2.4)
Queen Alexandra Hospital, Portsmouth 50 (2.3) 43 (2.1) 51 (2.4)
Royal Preston Hospital 34 (1.6) 37 (1.8) 36 (1.7)
Southampton General Hospital 189 (8.8) 187 (8.9) 178 (8.3)
Sunderland Royal Hospital 18 (0.8) 16 (0.8) 29 (1.4)
Musgrove Park Hospital, Taunton 8 (0.4) 10 (0.5) 6 (0.3)
Torbay Hospital 27 (1.3) 22 (1.0) 26 (1.2)
Yeovil District Hospital 36 (1.7) 36 (1.7) 42 (2.0)
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TABLE 12  Participant status at each time point
Time point Nitrofurazone: n = 2153 Silver alloy: n = 2097 PTFE: n = 2144
Three days
Death 12 (0.6) 9 (0.4) 11 (0.5)
Declined further follow-up 59 (2.7) 39 (1.9) 50 (2.3)
Non-response  188 (8.7) 209 (10.0) 177 (8.3)
Response 1894 (88.0) 1840 (87.7) 1906 (88.9)
One week
Death 26 (1.2) 23 (1.1) 22 (1.0)
Declined further follow-up 75 (3.5) 57 (2.7) 64 (3.0)
Non-response 488 (22.7) 526 (25.1) 491 (22.9)
Response 1564 (72.6) 1491 (71.1) 1567 (73.1)
Two weeks
Death 27 (1.3) 23 (1.1) 23 (1.1)
Declined further follow-up 75 (3.5) 57 (2.7) 64 (3.0)
Non-response 503 (23.4) 556 (26.5) 505 (23.6)
Response 1548 (71.9) 1461 (69.7) 1552 (72.4)
Six weeks
Death 42 (2.0) 30 (1.4) 28 (1.3)
Declined further follow-up 78 (3.6) 65 (3.1) 68 (3.2)
Non-response  218 (10.1) 237 (11.3) 241 (11.2)
Response 1815 (84.3) 1765 (84.2) 1807 (84.3)
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Chapter 5  
Outcomes and results
Primary outcome
The incidence of the primary outcome at any time up to 6 weeks post randomisation (number of 
participants with at least one occurrence of symptomatic UTI treated with antibiotics) was 10.6% 
(228/2153) and 12.5% (263/2097) in the nitrofurazone and silver alloy groups, respectively. The 
rate of symptomatic UTI in the PTFE control catheter group was 12.6% (271/2144). Table 13 
contains the estimated ORs and 97.5% CIs, for both the raw data and those adjusted using logistic 
regression models. The estimated absolute risk reduction between nitrofurazone and PTFE was 
2.1% (97.5% CI –0.1% to 4.2%). Between the silver alloy and PTFE this was estimated as 0.1% 
(97.5% CI –2.2% to 2.4%). Table 13 contains the estimated ORs and 97.5% CIs from unadjusted 
and adjusted logistic regression models. The full logistic regression model for the primary 
outcome can be found in Appendix 6.
Secondary outcomes
The incidence of a symptomatic UTI with a prescription of antibiotics within 6 weeks of 
randomisation (primary outcome), together with the additional criterion of an associated 
microbiologically positive urine result (≥ 104 CFU/ml) during the 6 weeks post randomisation 
was 3.2% in the nitrofurazone group, 5.0% in the silver alloy group and 4.6% in the PTFE control 
catheter group. ORs and CIs are presented in Table 14.
TABLE 13  Primary outcome: symptomatic antibiotic-treated UTI within 6 weeks of randomisation
Estimate Nitrofurazone (n = 2153) Silver alloy (n = 2097) PTFE (n = 2144)
Incidence n (%) 228 (10.6) 263 (12.5) 271 (12.6)
Absolute risk difference (97.5% CI) compared 
with PTFE, expressed as a percentage
–2.1 (–4.2 to 0.1) –0.1 (–2.4 to 2.2)
Comparison
OR (97.5% CI); p-value
Nitrofurazone vs PTFE
Unadjusted 0.82 (0.66 to 1.01); 0.037
Adjusted 0.81 (0.65 to 1.01); 0.031
Silver alloy vs PTFE
Unadjusted 0.99 (0.81 to 1.22); 0.92
Adjusted 0.96 (0.78 to 1.19); 0.69
OR < 1 favours catheter type listed first. Adjusted models corrected for age, sex, comorbidity, indication for catheterisation and antibiotic use prior 
to catheterisation. Analysis by intention to treat.36 Outcomes and results
The incidence of antibiotic-treated symptomatic UTI within 3 days post catheter removal, 
together with a positive urinary microbiology result, was 0.7% in the nitrofurazone group, 1.7% 
in the silver alloy group and 1.3% in the PTFE group. ORs and CIs are presented in Table 15.
Tertiary clinical outcomes
Incidence of bacteriuria at, or within, 3 days of catheter removal
The rate of bacteriuria at 3 days post catheterisation was 13.5% (249/1846) in the nitrofurazone 
group, 17.4% (310/1785) in the silver alloy group and 17.5% (321/1839) in the PTFE control 
catheter group. Estimates of ORs and CIs from adjusted and unadjusted logistic regression 
models are presented in Table 16. The estimated absolute risk reduction between the 
nitrofurazone and PTFE catheters was 3.5% (97.5% CI 0.8 to 6.1). Between the silver alloy and 
PTFE this was estimated as an increase of 0.4% (97.5% CI –3.2 to 2.4).
TABLE 14  Secondary outcome: microbiologically confirmed symptomatic UTI treated with antibiotics any time up to 6 
weeks post randomisation
Estimate Nitrofurazone (n = 2153) Silver alloy (n = 2097) PTFE (n = 2144)
Incidence n (%) 69 (3.2) 105 (5.0) 99 (4.6)
Absolute risk difference (97.5% CI) compared with 
PTFE, expressed as a percentage
–1.4 (–2.7 to –0.1) 0.4 (–1.2 to 1.9)
Comparison
OR (97.5% CI); p-value
Nitrofurazone vs PTFE
Unadjusted 0.68 (0.48 to 0.99); 0.017
Adjusted 0.68 (0.47 to 0.98); 0.019
Silver alloy vs PTFE
Unadjusted 1.08 (0.78 to 1.52); 0.55
Adjusted 1.09 (0.78 to 1.51); 0.58
OR < 1 favours catheter type listed first. Adjusted models corrected for age, sex, comorbidity, indication for catheterisation and antibiotic use prior 
to catheterisation. Analysis by intention to treat.
TABLE 15  Secondary outcome: microbiologically confirmed symptomatic antibiotic-treated UTI at 3 days after 
catheter removal
Estimate Nitrofurazone (n = 2153) Silver alloy (n = 2097) PTFE (n = 2144)
Incidence n (%) 15 (0.7) 35 (1.7) 28 (1.3)
Absolute risk difference (97.5% CI) compared with 
PTFE, expressed as a percentage
–0.6 (–1.3 to 0.1) 0.3 (–0.4 to 1.2)
Comparison
OR (97.5%CI); p-value
Nitrofurazone vs PTFE
Unadjusted 0.53 (0.24 to 1.12); 0.049
Silver alloy vs PTFE
Unadjusted 1.28 (0.70 to 2.36); 0.33
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Symptomatic urinary tract infection at 3 days of catheter removal
The rate of symptomatic UTI with a prescription of antibiotics at 3 days post catheter removal 
was 4.9% (106/2153) in the nitrofurazone group, 6.6% (137/2079) in the silver alloy group and 
5.9% (127/2144) in the PTFE control catheter group. Estimates of ORs and CIs from adjusted and 
unadjusted logistic regression models are presented in Table 17 below. The estimated absolute 
risk reduction between the nitrofurazone and PTFE catheters was 1.0% (97.5% CI –0.6 to 2.5). 
Between the silver alloy and PTFE this was estimated as an increase of 0.6% (97.5% CI 1.1 to 
–2.3). Table 17 contains the estimated ORs and 97.5% CIs from unadjusted and adjusted logistic 
regression models.
TABLE 16  Tertiary outcome: bacteriuria detected by urine culture within 3 days of catheter removal
Estimate Nitrofurazone (n = 1846) Silver alloy (n = 1785) PTFE (n = 1839)
Incidence n (%) 249 (13.5) 310 (17.4) 321(17.5)
Absolute risk difference (97.5% CI) compared with 
PTFE, expressed as a percentage
–3.5% (–6.1 to –0.8) 0.4% (–2.4 to 3.2) –
Comparison
OR (97.5% CI); p-value
Nitrofurazone vs PTFE
Unadjusted 0.74 (0.60 to 0.91); 0.001
Adjusted 0.73 (0.59 to 0.90); 0.001
Silver alloy vs PTFE
Unadjusted 0.99 (0.82 to 1.21); 0.944
Adjusted 0.99 (0.81 to 1.21); 0.887
OR < 1 favours catheter type listed first. Adjusted models corrected for age, sex, comorbidity, indication for catheterisation and antibiotic use prior 
to catheterisation. Analysis by intention to treat.
TABLE 17  Tertiary outcome: symptomatic UTI within 3 days of catheter removal
Estimate Nitrofurazone (n = 2153) Silver alloy (n = 2097) PTFE (n = 2144)
Incidence n (%) 106 (4.9) 137 (6.6) 127 (5.9)
Absolute risk difference (97.5% CI) compared with 
PTFE, expressed as a percentage
1.0 (–2.5 to 0.6) 0.6 (–2.3 to 1.1)
Comparison
OR (97.5% CI); p-value
Nitrofurazone vs PTFE
Unadjusted 0.82 (0.61 to 1.11); 0.144
Adjusted 0.81 (0.59 to 1.10); 0.123
Silver alloy vs PTFE
Unadjusted 1.12 (0.84 to 1.49); 0.369
Adjusted 1.09 (0.82 to 1.46); 0.502
OR < 1 favours catheter type listed first. Adjusted models corrected for age, sex, comorbidity, indication for catheterisation and antibiotic use prior 
to catheterisation. Analysis by intention to treat.38 Outcomes and results
Three-day symptom score
The three-day symptom score was the sum of ratings from ‘0’ (no symptoms) to ‘3’ (severe 
symptoms) for seven symptoms of UTI. The minimum score was therefore ‘0’ and the highest 
score was ‘21’, with a higher score indicating more severe symptoms. The proportion of 
participants within each study group who completed this score was similar, averaging 87%.
There was no statistically significant difference between either nitrofurazone or silver alloy 
catheters compared with control in terms of self-reported symptoms at 3 days (Table 18). A 
sensitivity analysis using multiple imputations did not change these results.
Catheter discomfort
There were no significant differences in self-reported discomfort between each of the 
interventional catheters and the control catheter reported at the stage of catheter insertion 
(Table 19).
TABLE 18  Tertiary outcome: overall rating of symptoms 3 days post catheter removal
Category
Nitrofurazone (n = 1857) Silver (n = 1794) PTFE (n = 1859)
n % n % n %
No discomfort 1257 67.7 1231 68.6 1306 70.3
Mild 423 22.8 419 23.4 412 22.2
Moderate 145 7.8 111 6.2 113 6.1
Severe 32 1.7 33 1.8 28 1.5
ORs from proportional odds model
OR (97.5% CI) 1.14 (0.98 to 1.35) 1.08 (0.93 to 1.28)
Difference in estimated percentage in each category and 97.5% CI compared with PTFE
No discomfort –3.0 (–6.4 to 0.5) –1.8 (–5.3 to 1.7)
Mild 1.9 (–0.4 to 4.2) 1.2 (–1.1 to 3.5)
Moderate 0.8 (–0.2 to 1.7) 0.5 (–0.5 to 1.4)
Severe 0.2 (0.0 to 5.0) 0.1 (–0.1 to 0.4)
TABLE 19  Tertiary outcome: self-reported discomfort for the process of inserting the catheter
Category
Nitrofurazone (n = 1834) Silver (n = 1794) PTFE (n = 1865)
n % n % n %
No discomfort 1729 94.3 1710 95.3 1773 95.1
Mild 80 4.4 58 3.2 78 4.2
Moderate 16 0.9 16 0.9 10 0.5
Severe 9 0.5 10 0.6 4 0.2
ORs from proportional odds model
OR (97.5% CI) 1.18 (0.84 to 1.65) 0.97 (0.68 to 1.39)
Difference in estimated percentage in each category and 97.5% CI compared with PTFE 
No discomfort –0.7 (–2.1 to 0.8) 0.1 (–1.3 to 1.5)
Mild 0.5 (–0.6 to 1.7) –0.1 (–2.1 to 1.0)
Moderate 0.1 (–0.1 to 0.3) 0 (–0.2 to 0.2)
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Participants randomised to nitrofurazone catheters were 5.3% (97.5% CI 2.1% to 8.4%) less likely 
to report no discomfort during the period of catheterisation (Table 20). Those randomised to 
silver catheters were more likely to report no discomfort: 3.3% (97.5% CI 0.3% to 6.3%).
At catheter removal, participants in the nitrofurazone group were 12.3% (8.8% to 15.8%) less 
likely than participants in the PTFE group to report having no discomfort (Table 21). They were 
more likely to rate discomfort during catheter removal as mild, moderate or severe. There was no 
significant difference in discomfort during catheter removal between the silver alloy and PTFE 
catheters, 2.3% (97.5% CI –1.1% to 5.6%).
There were no significant differences between interventional and control catheter groups in self-
reported discomfort in the period after the catheter was removed (Table 22). Multiple imputation 
of missing responses did not change any results of analyses of self-reported discomfort data.
TABLE 20  Self-reported discomfort for the period the catheter was in place
Category
Nitrofurazone (n = 1879) Silver (n = 1829) PTFE (n = 1889)
n % n % n %
No discomfort 1383 73.6 1507 82.4 1493 79.0
Mild 384 20.4 252 13.8 307 16.3
Moderate 77 4.1 44 2.4 66 3.5
Severe 35 1.9 26 1.4 23 1.2
ORs from proportional odds model
OR (97.5% CI) 1.34 (1.13 to 1.6) 0.81 (0.67 to 0.97)
Difference in estimated percentage in each category and 97.5% CI compared with PTFE 
No discomfort –5.3 (–8.4 to –2.1) 3.3 (0.3 to 6.3)
Mild 3.8 (1.5 to 6.1) –2.5 (–4.7 to –0.2)
Moderate 1.0 (0.4 to 1.6) –0.6 (–1.1 to –0.1)
Severe 0.5 (0.2 to 0.8) –0.3 (–0.5 to 0.0)
TABLE 21  Self-reported discomfort for the process of catheter removal
Category
Nitrofurazone (n = 1867) Silver (n = 1817) PTFE (n = 1881)
n % n % n %
No discomfort 1160 62.1 1296 71.3 1382 73.5
Mild 530 28.4 442 24.3 431 22.9
Moderate 126 6.7 65 3.6 56 3.0
Severe 51 2.7 14 0.8 12 0.6
ORs from proportional odds model
OR (97.5% CI) 1.77 (1.51 to 2.07) 1.12 (0.95 to 1.32)
Difference in estimated percentage in each category and 97.5% CI compared with PTFE
No discomfort –12.3 (–15.8 to –8.8) –2.3 (–5.6 to 1.1)
Mild 9.2 (6.6 to 11.9) 1.8 (–0.9 to 4.4)
Moderate 2.3 (1.6 to 3.1) 0.4 (–0.2 to 1.0)
Severe 0.8 (0.5 to 1.2) 0.1 (–0.1 to 0.3)40 Outcomes and results
Secondary economic outcome measures
Quality of life
Health-related QoL was measured using the EQ-5D. Response rates were low, at 63%, for diaries 
completed 1 week after catheter removal, which participants took home from hospital to return 
by post. However, response rates improved at the 6-week post-randomisation time point, at 
which 80% of trial participants returned the questionnaire containing the EQ-5D questions.
Table 23 and Figure 6 show that EQ-5D scores followed the same pattern in each group, with 
no evidence of a difference between the groups. Incorporating a time by treatment interaction 
showed that treatment effects were not different over time and these terms were dropped from 
the model for ease of interpretation. The mean (97.5% CI; p-value) difference in EQ-5D score 
between the nitrofurazone and PTFE groups was –0.001 (97.5% CI –0.022 to 0.003; 0.15), 
and for the silver alloy group compared with the PTFE group was –0.012 (97.5% CI –0.025 to 
0.001; 0.07).
The EQ-5D visual analogue scale (VAS) followed an almost identical pattern (Table 24 and 
Figure 7).
Significant clinical events
Significant clinical events are presented in Table 25. There were two cases of septicaemia in the 
trial; neither was due to catheterisation, with both being due to infections acquired from the 
participants’ intravenous line.
TABLE 22  Self-reported discomfort for the period since catheter removal
Category
Nitrofurazone (n = 1866) Silver (n = 1810) PTFE (n = 1881)
n % n % n %
None 1659 88.9 1620 89.5 1696 90.2
Mild 143 7.7 139 7.7 146 7.8
Moderate 54 2.9 35 1.9 24 1.3
Severe 10 0.5 16 0.9 15 0.8
ORs from proportional odds model
OR (97.5% CI) 1.15 (0.90 to 1.46) 1.08 (0.85 to 1.39)
Difference in estimated percentage in each category and 97.5% CI compared with PTFE 
None –1.3 (–3.5 to 1.0) –0.7 (–3.0 to 1.5)
Mild 0.9 (–0.7 to 2.5) 0.5 (–1.1 to 2.1)
Moderate 0.3 (–0.2 to 0.7) 0.2 (–0.3 to 0.6)
Severe 0.1 (–0.1 to 0.3) 0.1 (–0.1 to 0.2)
TABLE 23  European Quality of Life-5 Dimensions scores over time
Follow-up time point Nitrofurazone (n = 2153) Silver alloy (n = 2097) PTFE (n = 2144)
Baseline 2127, 0.717 (0.292) 2076, 0.723 (0.291) 2123, 0.722 (0.299)
3 days 1860, 0.592 (0.274) 1801, 0.579 (0.281) 1871, 0.593 (0.271)
1 week 1363, 0.619 (0.272) 1308, 0.602 (0.292) 1366, 0.614 (0.270)
2 weeks 1405, 0.696 (0.259) 1328, 0.687 (0.270) 1398, 0.695 (0.248)
6 weeks 1705, 0.777 (0.243) 1665, 0.783 (0.240) 1721, 0.795 (0.234)
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Subgroup analysis
The following subgroups analyses were performed to establish whether or not any risk or 
protective factors influenced rates of UTI in the trial groups:
  ■ sex
  ■ older age
  ■ comorbidity (immune suppression)
  ■ indication for catheterisation
  ■ antibiotic use prior to randomisation.
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FIGURE 6  Plot of EQ-5D scores over time. Bars are mean ± 1 SD. Note that the relative timing of responses compared 
with baseline varied for the 3-day, and 1- and 2-week time points and labels are notional only, for illustration.
TABLE 24  European Quality of Life-5 Dimensions VAS
Follow-up time point Nitrofurazone (n = 2153) Silver alloy (n = 2097) PTFE (n = 2144)
Baseline 2132, 70.46 (21.00) 2118, 70.94 (20.15) 2076, 70.61 (21.30)
3 days 1866, 65.09 (18.59) 1881, 65.20 (18.40) 1810, 64.94 (18.60)
1 week 1389, 68.80 (17.48) 1366, 68.06 (18.26) 1317, 68.21 (18.20)
2 weeks 1416, 75.01 (17.12) 1403, 74.53 (18.05) 1338, 74.62 (17.40)
6 weeks 1761, 78.47 (17.37) 1768, 78.30 (16.95) 1717, 78.53 (17.25)
Cell contents are valid n, mean (SD); higher score is better.42 Outcomes and results
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TABLE 25  Significant clinical events
Significant clinical events n (%) Nitrofurazone (n = 2153) Silver alloy (n = 2097) PTFE (n = 2144)
Haematuria 38 (1.8) 21 (1.0) 32 (1.5)
Septicaemiaa – 1 (< 0.1) 1 (< 0.1)
a  Unrelated to urethral catheterisation.
For most outcomes there was no apparent differential treatment effect between subgroups 
(Figures 8 and 9). The only potential exception to this was antibiotic use in the 7 days prior to 
randomisation, where there was marginal evidence that participants subsequently randomised to 
nitrofurazone who had received antibiotics in the previous 7 days had a greater incidence of UTI 
at any time up to 6 weeks after randomisation.
It is clear from Figure 10 the probability of suffering a catheter-associated UTI increased with age. 
The interaction between age and catheter type was not significant; there was no evidence that 
treatment effects were modified by age. The p-value for age-by-nitrofurazone and age-by-silver 
was 0.53 and 0.65, respectively.
As expected the probability of UTI increased with duration of catheterisation (Figure 11). The 
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that treatment effects were modified by duration of catheter. The p-value for duration-by-
nitrofurazone and duration-by-silver was 0.19 and 0.87, respectively.
Centre effect
Adjusting for centre by including a random effect for centre (Table 26, third column) had 
negligible effect on fixed-treatment-effect estimates (see Table 26, second column) and CIs for 
both the marginal adjusted and unadjusted models.
OR (99% CI)
Female 0.78 (0.59 to 1.04)
Male 0.93 (0.56 to 1.52)
> 60 years 0.75 (0.54 to 1.05)
< 60 years 0.91 (0.63 to 1.31)
Comorbidity – no 0.76 (0.58 to 1.01)
Comorbidity – yes 1.03 (0.62 to 1.72)
Catheterisation for monitoring 0.80 (0.62 to 1.03)
Catheterisation for emergency 1.03 (0.34 to 3.12)
Antibiotic use last 7 days – no 0.70 (0.53 to 0.94)
Antibiotic use last 7 days – yes 1.27 (0.78 to 2.09)
Antibiotic at catheterisation – no 0.76 (0.47 to 1.23)
Antibiotic at catheterisation – yes 0.84 (0.63 to 1.12)
3.2 0.3 2.25 1.75 1.25 1 0.67 0.5 0.4
OR (99% Cl)
OR (99% CI)
Female 0.95 (0.72 to 1.26)
Male 1.07 (0.66 to 1.75)
> 60 years 0.89 (0.65 to 1.23)
< 60 years 1.13 (0.79 to 1.60)
Comorbidity – no 0.96 (0.74 to 1.26)
Comorbidity – yes 1.09 (0.65 to 1.80)
Catheterisation for monitoring 0.98 (0.77 to 1.26)
Catheterisation for emergency 1.03 (0.34 to 3.12)
Antibiotic use last 7 days – no 0.92 (0.70 to 1.21)
Antibiotic use last 7 days – yes 1.27 (0.77 to 2.10)
Antibiotic at catheterisation – no 0.90 (0.56 to 1.45)
Antibiotic at catheterisation – yes 1.01 (0.76 to 1.33)
3.2 0.3 2.25 1.75 1.25
OR (99% Cl)
1 0.67 0.5 0.4
FIGURE 8  Forest plot of subgroup analyses, UTI at any point up to 6 weeks post randomisation for nitrofurazone vs 
PTFE comparison.
FIGURE 9  Forest plot of subgroup analyses, UTI at any point up to 6 weeks post randomisation for silver alloy vs PTFE 
comparison.44 Outcomes and results
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FIGURE 10  Plot of predicted probability of UTI at any point up to 6 weeks post randomisation by age (in years) and 
allocated catheter.
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FIGURE 11  Plot of predicted probability of UTI at any point up to 6 weeks post randomisation by duration of 
catheterisation (in days) and allocated catheter.
TABLE 26  Statistical exploration of centre interaction effect with primary outcome
Comparison
OR (97.5% CI); p-value
Fixed effects Random effects
Nitrofurazone vs PTFE
Unadjusted 0.82 (0.66 to 1.01); 0.037 0.83 (0.69 to 1.02); 0.039
Adjusted 0.81 (0.65 to 1.01); 0.031 0.83 (0.68 to 1.02); 0.045
Silver alloy vs PTFE
Unadjusted 0.99 (0.81 to 1.22); 0.92 1.00 (0.84 to 1.22); 0.88
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Chapter 6  
Resource use, costs and cost-effectiveness
Within-trial analysis
It was planned to conduct a within-trial analysis to estimate the incremental cost per infection 
averted and incremental cost per QALY gained for the two randomised comparisons: 
nitrofurazone compared with PTFE and silver alloy compared with PTFE. As is described 
below, these analyses are not reported in the main body of the report because of concerns that 
the estimates of costs and to a lesser extent effectiveness as measured by participant response to 
the EQ-5D derived from within the trial comparison were unreliable. The planned ‘within-trial’ 
analyses are therefore not reported in the main body of the report but are included as Appendix 7. 
In this section we report the within-trial data describing resource use, costs and QALYs. We 
have refrained from reporting comparisons between randomised groups, except to illustrate the 
reasoning behind our decision that such comparisons are surrounded by sufficient uncertainty to 
make any interpretation hazardous.
Analysis of resource use and costs
Table 27 details the average resource use for the three randomised groups. As this table shows, the 
use of health services was generally similar. The exception to this is differences in length of stay 
where mean differences between nitrofurazone and PTFE groups may be economically important 
(see Appendix 7, Table 44).
TABLE 27  NHS resource use for each trial intervention
Resource type Nitrofurazone: n, mean (SD) Silver alloy: n, mean (SD) PTFE: n, mean (SD)
Intervention
No. of catheters used 2153, 1.03 (0.21) 2097, 1.04 (0.29) 2144, 1.03 (0.21)
Secondary care resource use
Length of stay (days) 2104, 7.27 (6.58) 2047, 7.72 (6.87) 2102, 7.57 (7.00)
No. of outpatient visits  1668, 0.02 (0.28) 1614, 0.02 (0.17) 1671, 0.02 (0.19)
No. of visits to other providers 1656, 0.02 (0.41) 1605, 0.01 (0.14) 1662, 0.01 (0.20)
No. of inpatient readmissions 1669, 0.08 (1.26) 1605, 0.01 (0.24) 1673, 0.02 (0.54)
Primary care resource use
Primary care doctor visit 1661, 0.11 (0.44) 1605, 0.13 (0.47) 1659, 0.12 (0.45)
Primary care nurse visit 1667, 0.03 (0.27) 1606, 0.04 (0.34) 1669, 0.05 (1.05)
Medications
Treatment course of antibiotics for UTIa 1160, 0.18 (0.38) 1130, 0.18 (0.39) 1154, 0.20 (0.40)
a  As reported on participant-completed questionnaire.46 Resource use, costs and cost-effectiveness
Estimation of NHS costs
Table 28 is a conversion of Table 27 into costs to the NHS. As indicated by the SD, the cost data 
were highly skewed to the right; while most of the participants incurred low costs, some of them 
incurred very high costs. In terms of NHS costs incurred after trial participants were catheterised, 
the mean total cost per patient was £3259 (SD £3152) in the nitrofurazone group, £3438 (SD 
£3270) in the silver alloy group and £3390 (SD £3405) in the PTFE group. The main driver of 
total costs was length of stay. The cost of catheters themselves did differ (although the use of 
catheters was very similar) but the magnitude of differences was comparatively small. The reason 
for this was that the unit costs were higher for nitrofurazone and silver alloy catheters than for 
PTFE catheters.
Quality-adjusted life-years
Table 29 reports the within-trial EQ-5D scores for groups randomised at baseline, 3 days after 
catheter removal, 1 and 2 weeks after catheter removal, and 6 weeks after randomisation. QALYs 
were estimated from these data. The results were very similar between each of the intervention 
groups and control: the mean (SD) QALYs were 0.081 (0.02) for the nitrofurazone group, 0.079 
(0.02) for the silver alloy group, and 0.081 (0.02) for the PTFE group.
TABLE 28  NHS costs
Resource type Nitrofurazone (n), mean £ (SD) Silver alloy (n), mean £ (SD) PTFE (n), mean £ (SD)
Intervention
Catheter 2153, 5.15 (1.19) 2097, 6.34 (1.86) 2144, 0.96 (0.65)
Secondary care resource use
Length of stay 2104, 3302.98 (3107.74) 2047, 3505.72 (3266.80) 2102, 3444.63 (3397.18)
Outpatient visit 1668, 1.63 (26.10) 1614, 1.81 (16.28) 1671, 1.91 (18.30)
Visit to other providers 1661, 0.87 (12.13) 1606, 1.04 (13.05) 1664, 1.16 (18.70)
Inpatient readmissions 1669, 26.53 (412.18) 1605, 3.88 (77.16) 1673, 6.67 (177.44)
Primary care resource use
GP doctor visit 1661, 3.88 (15.80) 1605, 4.67 (17.08) 1659, 4.32 (16.33)
GP nurse visit 1667, 0.35 (2.68) 1606, 0.45 (3.43) 1669, 0.51 (10.49)
Medications
Antibiotics for UTIa 1160, 0.96 (2.06) 1130, 0.98 (2.09) 1154, 1.07 (2.16)
Total 2153, 3259.24 (3151.69) 2097, 3438.08 (3269.61) 2144, 3390.02 (3405.13)
a  As based on data collected on participant-completed questionnaire.
TABLE 29  Quality of life for each trial intervention
EQ-5D Nitrofurazone (n), mean (SD) Silver alloy (n), mean (SD) PTFE (n), mean (SD)
Baseline 2126, 0.717 (0.29) 2076, 0.722 (0.29) 2123, 0.722 (0.30)
3 days 1859, 0.592 (0.27)  1801, 0.578 (0.28) 1871, 0.593 (0.27)
1 week 1363, 0.618 (0.27)  1308, 0.601 (0.29) 1366, 0.614 (0.27)
2 weeks 1405, 0.696 (0.26)  1328, 0.686 (0.27) 1398, 0.694 (0.25)
6 weeks 1704, 0.776 (0.24)  1665, 0.782 (0.24) 1721, 0.794 (0.23) 
QALYsa 1116, 0.081 (0.02) 1077, 0.079 (0.02) 1123, 0.081 (0.02)
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Interpretation of cost and effects data
As noted above, a within-trial economic evaluation is not reported in the main body of the text. 
The reason for this is that there are concerns that chance differences between participants in each 
of the randomised groups in terms of their overall medical care are likely to be influencing the 
estimates of differences in costs (and effects) derived from the trial data.
From the data reported in Tables 27 and 28, above, it can be seen that the estimates of total cost 
for each catheter and difference in cost between nitrofurazone and silver alloy groups compared 
with PTFE are driven by length of stay. The length of stay was on average 0.30 days less for 
nitrofurazone than for PTFE (Appendix 7, Table 44, reports the 97.5% CI as –0.77 to 0.17 days). 
The length of stay was on average 0.15 day longer for silver alloy than for PTFE (Appendix 7, 
Table 44, reports the 97.5% CI as I –0.34 to 0.63 days). These differences are not statistically 
significant at the 2.5% level but will be reflected in the CEACs, which describe the probability 
that an intervention is cost-effective. Our concern was that the mean difference in length of 
stay recorded between randomised groups was clinically implausible, and was being driven by 
imbalances between groups unrelated to the type of catheter to which they were randomised, 
such as the treatment course of their underlying health problem. For example, if nitrofurazone 
catheters prevent 2 infections per 100 people receiving this type of catheter compared with PTFE 
catheters, then, assuming that the only driver of differences in length of stay was the difference 
in infection rate, this means that each episode of infection was accompanied by a reduction in 
length of stay of 15 days [(0.3 days × 100)/2]. Although it is possible that there may be other 
mechanisms apart from catheter-associated UTI by which the catheter choice may influence 
length of stay other than a UTI, we made the judgement that a within-trial economic evaluation 
based on these data would be misleading.
Modelling results
A second pre-planned analysis was to base the economic evaluation on a simple decision-analytic 
model. Within this exercise an analysis has been performed that is centred on the cost and QALY 
implications caused by differences in UTI rates. For the base-case analysis the risk of infection 
is based on the risk of infection associated with PTFE catheters, and the separate absolute risk 
differences for each of nitrofurazone or silver alloy catheters compared with PTFE (these data are 
reported in Chapter 5).
This analysis makes the assumption that differences between the catheters in terms of costs and 
QALYs are driven by the difference in the risk of suffering a UTI for participants allocated to 
differing catheters and the cost of the catheter. One concern with this analysis is that those who 
suffer an infection may be more likely to incur extra costs or suffer worse QoL for reasons that 
are unconnected to having an infection, such as a more severe underlying illness or worse general 
health. In an attempt to explore the importance of this issue, a series of alternative analyses were 
defined that were believed to represent a more homogeneous population.
In this section we report on the base-case model analysis, the analyses based on potentially 
homogeneous subpopulations, and additional sensitivity analyses conducted to explore the 
impact of excluding data on the main driver of the results – length of stay.48 Resource use, costs and cost-effectiveness
Base-case analysis based on risk of infection as defined for the primary 
trial outcome
For the model-based analysis data inputs to the model relate to:
  ■ The absolute risk of infection for participants randomised to PTFE (control).
  ■ The absolute risk difference for infection for nitrofurazone compared with PTFE and silver 
alloy compared with PTFE.
  ■ The cost of care over the 6-week study period for those participants who did not suffer a UTI.
  ■ The difference in costs over the 6-week study period for those who suffered an infection 
compared with those who did not.
  ■ The number of catheters used per participant and the unit cost of each type of catheter.
  ■ The estimate of QALYs for the 6-week study period for those who did not suffer an infection.
  ■ The difference in QALYs for the 6-week study period for those who suffered an infection 
compared with those who did not.
Data on the risk of infection for PTFE and the absolute risk differences were based on trial 
primary outcomes results reported in Chapter 5. Tables 30 and 31 report the NHS resource use 
and NHS costs for those who have a UTI and those who did not. As expected, the results of the 
comparison showed that participants who suffered a UTI had statistically significantly higher 
resource use (see Table 30) and hence costs (see Table 31). The main driver of the difference in 
total costs (excluding the unit cost of the catheter) appeared to be differences in length of stay. 
The total costs when the cost of the catheter was excluded for those both with and without a UTI 
were used to populate the economic model. It was also assumed that for each arm of the model 
(each arm representing one of the three catheters) one catheter per person would be used.
Table 32 reports the EQ-5D scores for those who suffered a UTI and those who did not. From 
these data it was estimated that the mean QALYs were 0.075 (SD 0.03) for the group that suffered 
a UTI and 0.081 (SD 0.02) for the group that did not. The mean difference in QALYs after 
TABLE 30  NHS resource use based on whether or not patient had a UTIa
Resource type UTI (n), mean (SD) No UTI (n), mean (SD) Difference, mean (97.5% CI)
Intervention
Catheter (no. used) 762, 1.07 (0.31)  5630, 1.03 (0.22) 0.04 (0.02 to 0.06)
Primary care
GP doctor visit 598, 0.66 (0.95) 4325, 0.04 (0.26) 0.62 (0.58 to 0.66)
GP nurse visit 611, 0.22 (1.79) 4329, 0.02 (0.19) 0.20 (0.15 to 0.26)
Secondary care
Length of stay (days) 759, 8.08 (7.73) 5492, 7.44 (6.68) 0.63 (0.04 to 1.23)
Outpatient visit 614, 0.07 (0.33) 4337, 0.01 (0.20) 0.06 (0.04 to 0.08)
Visit to other providers 607, 0.05 (0.26) 4314, 0.01 (0.28) 0.04 (0.02 to 0.07)
Inpatient readmissions 618, 0.17 (1.66) 4327, 0.02 (0.59) 0.15 (0.07 to 0.22)
Medications
Antibiotic prescriptions for UTIb 637, 0.62 (0.49) 2805, 0.08 (0.28) 0.54 (0.50 to 0.57)
a  Based on data reported for the primary outcome.
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adjusting for baseline EQ-5D and other characteristics was 0.006 (97.5% CI –0.009 to –0.003) 
lower for the participants who suffered a UTI.
A summary of the parameters, their values, source and the distribution used in the probabilistic 
sensitivity analysis is reported in Table 33.
The results of the model using the absolute risk reduction recorded as the primary outcome for 
trial data suggest that nitrofurazone is, on average, the least costly trial intervention, followed by 
PTFE and then silver alloy (Table 34). It is also, on average, the most effective catheter, with PTFE 
and silver alloy having similar effectiveness. This latter finding was expected, given the very small 
mean difference in risk of an infection between silver alloy and PTFE catheters. Overall, there is a 
70% chance that nitrofurazone would be the least costly option and over an 80% probability that 
it would be considered cost-effective when society is willing to pay a maximum of £30,000 per 
QALY. Silver alloy has virtually no chance of being considered cost-effective when compared with 
TABLE 31  Costs based on whether or not patient had a UTI (£ sterling)
Resource type UTI (n), mean (SD) No UTI (n), mean (SD
Adjusted difference,a 
mean (97.5% CI)
Unadjusted difference, 
mean (97.5% CI)
Intervention
Catheter 762, 4.11 (2.79) 5630, 4.14 (2.65) –0.07 (–0.32 to 0.19) 0.03 (–0.20 to 0.27)
Primary care 
GP doctor visit 598, 23.90 (34.16) 4325, 1.56 (9.19) 22.26 (18.99 to 25.54) 22.33 (20.90 to 23.77)
GP nurse visit 611, 2.21 (17.94) 4329, 0.18 (1.91) 2.13 (0.32 to 3.95) 2.02 (1.39 to 2.66)
Secondary care
Length of stay 759, 3652.60 (3538.76) 5492, 3385.18 (3218.75) 471.85 (178.05 to 765.67) 267.42 (15.54 to 550.38)
Outpatient visit 614, 6.58 (31.31) 4337, 1.08 (18.58) 5.62 (2.55 to 8.69) 5.50 (3.51 to 7.49)
Visit to other providers 611, 4.12 (23.58)   4318, 0.58 (13.21) 3.57 (1.38 to 5.76) 3.54 (2.10 to 4.98)
Inpatient readmissions 618, 54.14 (543.35) 4327, 6.52 (193.93) 46.77 (–8.50 to 102.06) 47.62 (22.15 to 73.08)
Medications
Antibiotics 637, 3.36 (2.63) 2805, 0.46 (1.52) 2.85 (2.60 to 3.10) 2.90 (2.72 to 3.07)
Total (excluding catheter 
cost)
762, 3779.42 (3573.4) 5630, 3375.42 (3232.91) 547.63 (288.55 to 860.71) 403.97 (120.53 to 687.41)
a  All differences adjusted for sex, age, reason for catheterisation, comorbidities, antibiotic use at 7 days, antibiotic use at catheterisation and CI 
based on bootstrapped data.
TABLE 32  Quality-adjusted life-years according to UTI status
EQ-5D UTI (n), mean (SD) No UTI (n), mean (SD) Difference
Baseline 751, 0.734 (0.29) 5573, 0.719 (0.29)
–0.006 (–0.009 to –0.003)b
3 days 671, 0.555 (0.28)  4858, 0.593 (0.27)
1 week 516, 0.565 (0.29)  3519, 0.619 (0.27)
2 weeks 524, 0.645(0.28)  3605, 0.700 (0.26)
6 weeks 652, 0.750 (0.27)  4436, 0.790 (0.23)
QALYsa 424, 0.075 (0.02)  2891, 0.081 (0.02)
a  Small value for QALYs is because the trial follow-up is 6 weeks. The maximum QALYs would have been 0.115.
b  Adjusted for sex, age, reason for catheterisation, comorbidities, antibiotic use at 7 days, antibiotic use at catheterisation.50 Resource use, costs and cost-effectiveness
the other two catheters. For nitrofurazone the reduction in the subsequent cost of care caused by 
a likely reduction in the risk of infections more than compensates for the increased cost of the 
catheter. However, the same is not true for silver alloy.
What the probabilistic analysis reported in Table 34 does not portray is the magnitude and 
variation in cost. The difference in cost between nitrofurazone and PTFE is graphically illustrated 
in Figure 12 and that for silver alloy and PTFE in Figure 13. For the comparison of nitrofurazone 
against PTFE, the 97.5% CI was –£36.19 to £11.45 and for the comparison of silver alloy against 
PTFE the 97.5% CI was £4.13 to £5.92.
Analyses for more ‘homogeneous’ patient groups
Three participant groups believed to represent more homogeneous patient populations were 
defined. These were:
  ■ Those admitted to an obstetrics and gynaecology specialty ward only. For this analysis the 
costs and QALY for those with and without a UTI were based on this subgroup. We used the 
same risk of a UTI as in the base case, as these data were assumed to be robust and precise.
TABLE 33  Parameters used in the base-case economic model
Variable name Value Source and distributiona
Risk of infection for PTFE 0.126 Based on the value from the trial analysis (see Table 13). Beta distribution; α = number of events in 
group = 271; β = number of people without the event in the group = 1873
Relative risk of infection for 
nitrofurazone
–0.021 Based on the estimated absolute risk difference between nitrofurazone and PFTE (see Chapter 5, 
Primary outcome). Normal distribution: SD = 0.01
Relative risk of infection for 
silver alloy
–0.001 Based on the estimated absolute risk difference between nitrofurazone and PTFE (see Chapter 5, 
Primary outcome). Normal distribution: SD = 0.01
Utility associated with a 
catheter infection
0.075 Based on data reported in Table 32. Beta distribution: α and β derived from mean (0.075369) and 
SD (0.02454) of QALYs for a UTI
Additional utility associated 
with not suffering a UTI
+0.006 Based on the adjusted analysis difference in QALYs reported in Table 32. Normal distribution: 
SD = 0.001
Health-care costs for those 
without UTI
£3375.42 Based on cost estimate reported in Table 31. Log-normal distribution: Derived from mean = 3375.42 
and median costs = 2359 derived from trial data
Additional health-care costs 
for those suffering a UTI
£547.63 Based on the adjusted analysis results cost difference estimate in Table 31. Normal distribution: 
mean = 547.63, SD = 425.62
Cost of nitrofurazone catheter £5.29 Personal communication with the manufacturer (Rochester). Point estimate, no distribution attached
Cost of silver alloy catheter £6.46 Personal communication with the manufacturer (CR Bard). Point estimate, no distribution attached
Cost of PTFE catheter £0.86 NHS Supplies. Point estimate, no distribution attached
a  Details of the values and calculations used to derive the distributions are described in Appendix 9.
TABLE 34  Base-case cost-effectiveness results using adjusted risk of infection of primary outcome
Intervention Cost (£)
Incremental 
cost (£) QALY
Incremental 
QALY ICER
Probability (%) of being cost-effective at different 
threshold values for society’s willingness to pay for 
an additional QALY:
£0 £10,000 £20,000 £30,000 £50,000
Nitrofurazone 3438.43 0.08232  73 77 81 84 89
PTFE 3445.50 7.10 0.08218  –0.0001 Dominated 27 23 19 16 11
Silver alloy 3450.55 12.10 0.08219  0 Dominated 0 0 0 0 0
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FIGURE 12  Distribution of health-care cost differences for participants randomised to nitrofurazone compared with 
PTFE. Based on 1000 Monte Carlo simulations.
FIGURE 13  Distribution of health-care cost differences for participants randomised to silver alloy compared with PTFE. 
Based on 1000 Monte Carlo simulations.
  ■ Those with an EQ-5D score of 1 at 3 days after catheter removal. Again the costs and QALY 
for those with and without a UTI were based on this subgroup and the risk of a UTI was 
taken to be the same as the base case.
  ■ Those participants who were recorded as having a symptomatic CAUTI treated with 
antibiotics at 3 days post catheter removal. Costs and QALY risks were defined in the same 
way as for the two previous subgroup analyses.
Tables 35–37 describe the costs and QALYs for each of these analyses. The first subgroup 
considered consisted of women who were admitted to an obstetrics and gynaecology specialty 
ward (n = 1736; UTI 336; no UTI 1400). For this subgroup, the adjusted difference in total costs 
between those who had an infection and those who did not was £141 (97.5% CI –117 to 400) and 
the QALY difference was –0.007 (97.5% CI –0.011 to –0.003) (see Table 35). The second subgroup 
we analysed, based on data from participants who reported that they had an EQ-5D score of ‘1’ 
(full health) at 3 days post catheter removal (n = 436; UTI 33; no UTI 403), resulted in a £988 
(97.5% CI –64 to 2052) difference in costs and –0.002 (97.5% CI –0.012 to 0.007) difference in 
QALYs (see Table 36). Finally, Table 37 describes costs and QALYs for all trial participants, based 
on their infection status using the secondary trial outcome of symptomatic antibiotic-treated UTI 52 Resource use, costs and cost-effectiveness
TABLE 35  Costs (£ sterling) from results of exploratory analysis based on participants who were treated in obstetrics 
and gynaecology specialty area
Resource type UTI (n), mean (SD) No UTI (n), mean (SD) 
Adjusted difference,a  
mean (97.5% CI)
Unadjusted difference, 
mean (97.5% CI)
Intervention
Catheter 336, 4.21 (3.03) 1400, 4.15 (3.01)  –0.01 (–0.43 to 0.41) 0.06 (–0.34 to 0.48 )
Primary care
GP doctor visit 273, 31.78 (4.81) 1077, 3.07(12.81) 29.31 (24.28 to 34.35 ) 28.71 (25.76 to 31.65 )
GP nurse visit 285, 1.37 (4.81) 1085, 0.14 (1.89) 1.24 (0.55 to 1.94 ) 1.23 (0.82 to 1.64 )
Secondary care
Length of stay 335, 1958.21 (2003.18) 1370, 1805.98 (1870.84) 57.49 (–190.71 to 305.68 ) 152.24 (–107.18 to 411.66)
Outpatient visit 287, 8.18 (33.73) 1088, 1.55 (14.45) 6.79 (2.20 to 11.37 ) 6.63 (3.65 to 9.62 )
Visit to other providers 288, 5.07 (24.41) 1078, 0.30 (8.66) 4.91 (1.56 to 8.25 ) 4.77 (2.75 to 6.79 )
Inpatient readmissions 286, 41.28 (78.50) 1082, 2.12 (51.79)  40.43 (4.10 to 76.75 ) 39.16 (18.98 to 59.35 )
Medications
Antibiotics 311, 3.58 (2.56) 765, 0.63 (1.74) 2.95 (2.59 to 3.31 ) 2.95 (2.65 to 3.26 )
Total 336, 2033.38 (2084.74) 1400, 1777.32 (1871.29) 141.46 (–116.76 to 399.68) 256.06 (–4.83 to 516.96)
Total without cost of 
catheter (used in model)
336, 2029.17 (2084.76) 1375, 1805.41 (1872.72) 127.93 (–136.78 to 392.64) 233.76 (–37.3 to 485.36)
QALYs 219, 0.080 (0.02) 832, 0.086 (0.02) –0.007 (–0.011 to –0.003 ) –0.006 (–0.010 to –0.003)
a  All differences adjusted for sex, age, reason for catheterisation, comorbidities, antibiotic use at 7 days, antibiotic use at catheterisation and CI 
based on bootstrapped data.
TABLE 36  Costs (£ sterling) from exploratory analysis based on participants reporting an EQ-5D score of ‘1’ (full health) 
at 3 days
Resource type UTI (n), mean (SD) No UTI (n), mean (SD)
Adjusted difference,a mean 
(97.5% CI)
Unadjusted difference, mean 
(97.5% CI)
Intervention
Catheter 33, 4.20 (2.61) 403, 4.20 (2.43)  –0.30 (–1.40 to 0.80) 0.01 (–0.99 to 1.00)
Primary care 
GP doctor visit 27, 20 (23.06) 333, 1.08 (6.15) 18.63 (8.41 to 8.85) 19.92 (15.05 to 22.79)
GP nurse visit  28, 2.14 (5.68) 332, 0.27 (3.05) 1.96 (–0.51 to 4.44) 1.87 (0.40 to 3.34)
Secondary care
Length of stay 33, 3154.36 (2946.53) 400, 2468.29 (2341.09) 912.73 (–164.41 to 1989.87) 686.07 (–288.09 to 1660.24)
Outpatient visit 30, 0 (0)  334, 0.844 (8.88) 1.00 (–2.40 to 0.39) –0.84 (–4.50 to 2.81)
Visit to other providers 28, 0.10 (0.57) 333, 0.61 (6.76) –0.26 (–0.99 to 0.48) 0.50 (–3.38 to 2.38)
Inpatient readmissions 30, 54.67 (299.42) 332, 0 (0)  57.19 (–38.88 to 153.25) 54.67 (18.20 to 91.13)
Medications
Antibiotics 31, 3.32 (2.68) 239, 0.14 (0.85) 3.14 (2.07 to 4.21) 3.18 (2.66 to 3.70)
Total 33, 3229.65 (2944.67) 403, 2456.51 (2342.01) 988.45 (–64.47 to 2051.50) 773.14 (–200.85 to 1747.14)
Total without cost of 
catheter (used in model)
33, 3225.45 (2944.27) 403, 2452.31 (2342.01) 988.75 (–64.01 to 2051.74) 773.15 (–200.86 to 1747.15)
QALYs 25, 0.099 (0.02) 252, 0.102 (0.02) –0.002 (–0.012 to 0.007) –0.003 (–0.011 to 0.004)
a  All differences adjusted for sex, age, reason for catheterisation, comorbidities, antibiotic use at 7 days, antibiotic use at catheterisation and CI 
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at 3 days post catheter removal (n = 6394; UTI 370; no UTI 6023). Participants who suffered a 
UTI had, on average, £1417 higher cost (97.5% CI 982 to 1925) and –0.004 fewer QALYs (97.5% 
CI –0.009 to 0.000) compared with those who did not suffer a UTI.
Table 38 summarises the data used for each subgroup analysis, along with details of the 
distribution and the data used to define that distribution.
TABLE 37  Cost results of exploratory analysis based on whether or not patient had a symptomatic antibiotic-treated 
UTI at 3 days post catheter removal
Type of sensitivity UTI (n), mean (£) No UTI (n), mean(£) Differencea
Costs using 3-day post-catheter removal UTI 
outcomea
370, 4748.72 6023, 3331.24 1417.48 (981.60 to 1925.18)
QALYs 184, 0.076 3132, 0.081 –0.004 (–0.009 to 0.000)
a  All differences adjusted for sex, age, reason for catheterisation, comorbidities, antibiotic use at 7 days, antibiotic use at catheterisation and CI 
based on bootstrapped data.
TABLE 38  Cost and QALY values used for each subgroup analysisa
Variable name Value Source
Maternity specialty participants
Health-care costs for participants without 
reported UTI
£1805.41 Based on cost estimate reported in Table 35. Log-normal distribution: derived from 
adjusted mean = 1805.41 and median costs = 1383 derived from trial data
Cost difference between UTI and no UTI £127.93 Based on the adjusted analysis results cost difference estimate in Table 35. Normal 
distribution: mean = 127.93, SD = 116.55
QALYs for participants who experienced UTI 
over 6-week trial period
0.080 Based on data reported in Table 35. Beta distribution: α and β derived from mean 
(0.07961) and SD (0.02061) of QALYs for a UTI
QALY difference UTI and no UTI 0.007 Based on the adjusted analysis difference in QALYs reported in Table 35. Normal 
distribution: SD = 0.0015
All other parameters Same as base case
EQ-5D score at 3 days = 1
Health-care costs for participants without 
reported UTI
£2452.31 Based on cost estimate reported in Table 36. Log-normal distribution: derived from 
adjusted mean = 2452.31 and median costs = 1844 derived from trial data
Cost difference between UTI and no UTI £988.75 Based on the adjusted analysis results cost difference estimate in Table 36. Normal 
distribution: mean = 988.75, SD = 471.97
QALYs for participants who experienced UTI 
over 6-week trial period
0.099 Based on data reported in Table 36. Beta distribution: α and β derived from mean 
(0.09909) and SD (0.01904) of QALYs for a UTI
QALY difference UTI and no UTI 0.002 Based on the adjusted analysis difference in QALYs reported in Table 36. Normal 
distribution: SD = 0.0050
All other parameters Same as base case
At 3 days post catheterisation
Health-care costs for participants without 
reported UTI
£3331.25 Based on cost estimate reported in Table 37. Log-normal distribution: derived from 
adjusted mean = 3331.25 and median costs = 2317 derived from trial data
Cost difference between UTI and no UTI £1417.48 Based on the adjusted analysis results cost difference estimate Table 37. Normal 
distribution: mean = 1417.48, SD = 209.10
QALYs for participants who experienced UTI 
over 6-week trial period
0.076 Based on data reported in Table 37. Beta distribution: α and β derived from mean 
(0.07553) and SD (0.02553) of QALYs for a UTI
QALY difference UTI and no UTI 0.004 Based on the adjusted analysis difference in QALYs reported in Table 36. Normal 
distribution: SD = 0.0021
All other parameters Same as base case
a  Details of the values and calculations used to derive the distributions are described in Appendix 9.54 Resource use, costs and cost-effectiveness
Table 39 describes the results of each of these three subgroup analyses. Also shown in this table 
are the results of the base-case analysis to facilitate comparison. In the first subgroup analysis, 
considering those admitted to the obstetrics and gynaecology specialty ward, the cost associated 
with PTFE was on average the lowest and silver alloy catheters were on average the most costly 
(£5.47 more costly than PTFE). The most effective catheter was nitrofurazone. When society 
was unwilling to pay any price for additional QALYs, PTFE had almost an 80% chance of being 
considered cost-effective. This likelihood fell to 30% when the threshold value for society’s 
willingness to pay was £30,000. When society’s willingness to pay was £30,000, nitrofurazone 
had a 70% chance of being considered cost-effective; however, this result is driven by the small 
difference in QALYs gained over PTFE, which may not be of clinical significance.
When the analysis was restricted to those with an EQ-5D score of ‘1’ at 3 days, or based on UTI 
status at 3 days post catheter removal, the nitrofurazone-impregnated catheter was least costly 
and the silver alloy-coated catheter was most costly. Nitrofurazone was also associated with more 
QALYs gained on average. In both of these analyses, nitrofurazone had a greater than 90% chance 
of being considered cost-effective when society was unwilling to pay any price for additional 
QALYs (willingness-to-pay value = 0). The likelihood of nitrofurazone being cost-effective 
increased as society’s threshold value for a QALY increased, although it should be noted that any 
QALY gains from the use of nitrofurazone over standard catheters were small and may not be 
clinically important.
For illustrative clarity, Figures 14 and 15 show the cost difference for nitrofurazone compared 
with PTFE and silver alloy compared with PTFE for those participants admitted to obstetrics and 
gynaecology ward. For this subgroup the 97.5% CI for nitrofurazone versus PTFE was –£6.65 to 
7.59, and for silver alloy compared with PTFE it was £5.21 to £5.73.
TABLE 39  Results of subgroup analysesa
Intervention Cost (£)
Incremental 
cost (£) QALY
Incremental 
QALY ICER
Probability (%) of being cost-effective at different 
threshold values for society’s willingness to pay for 
an additional QALY:
£0 £10,000 £20,000 £30,000 £50,000
Base-case analysis
Nitrofurazone  3438.4 0.08232 73 77 80 84 89
PTFE 3445.5 7.1 0.08218 –0.0001 Dominated 27 23 20 16 11
Silver alloy 3450.55 12.1 0.08219 0 Dominated 0 0 0 0 0
Participants admitted into the obstetric and gynaecology specialty ward
PTFE 1918.27 0.08712 77 60 41 29 15
Nitrofurazone 1920.01 1.74 0.08726 0.00015 £11,497 23 40 59 71 85
Silver alloy 1923.74 3.73 0.08712 –0.00014 Dominated 0 0 0 0 0
EQ-5D score at 3 days = 1 (full health)
Nitrofurazone 2561.8 0.10106  91 91 91 91 92
PTFE 2578.2 16.3 0.10098  –0.00008 Dominated 9 9 9 9 8
Silver alloy 2582.8 20.9 0.10098  –0.00007  Dominated 0 0 0 0 0
Three-day symptomatic antibiotic-treated UTI outcome
Nitrofurazone 3485.9 0.08118  97 97 97 97 97
PTFE 3511.3 25.3 0.08108  –0.00010  Dominated 3 3 3 3 3
Silver alloy 3515.5 29.5 0.08109  –0.00009  Dominated 0 0 0 0 0
a  Plots of cost and QALYs and CEACs are shown in Appendix 10.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Pickard et al. under the terms of a commissioning contract issued by the Secretary of State for Health. 
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that 
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to NETSCC.
55   Health Technology Assessment 2012; Vol. 16: No. 47 DOI: 10.3310/hta16470
Figures 16 and 17 show the cost differences for the subgroup of participants who had an EQ-5D 
score of ‘1’ at 3 days. For this subgroup the 97.5% CI for nitrofurazone compared with PTFE was 
–£61.42 to 7.09, and for silver alloy compared with PTFE it was £3.53 to £5.62.
Figures 18 and 19 show the cost differences when costs and QALYs are based on those with and 
without a UTI at 3 days post catheter removal. For this analysis, the 97.5% CI for nitrofurazone 
compared with PTFE was –£62.62 to £3.78, and for silver alloy compared with PTFE it was £3.71 
to £4.66.
Other sensitivity analysis
As already noted, one driver of the cost differences between trial intervention groups and 
between participants who did or did not report UTI was the differences in length of stay, which 
may have been influenced by imbalances in care and illness factors between groups. In this 
sensitivity analysis the base-case analysis is repeated but with inpatient costs excluded in an 
attempt to neutralise the influence of initial inpatient treatment costs incurred during the period 
of catheterisation.
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FIGURE 14  Distribution of health-care cost differences for participants from the obstetrics and gynaecology specialty 
subgroup randomised to nitrofurazone compared with PTFE. Based on 1000 Monte Carlo simulations.
FIGURE 15  Distribution of health-care cost differences for participants from the obstetrics and gynaecology specialty 
subgroup randomised to silver alloy compared with PTFE. Based on 1000 Monte Carlo simulations.56 Resource use, costs and cost-effectiveness
Table 40 describes the differences in costs and QALYs between those with and without a UTI 
once inpatient costs are excluded. Details of parameter values used in the model are described in 
Appendix 9, Tables 56–58, and the results of the analysis are shown in Table 41, below.
The results of the analysis described in Table 41 show that when inpatient costs are excluded 
then the savings in health-care costs incurred after discharge from hospital are not large enough 
to compensate for the higher unit price of the nitrofurazone or silver alloy catheter. On average 
the nitrofurazone catheters are marginally more effective than the PTFE or silver alloy catheters 
but the difference in QALYs may not be of clinical significance. When society is unwilling to 
pay anything for an additional QALY then PTFE would have a probability of being considered 
cost-effective that approaches 100%. When society’s willingness to pay for a QALY approaches 
£30,000 then the likelihood that nitrofurazone would be considered cost-effective increases to 
50%. It should be noted that this result arises from the assumption made in the analysis that any 
difference in QALYs, no matter how small, is important.
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FIGURE 16  Distribution of health-care cost differences for participants from the subgroup with perfect health (EQ-5D 
score = 1) at 3 days post catheter removal randomised to nitrofurazone compared with PTFE. Based on 1000 Monte 
Carlo simulations.
FIGURE 17  Distribution of health-care cost differences for participants from the subgroup with perfect health (EQ-5D 
score = 1) at 3 days post catheter removal randomised to silver alloy compared with PTFE. Based on 1000 Monte Carlo 
simulations.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Pickard et al. under the terms of a commissioning contract issued by the Secretary of State for Health. 
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that 
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to NETSCC.
57   Health Technology Assessment 2012; Vol. 16: No. 47 DOI: 10.3310/hta16470
Figures 20 and 21 display the differences in costs more clearly. For this analysis the 97.5% CI for 
nitrofurazone compared with PTFE is £0.82 to £4.53 and for silver alloy compared with PTFE it 
is £5.49 to £5.57.
FIGURE 18  Distribution of health-care cost differences for participants with the outcome of UTI at 3 days post catheter 
removal randomised to nitrofurazone compared with PTFE. Based on 1000 Monte Carlo simulations.
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FIGURE 19  Distribution of health-care cost differences for participants with the outcome of UTI at 3 days post catheter 
removal randomised to silver alloy compared with PTFE. Based on 1000 Monte Carlo simulations.
0
20
40
60
80
100
F
r
e
q
u
e
n
c
y
–80 –60 –40 –20 0 20
Nitrofurazone vs PTFE cost difference58 Resource use, costs and cost-effectiveness
TABLE 40  Costs (£ sterling) results of exploratory analysis based on whether or not participant had a UTI at 3 days post 
randomisation and excluding costs associated with the inpatient stay
Type of sensitivity UTI (n), mean (£) No UTI (n), mean (£) Differencea
Costs excluding the length of stay 762, 81.54 5629, 13.30 67.41 (21.88 to 112.87)
QALYs 424, 0.077 2891, 0.083 –0.006 (–0.009 to –0.003)
a  All differences adjusted for sex, age, reason for catheterisation, comorbidities, antibiotic use at 7 days, antibiotic use at catheterisation and CI 
based on bootstrapped data.
TABLE 41  Results of sensitivity analysesa
Intervention Cost (£)
Incremental 
cost (£) QALY
Incremental 
QALY ICER
Probability (%) of being cost-effective at different 
threshold values for society’s willingness to pay for 
an additional QALY:
£0 £10,000 £20,000 £30,000 £50,000
Base-case analysis
Nitrofurazone  3438.4 0.08232  73 77 80 84 89
PTFE 3445.5 7.1 0.08218  –0.0001 Dominated 27 23 20 16 15
Silver alloy 3450.55 12.1 0.08219  0 Dominated 0 0 0 0 0
No inpatient costs
PTFE 23.0 0.08102 100 93 69 47 23
Nitrofurazone 26.0 3.0 0.08113 0.00011 28,602 0 7 31 53 77
Silver alloy 28.6 2.5 0.08103 –0.00010 Dominated 0 0 0 0 0
a  Plots of cost and QALYs and CEACs are shown in Appendix 10.
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FIGURE 20  Distribution of health-care cost (£ sterling) differences for participants randomised to nitrofurazone 
compared with PTFE and excluding costs of the initial episode of hospital stay. Based on 1000 Monte Carlo simulations.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Pickard et al. under the terms of a commissioning contract issued by the Secretary of State for Health. 
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FIGURE 21  Distribution of health-care cost (£ sterling) differences for participants randomised to silver alloy compared 
with PTFE and excluding costs of the initial episode of hospital stay. Based on 1000 Monte Carlo simulations.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Pickard et al. under the terms of a commissioning contract issued by the Secretary of State for Health. 
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Chapter 7  
Discussion
T
he UK government NIHR HTA programme commissioned this research in order to answer 
the question: ‘Is there a benefit to using antimicrobial-coated urethral catheters over 
catheters without antimicrobial coatings in adults requiring catheterisation expected to be of 
limited duration, and what are the costs?’ from the perspective of the UK NHS.
Minimum important difference
Interpretation of the findings of the CATHETER trial depends on the level of benefit that 
would justify changes in policy and/or practice. We judged that if 1 in around 30 people having 
short-term urethral catheterisation in hospital avoided a UTI as a consequence of using an 
antimicrobial- or antiseptic-impregnated catheter, this would offset the known extra ‘upfront’ 
costs of these catheters. This was the basis of the sample size calculations described in Chapter 3: 
an absolute effect of this size was equivalent to an OR of 0.67, and the trial had 90% power to 
detect this difference at an adjusted alpha error rate of 0.025 [set at this level to reflect the two 
principal comparisons being made: (1) nitrofurazone-impregnated catheters compared with 
PTFE catheters and (2) silver alloy-coated catheters compared with PTFE catheters].
The collection of resource use data allowed us subsequently to compare the costs of those 
participants who had a UTI with those who did not, and hence estimate the extra costs of a 
UTI. As can be seen in Table 31, the estimates based on all participants were around £400–500 
per infection, although the figure did vary more widely in subgroup comparisons. A saving 
of £400–500 for each UTI avoided does, however, suggest that the ‘break-even’ point in terms 
of costs would be a smaller benefit. The antimicrobial catheters cost about £4 and £5 more 
than the standard, suggesting that avoiding just one UTI every 100 times the more expensive 
catheters were used would offset the extra costs. Comparison of those who had a UTI with 
those who did not also allowed estimation of the health-related QoL gained by avoiding a UTI 
(0.006; CI 0.003 to 0.009) (see Table 32). The figures for costs avoided and QALYs gained were 
then used in an economic model to derive estimates of cost–utility. As discussed in Chapter 5, 
there are substantial uncertainties in deriving the estimates of the cost of a UTI and QALYs lost 
as a consequence of a UTI and this should not be forgotten. Nevertheless, a tension between 
what is considered to constitute a ‘minimum important difference’ clinically, or indeed from an 
individual patient point of view, and what is the minimum difference economically lies at the 
heart of interpretation of the trial’s results.
Principal findings of the trial
Nitrofurazone-impregnated catheter
The primary end point results of the trial are summarised in Table 13. The adjusted OR when 
comparing nitrofurazone with PTFE was 0.81, with 97.5% CI of 0.65 to 1.01. The best estimate 
of effect (0.81) is thus less than the clinical effect that was the basis of the sample size calculation 
(OR 0.67). The CI just includes the OR sought (lower boundary 0.65) and just crosses the point 
of ‘no difference’ (1.0). Our conclusion, therefore, is that nitrofurazone catheters do not provide 
the protective effect that we prespecified as clinically important. Putting this another way, the 62 Discussion
best estimate is that the use of a nitrofurazone catheter would prevent 1 UTI in every 48 people 
catheterised but that the ‘true’ figure lies anywhere between 1 in 24 people and no protective 
effect at all. Reflecting the considerations about costs above, the cost–utility analysis was more 
encouraging, suggesting that there was a 70% chance that the nitrofurazone catheter would be the 
least costly option, with an 80% chance of cost-effectiveness at a threshold of £20,000 per QALY.
Silver alloy-coated catheter
The primary end point results are again summarised in Table 13. The adjusted OR for the 
comparison of the silver alloy catheters compared with PTFE catheters was 0.96, with 97.5% CI 
of 0.78 to 1.19. The best estimate of effect 0.96 is thus close to no difference (1.0). The lower end 
of the CI (0.78) is well short of the pre-set difference considered to be clinically important (0.67) 
and hence can be said to rule out such a difference. Furthermore, the other end of the CI (1.19) is 
consistent with a substantially increased risk of UTI. To put this in terms of numbers needed to 
treat, the best estimate is that 1000 people would need to receive a silver alloy catheter to prevent 
one UTI, but that the true effect may be anywhere between 1 infection prevented in 42 people 
and 1 infection caused in 45 people. In the economic analysis, when compared with the other 
catheters, it was very unlikely that the silver alloy catheter could be cost-effective.
Strengths and weaknesses of the trial
Effectiveness
The trial was designed at the outset to provide primary outcome information that could be 
directly used by NHS policy-makers to help decide whether or not antimicrobial catheters 
should be implemented as the standard for short-term catheterisation, predominantly following 
surgery or other interventional procedures. The resultant pragmatic trial design encompassed 
recruitment of a large sample of the relevant population across a representative spectrum of NHS 
hospitals and services. The only additional interventions to routine care for trial participants were 
random allocation of type of catheter, a urine sample at 3 days after catheter removal and trial 
questionnaires. The primary outcome, symptomatic UTI, defined as the presence of symptoms 
suggestive of UTI together with physician prescription of an antibiotic to treat UTI within 
6 weeks of randomisation, was recorded by completion of case report forms during hospital stay, 
participant questionnaire after discharge and review of primary care records. These methods 
were highly effective in that all participant-reported prescriptions of antibiotic for UTI were 
confirmed from clinician record and that primary outcome data were obtained for all except 
one non-responder (for whom we assumed no UTI). We therefore believe that the results of 
this trial are indicative of the clinical effectiveness of the different antimicrobial catheters in 
preventing UTI. Estimates of QoL changes and, in the context of a large RCT, costs should also be 
representative. However, given the wide variety of health problems and interventions experienced 
by participants, some parameters, such as length of hospital stay, show such variability that 
chance differences in illness trajectory are likely to obscure any impact of urethral catheterisation.
A key criticism of previous studies has been the use of outcomes that are not directly relevant 
to patient experience or health-care costs, such as a microbiological finding of bacteriuria 
alone without taking account of patient-reported symptoms or prescription of antibiotic for 
UTI.42 Indeed, the lack of clinically meaningful end points in all previous clinical trials of 
antimicrobial-coated catheters has hindered the assessment of clinical effectiveness and cost-
effectiveness of such catheters.23,42,58 There is some evidence that clinician-defined CAUTI may 
not align well with the presence of bacteriuria on microbiological culture.10 To address this, 
we chose a definition of CAUTI that included both patient-reported symptoms and clinician 
action in terms of prescription of an appropriate antibiotic. This did conform to criterion 2g 
of the 2004 CDC definition of CAUTI, and was more relevant to both patient experience and © Queen’s Printer and Controller of HMSO 2012. This work was produced by Pickard et al. under the terms of a commissioning contract issued by the Secretary of State for Health. 
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the requirement for additional health-care resource use.38 We chose a 6-week period of trial 
observation following randomisation, as this would generally encompass at least a 4-week period 
following catheter removal and capture events occurring following discharge from hospital; lack 
of community follow-up being a further criticism of previous trials.42 Reassuringly, we found 
agreement in direction of effect between bacteriuria and clinical diagnosis of CAUTI with 13.5% 
of the nitrofurazone group and 17.4% in the silver alloy group having urinary bacterial counts 
of 104 CFU/ml within 3 days of catheter removal compared with 17.5% of those receiving the 
standard catheter (see Table 16). In addition, when a concurrent finding of bacteriuria was used 
as an additional criterion to the primary outcome of symptomatic UTI, the relative risk reduction 
was maintained with rates of 3.2%, 5.0% and 4.6% seen in the nitrofurazone, silver alloy, and 
control groups, respectively (see Table 14). These additional data provide some evidence that 
microbiological and symptomatic infection were linked in the present trial. In summary, we feel 
that our primary outcome did successfully address the aim of this pragmatic trial and our use of 
other definitions of UTI allows comparison with previous studies. The differing overall incidence 
rates found for these outcomes suggest that they are capturing distinct diagnostic constructs that 
do, however, have considerable overlap in terms of attribution of each outcome to individual 
trial participants.
As expected for a RCT of this size, all groups were well balanced at baseline on predicted 
risk factors of CAUTI (female sex, older age, diabetes and pre-existing lower urinary tract 
dysfunction). Furthermore, clinician-driven variables (e.g. antibiotic use prior to catheterisation, 
duration of catheterisation29,35,78) were also balanced between groups. Regarding patient 
factors thought to confer increased risk, we did find higher CAUTI rates among women, older 
participants, and those who experienced longer duration of catheterisation, but not among 
those with comorbidities such as diabetes, urinary tract dysfunction or immune suppression. 
Our analyses for interaction did not provide any evidence that these risk factors differentially 
affected the incidence of UTI within the three trial groups. We acknowledge that there were many 
possibly relevant characteristics of participant care that we did not capture. The wide variety 
of surgical interventions received by participants for disparate conditions may have resulted in 
imbalance of uncollected characteristics, which may have particularly affected the small effect 
sizes recorded and may also have influenced the magnitude and distribution of key economic 
parameters such as length of stay.
For the purposes of this trial a key eligibility criterion was an intended duration of catheterisation 
of between 1 and 14 days. Recruitment was therefore concentrated on clinical areas admitting 
men and women for elective surgical or interventional procedures where temporary indwelling 
catheterisation was part of the standard care pathway, with few participants recruited from 
patients primarily admitted to medical or critical care areas. Similarly, we deliberately avoided 
recruiting patients from the urology wards, as such patients represent a group at high risk 
of developing CAUTI, and they are not representative of the majority of patients receiving 
short-term catheters in NHS hospitals. The problems associated with using urology patients in 
antimicrobial catheter trials have been well documented, the most important of which is the 
higher background bacteriuria rate, which may lead to an overestimation of the effect size of the 
catheters.23,58 The prevalence of short-term catheterisation in different clinical areas is uncertain 
but a previous study did document that elective surgical areas predominate, accounting for 78% 
of cases.10 In addition an increased rate of CAUTI has been documented in patients treated in 
medical areas, although it was unclear if this was adjusted for duration of catheterisation, which 
is likely to be longer for medical patients who are generally admitted as emergencies.39
We were unable to carry out a planned subanalysis concerning participants who were 
catheterised as part of their admission to a critical care area. Many of our trial participants 
did have part of their hospital stay on a critical care ward, particularly those undergoing 64 Discussion
neurosurgery or cardiothoracic surgery. The duration of such stays was difficult to measure 
within the logistical constraints of such a large trial, as they varied from a few hours to a number 
of days. We therefore decided against capturing this information. Recruitment of patients 
undergoing unplanned catheterisation as part of urgent care of critical illness or trauma proved 
logistically difficult and resource intensive and therefore was not prioritised. In addition, the 
need for randomisation prior to obtaining participant consent, although approved by our Ethics 
Committee, was associated with a relatively high rate of subsequent refusal of consent.
Given the recruitment policy for our trial, the results may therefore not be generalisable to 
patients admitted as emergencies to medical, trauma or critical care areas, or to urology patients, 
as the baseline bacteriuria rate is likely to be higher owing to underlying disease, the average 
duration of catheterisation is likely to be longer and the range of infecting organisms may differ. 
In line with the recruitment policy, the average duration of catheterisation was short, being 
≤ 3 days for 75% of participants, which is similar to that found in a large cohort study from the 
USA.11 As expected, we found CAUTI rates to be higher in those catheterised for at least 4 days 
but the three trial groups were well balanced for duration of catheterisation, with all showing a 
median [interquartile range (IQR)] of 2 (1–3) days.
In theoretical terms, the clinical and bacteriological effectiveness of both technologies involves 
a balance between the duration of their antimicrobial effect in terms of profile of antimicrobial 
activity and the underlying risk of infection in each individual. All studies, including ours, 
document that the risk of infection increases with increasing duration of catheterisation. 
Previous reviews have suggested that the key potential benefit of such catheters will occur during 
short periods of catheterisation of up to 2–3 weeks.30 This recommendation is in line with in vitro 
findings suggesting that the antimicrobial activity of nitrofurazone-impregnated catheters was 
limited to 5 days’ exposure and that for silver alloy hydrogel-coated catheters was limited to 1 day 
of exposure to common bacterial strains causing CAUTI.79 Given that the antimicrobial activity 
for both devices would be predicted to be maximal within the first 2 weeks of catheterisation 
and that for the majority of hospitalised patients any planned urinary catheterisation is of 
short duration,11 our decision to restrict trial participation to those patients predicted to have 
a period of catheterisation of between 1 and 14 days appears appropriate and does not restrict 
valid conclusions to be drawn concerning the clinical effectiveness of either technology. A test 
subanalysis adjusting for interaction catheterisation confirmed that the incidence of UTI did 
increase with increasing duration but did not provide any evidence that either antimicrobial 
catheter had greater or lesser effectiveness with its continued use up to 14 days compared 
with control.
Another key possible confounding variable was the use of prophylactic antibiotics at the time 
of catheterisation, given principally to reduce infective complications of the particular surgery 
being carried out. Again, all groups were well balanced for this variable, with approximately 
72% receiving prophylactic antibiotic, and CAUTI rates were similar irrespective of prophylactic 
antibiotic use. These findings were not altered when only participants receiving antibiotics active 
against common uropathogens were separately considered (data not shown).
In contrast to the majority of previous randomised trials concerning this technology, allocation 
concealment was managed using a computerised system that was remote from the users, thereby 
protecting against selection bias.42 The slightly higher rates of participants receiving a different 
catheter to the one allocated seen among those randomised to nitrofurazone catheters (6.7%) 
and those randomised to silver alloy catheters (4.9%) compared with control (1.1%) are most 
likely to be related to PTFE being the standard widely available control catheter and hence this 
was more likely to be chosen as an alternative if there were difficulties inserting one or other 
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guard against any bias that this might have introduced. The lack of difference in duration of 
catheterisation across the groups also suggests the inability to blind participants and clinicians 
to the allocated intervention did not result in a systematic bias in terms of one type tending to be 
removed earlier than another. In addition, the median (IQR) length of hospital stay was similar 
in all three groups at 6 (3–9) days. Follow-up was high across the groups, especially in terms of 
the primary outcome where antibiotic use was confirmed by the participant’s GP, who was likely 
to be unaware of the intervention received. Attrition throughout the trial (due to participants 
declining further follow-up or not responding to requests or due to intervening death) was low 
and there was no apparent differential loss to follow-up in the trial arms. In all other respects 
there was no evidence of bias. The pragmatic nature of our trial did have drawbacks. We did 
not monitor any other interventions that may have influenced CAUTI rates, such as methods of 
catheter insertion and catheter care violations,48 although efforts were made at all participating 
centres to emphasise the need for adherence to established best practice guidelines throughout 
the duration of the trial. To assess whether or not catheter care differed between centres, we 
did carry out a subanalysis adjusting for centre and found no difference in rates of infection 
between trial groups. There was variation in overall infection rates between centres, the reasons 
for which are likely to be multifactorial. Possible factors include differing specialties from which 
participants were recruited, variation in duration of catheterisation and variation in use of 
surgical antibiotic prophylaxis. Our pragmatic approach to trial design was intended to ensure 
that it was representative of current practice across the NHS, which enhances the generalisability 
of the trial results. It is also possible that adherence to emerging NHS-wide standards for catheter 
care may have increased over the relatively long duration of the trial as a consequence of the High 
Impact Actions initiative in NHS England.28
We decided on the 6-week period of trial participation after review of the literature, internal 
discussion and consultation with external clinical and microbiologist experts. Our rationale was 
that we aimed to have outcome data collected for at least 4 weeks after catheter removal for all 
participants and therefore allowed for a 14-day duration of catheterisation and ensured that we 
had a certain starting time and date for each participant. This was longer than previous trials 
because, in line with the pragmatic design and anticipating the short hospital stay experienced 
by most participants, we captured all relevant events and included an ongoing patient and 
community health-care perspective. It is likely that a small number of participants suffered a 
community-acquired UTI at some time during the 6-week period of trial participation, although 
their recent catheterisation will have remained a risk factor. Given the large sample size and 
consequently well-matched baseline participant characteristics we cannot envisage that the rate 
of occurrence of community-acquired UTI subsequent to catheter removal differed between the 
trial groups.
Cost-effectiveness
Within-trial analysis
The trial was not powered to detect a difference in QoL score or any health economic outcome 
and it was anticipated that it would be difficult to identify any differential effect on QoL between 
the three study groups given that the catheterisation episode itself was a minor part of the 
participants’ overall care. Despite this caveat, the economic analysis envisaged as part of this 
trial is important as it was the first opportunity to evaluate the cost-effectiveness of current 
commercially available antimicrobial catheters in a pragmatic setting and, in particular, using 
data from a large RCT. The methods of the economic analysis were rigorous and reproducible 
and efforts were made to assess the importance of uncertainty surrounding the estimates of costs, 
effects and cost-effectiveness.
The underlying assumption for the pre-planned within-trial economic evaluation was that the 
data produced by the trial would represent the best available evidence. The lack of statistical 66 Discussion
significance for key secondary outcomes is predominantly a reflection of lack of power within the 
trial for these outcomes but it is still likely that underlying distributions are reflective of reality. 
In the within-trial analysis (see Appendix 7) the main driver of likely cost-effectiveness was cost 
and, more specifically, for both nitrofurazone and silver alloy catheters, relative differences in 
length of stay. As noted above, these data require careful interpretation. The cost differences 
were not in themselves statistically significant at the 2.5% level but they drive the results of the 
within-trial analysis owing to the lack of apparent effect on QoL. A judgement is required as to 
whether or not the estimated difference in length of stay between groups is clinically plausible. 
In the base-case trial analysis the difference in length of stay is, on average, 0.3 days shorter in 
the nitrofurazone group than in the PTFE group. If the only determinant of differences in length 
of stay was whether or not an infection was suffered then this would equate to each infection 
avoided, resulting in 15 fewer days in hospital, a clearly implausible result. It is possible that there 
are other mechanisms by which the use of different catheters might influence length of stay, such 
as the bright colour of the nitrofurazone device and its association with more discomfort in use 
but the study team made a judgement that such differences were unlikely to be having such a 
sizeable effect and hence any results of an economic evaluation based on such data would also 
be unsound.
Model-based analysis
As an alternative to a within-trial analysis, a model-based analysis was also planned primarily 
to focus more closely on the costs and QALY differences between those who suffered an 
infection and those who did not. The model assumed that differences in costs and QALYs 
between randomised groups were solely a consequence of potential differences in the incidence 
of UTI. The base-case analysis did not account for unobserved heterogeneity in uncontrolled 
characteristics between those who suffered an infection and those who did not. The implication 
of this is that the analysis may be confounded by the scenario that those participants who 
suffered an infection were more likely to (1) suffer an infection because of underlying ill health; 
(2) incur extra costs not only because they have an infection but also because of the increased 
severity of their underlying condition; and (3) lose QoL again not just because they have an 
infection but because of the increased severity of their underlying condition. In order to explore 
these possibilities, a number of sensitivity analyses were performed, considering comparisons 
between those who had a UTI and those who did not in a number of subgroups that were 
hypothesised post hoc to be more homogeneous than the whole trial population.
For the model-based analysis, the mean health-care cost differences between the different trial 
groups were considerably less than the mean cost differences estimated in the within-trial 
analysis, although the direction of the differences was unaltered. This was primarily because 
the costs in the model were determined by the modest differences in infection rates and the 
difference in costs between those participants who did or did not suffer a UTI. Again, differences 
in QALYs were very small and not statistically significant.
The sensitivity analyses were conducted using more homogeneous patient subsets defined post 
hoc. These included considering only patients admitted to obstetric and gynaecology specialty 
wards; using infection rates at 3 days after catheter removal; and including only those patients 
who had an EQ-5D score of ‘1’ at 3 days. For each of these three sensitivity analyses, differences 
in QALYs were very small, but for two analyses (infection rate at 3 days and EQ-5D = 1) the 
magnitude of the estimated cost of a UTI was greater than that observed in the analysis based on 
all participants and hence the cost saving for the nitrofurazone group was greater. For the third 
sensitivity analysis, both nitrofurazone and silver alloy catheters were, on average, slightly more 
costly than PTFE and there was a < 25% probability that nitrofurazone would be less costly than 
PTFE (the probability for silver alloy was approximately 0%). However, given the distributions 
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nitrofurazone would be the most likely option to be considered cost-effective when the threshold 
value for society’s willingness to pay for a QALY was £30,000.
As already noted, one of the main components of cost was the inpatient stay. These data were 
highly skewed to the right, as they are naturally bounded by zero, but they have no logical upper 
bound and with such a large sample size there was likely to be a number of outliers with long stay 
and hence high cost. Hospital stay was truncated in line with the duration of trial participation 
at maximum of 6 weeks. This has the impact of omitting very long stays. A recent review of 
difficulties faced in handling skewed data concluded that most of the methods identified had 
undergone limited testing in different situations and their use in practice was very restricted; 
therefore, no detailed guidance could be provided.80 The authors outlined three groups of 
methods, termed orbits, which had been previously used but all related to studies with small 
sample size. The simple truncation method we applied seems a credible option for the data 
produced by our trial.
During planning of the trial we elected to measure QoL changes by participant completion of 
a relevant questionnaire (EQ-5D) at baseline, 3 days after catheter removal, at 1 and 2 weeks 
after catheter removal, and at 6 weeks after randomisation. The collection of QoL measures at 
these time points would reflect the global changes incurred by each individual as a consequence 
of undergoing and recovering from specific health-care interventions. However, the number 
of different factors influencing each participant’s score makes determining the impact of a 
particular catheter on the risk of UTI and on QoL difficult to identify. Our sensitivity analyses, 
using homogeneous participant subsets defined post hoc, suggest that there would be a trend in 
favour of nitrofurazone because, based on the primary trial outcome, there was a trend towards 
reduced infections and lower QALYs among those who suffered a UTI. For the subgroup with 
a UTI 3 days post catheter removal the mean (97.5% CI) loss of QALYs was –0.004 (–0.009 to 
0), for those who suffered a UTI but had a EQ-5D score of ‘1’ at 3 days post catheter removal it 
was –0.002 (–0.012 to 0.007) and for those admitted to obstetrics and gynaecology it was –0.007 
(–0.011 to –0.003). It is likely that the pain and discomfort associated with catheter insertion or 
removal was not captured by the EQ-5D, as the EQ-5D elicits QoL on the day it is completed, 
potentially missing the impact of preceding events of short duration.
Alternative approaches to capture short but severe effects on QoL would have been to increase 
the frequency of QoL measurement or to ask respondents to complete QoL measures when 
events occurred. The practicalities of this in terms of administrative and respondent burden make 
it unfeasible. Furthermore, even if it were possible to ask those suffering a UTI or discomfort to 
complete a QoL measure, we would need some form of control to know what the QoL decrement 
should be compared with those who are not suffering a UTI or discomfort. An alternative 
approach would be to use some of the stated preference techniques used in economics, such as 
a time trade-off, standard gamble or contingent valuation method to elicit valuations for the 
different states of health that might exist. These approaches might value the profile of outcomes 
expected following the use of each of the different types of catheter or elicit the valuations of the 
presence or absence of specific events, such as UTI or discomfort of use. Such data could then be 
used in either a within-trial or a model-based analysis.
Nitrofurazone catheters
In the first section of this chapter we summarised the main findings.81 Some evidence from our 
trial for possible modest bacteriological effectiveness of the nitrofurazone catheter is provided 
by the results using differing definitions of CAUTI reported as secondary outcomes, which show 
a consistent direction of effect. The rate of symptomatic CAUTI at 3 days following catheter 68 Discussion
removal, an outcome particularly relevant to the control of health-care-related infection in 
hospitals, showed a modest trend from 5.9% to 4.9% (p = 0.14). The rate of the more stringent 
CDC criterion outcome of microbiologically proven symptomatic UTI at 3 days was reduced 
from 1.3% to 0.7% (p = 0.05) and at 6 weeks from 4.6% to 3.2% (p = 0.02), the latter representing 
a 30% relative risk reduction. None of these results was changed by adjustment for pre-set 
confounding factors. The suggestion that, in this trial, the findings related to nitrofurazone-
impregnated catheters for secondary bacteriological outcomes have borderline statistical 
significance would be in line with those reported from the most recent meta-analysis of previous 
RCTs.42 The study given most weight in this meta-analysis was that by Stensballe et al.,82 which is 
also methodologically closest to the present trial. They used treatment for CAUTI with antibiotics 
as a secondary outcome, finding a RR of 0.27 (a reduction in incidence from 17.5% to 4.8%) in 
favour of nitrofurazone catheters among 200 patients admitted with trauma. The difference in 
our results is likely to reflect a lower risk profile in our sample together with a shorter catheter 
duration and lower intensity of care.
Our trial was not designed to explain any superiority in clinical effectiveness found for 
the technology under study and, given the lack of evidence for overall effectiveness of the 
nitrofurazone catheters, the results of any subgroup analysis should be interpreted with great 
caution. None of the tests for interaction was significant. It is plausible that participants 
randomised to use of nitrofurazone-impregnated catheters who had used antibiotics in the 
7 days prior to catheterisation would be less likely to benefit in terms of reduction in CAUTI rate 
compared with those with no previous antibiotic use, and there is some suggestion of this. This 
might reflect alteration of urogenital flora that protect against UTI.83 There is also some in vitro 
data to suggest that nitrofurazone-impregnated catheters inhibit the growth of a wider range of 
uropathogens and for a longer period compared with silver alloy-coated catheters.79 This in vitro 
superiority may not be relevant to day-to-day use for short-term catheterisation and also may be 
affected by differing release mechanisms for the antimicrobial agents in the two catheter designs.
The nitrofurazone catheters were made from silicone impregnated with the active agent, 
unlike the latex-based coated construction of the silver alloy and standard catheters. They 
might therefore be expected to have different physical characteristics that may impact on their 
use. We did find evidence that participants allocated to nitrofurazone catheters found the 
presence and removal of the catheter more uncomfortable than the standard group. The cause 
of these differences are not known but, given that the Cochrane review found that silicone 
catheters tended to result in fewer urethral side effects than latex catheters, then the material 
of manufacture is unlikely to be the problem.42 It is possible that surface changes resulting 
from the impregnation technique may be at fault or that the catheter was more rigid or had 
subtle differences in retention balloon or drainage eyelet configuration. We understand that the 
manufacturer has recently changed the manufacturing process with the aim of greater comfort of 
use (Rochester Medical, personal communication, 2010).
Evidence from previous studies comparing nitrofurazone catheters with standard silicone 
controls suggest that it is unlikely that the possible lower rate of CAUTI seen in the nitrofurazone 
group was due to its latex-free construction rather than the antibiotic content.42,82 In addition, we 
found no evidence of unsuspected latex allergy among randomised participants, although we did 
not collect data concerning the number of participants deemed ineligible because of known or 
suspected latex allergy.
Previous studies have suggested that the antimicrobial activity of the nitrofurazone coating has 
reduced effectiveness beyond 7 days of catheterisation.42 In the present trial, the effect size in 
terms of reduction in rate of symptomatic UTI in comparison with the control group did reduce 
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longer, although the study lacked power to specifically address this question with any certainty. 
Overall we did not find any evidence of interaction between duration of catheterisation and 
relative clinical effectiveness in terms of reduction in UTI risk.
Although our model-based health economic analysis suggested that nitrofurazone-impregnated 
catheters may be cost-effective, the principal driver of these results was that, based on the balance 
of data, the cost savings from avoiding an infection would compensate for the increased unit cost 
of the nitrofurazone catheter compared with PTFE. The 97.5% CI for cost savings per patient 
includes £0 but even at the upper end are relatively modest (mean difference –£7.07; 97.5% CI 
–£36.19 to £11.45). Nevertheless, given the volume of catheterisation within the NHS, even this 
small difference may lead to substantial savings overall. This finding should be treated cautiously 
given the limitations of the analysis and the considerable uncertainty particularly regarding 
estimates of key parameters, such as length of stay.
Silver alloy catheters
Following the positive findings of recent meta-analyses of the results of previous trials and the 
success of ‘fast-track’ implementation to the UK NHS in ‘Showcase Hospitals’ under the UK 
government’s Healthcare Associated Infections (HCAI) Technology Innovation Programme,52 
silver alloy-coated catheters have already been adopted by some NHS organisations as the 
preferred catheter for routine, short-term use. This was supported by uncontrolled audit data 
from the UK and USA suggesting benefit in terms of reduction in health-care-associated 
infections,63,84 although other such studies have found no beneficial effect over standard 
catheters.85 Current guidance documents from the USA and the UK still consider that although 
there is low-quality evidence in favour of the use of silver alloy antimicrobial catheters, more 
evidence of benefit, in particular in combating symptomatic UTI, is needed.29,38,86 It is therefore 
crucial that the findings of the present pragmatic trial, which failed to provide evidence that this 
technology would reduce CAUTI, are considered in the context of previous more explanatory 
trials that did find benefit.
As discussed at the start of this chapter, CIs for the present trial results were wide enough to 
include what some people would consider clinically important reductions in CAUTI {absolute 
risk reduction [mean (97.5% CI)] for silver compared with standard –0.1% (–2.4 to 2.2)}, but 
not to the extent considered important in the design of this trial. It is worth noting that this trial 
population was recruited from a range of different clinical areas and across multiple NHS hospital 
sites. This heterogeneity in population provides generalisability of our findings. Furthermore, the 
OR for the primary outcome and secondary outcomes using alternative definitions for CAUTI 
was consistently close to 1. We were also unable to identify, on post hoc analysis, a subgroup 
where use of silver alloy catheters resulted in a reduction in CAUTI compared with standard 
PTFE catheters. The recently updated meta-analysis42 found that silver alloy catheters resulted 
in a relative risk reduction for the outcome of bacteriuria (asymptomatic and symptomatic) of 
between 0.54 and 0.64 dependent on catheter duration. By far the largest study for this review 
with an associated high weighting was that by Maki et al.,87 which was published only in abstract 
form and showed a risk ratio of 0.74 (95% CI 0.56 to 0.99). The other smaller included studies 
did, however, have the same direction of effect. There are few published details of the Maki et 
al.87 study, although it does appear to have used microbiological bacteriuria found by multiple 
sampling during the period of catheterisation as the primary outcome rather than symptomatic 
UTI occurring during, or for a specified period after, catheterisation. From our trial design we 
are unable to comment whether or not bacteriuria rates during catheterisation were reduced in 
participants allocated to the silver alloy groups. Urine samples were purposefully only sampled at 
or within 3 days following catheter removal, when both bacteriuria and microbiologically proven 70 Discussion
CAUTI rates in the silver alloy group were similar to control group. What we can say is that if 
such a difference existed it did not translate to a definite reduction in the rate of symptomatic 
UTI either at 3 days or at 6 weeks. Although asymptomatic to the host, bacteria can be implicated 
in cross-infection in the clinical area. We did not collect any data concerning this possibility but 
for most surgical units with predominantly short stay and short catheter duration it may not be a 
major problem.
The study by Maki et al.87 also found no apparent correlation between bacteriuria with either 
symptoms or antibiotic use; indeed a further published report using the same patient sample 
reported no relationship between documented bacteriuria and symptomatic UTI.10 The Maki 
et al. trial87 therefore used an explanatory trial design that may not have necessarily been 
appropriate to capture information regarding relative clinical effectiveness and cost-effectiveness. 
The other large trial finding fewer cases of UTI in the silver alloy catheter group was that by 
Karchmer et al.62 This had a very different design being a cluster randomised trial involving 
clinical areas and included a crossover to the alternative intervention, the analysis of which 
prevented inclusion in the Cochrane meta-analysis. The trial objective appeared pragmatic but 
the differing trial design makes comparison with our findings difficult. In this trial, although 
clinical areas using silver alloy catheters experienced lower rates of CAUTI than areas using 
standard catheters, the actual number of patients catheterised – and of those, the number 
suffering UTI – was not stated. It appears from the report that the absolute rate of CAUTI among 
patients in the participating clinical areas was low with a difference of 3.1% compared with 2.1% 
in favour of silver alloy-coated catheters. Our more straightforward randomisation of individual 
participants led to a much lower contamination of trial arms and more explicit balancing 
of baseline characteristics to limit confounding. The trial by Karchmer et al.62 also included 
critical care areas for which the incidence was higher but no reduction in CAUTI was seen on 
subgroup analysis.
Other systematic reviews23,58 attempted to account for the apparent disparity in effect estimates 
between different trials of silver alloy catheters by stratifying studies into those published pre 
1995 and those published post 1995. This categorisation revealed that studies prior to 1995 
resulted in median relative risk reductions of bacteriuria of 56–76% (absolute risk reduction 
13–32%), whereas those from after 1995 found lower relative risk reductions of 6–47% with a 
median of 16% (absolute risk reduction 0.5–6%). One review noted that the older studies tended 
to be methodologically weaker and suggested that the earlier higher estimates of significant 
efficacy may have been unreliable. Our study finding no evidence of a benefit does fit with this 
trend of decreasing beneficial effect size for the use of silver alloy catheters in later studies that 
seem likely to have been methodologically more robust. Lack of agreement between a large, 
robustly designed, pragmatic trial and smaller initial explanatory trials has been observed 
previously where an initially promising intervention has subsequently been found to lack clinical 
effectiveness and cost-effectiveness.88 Indeed, up to one-third of meta-analyses purporting 
successful therapy are later discredited after a large-scale, well-done RCT is completed.88
Our economic model predicted that silver alloy-coated catheters were highly unlikely to be 
considered cost-effective for the UK NHS. The main driver for this was that it was unlikely that 
any reduction in cost consequent on the observed reduction in risk of CAUTI would compensate 
for the higher unit cost of the catheter. Furthermore, any gain in QALYs consequent on the 
observed reduction in CAUTI rate was unlikely to be large enough to justify any increased 
expenditure. Reflecting this, the estimated mean (97.5% CI) net additional NHS cost of silver 
alloy catheters per patient compared with PTFE was £5.00 (£4.13 to £5.92), which is about £1 less 
than the current price of a silver alloy-coated catheter currently charged to the NHS. This is an 
important conclusion given that some NHS organisations have deployed this catheter for routine 
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patient population that would be expected to receive the silver alloy catheter if routinely used. 
The population studied was also consistent with that targeted in the commissioning outline for 
the trial which reflected the information needs of the NHS.
Implications for clinical practice and the NHS
Health-care policy initiatives in both the UK and US seek to reduce health-care-associated 
infection in general, and catheter-associated in particular, by providing support for health-
care providers to follow best practice, by monitoring the incidence of health-care-associated 
infection and, in the future, by introducing financial penalties for event occurrence.89,90 Current 
strategies include primary prevention by reducing use and duration of catheterisation, secondary 
prevention by correct catheter care, and tertiary prevention by antimicrobial use.38,48 The use of 
catheters that incorporate antimicrobial agents potentially fulfils the last objective but requires 
development and successful testing of appropriate technology. Clinicians and health-care 
organisations will therefore be attentive to the findings of this trial, particularly as the volume of 
catheter usage remains high at 2.1 million people (14.5%12 of the 14.5 million people admitted to 
hospitals in the NHS in England during 2010)91 and the numbers suffering CAUTI are substantial 
– approximately 49,000 in Scotland in 2004 (Scottish CAUTI report14) and 562,000 in the USA 
in 2002.92
Antiseptics such as silver are attractive as the preventive antimicrobial component because they 
are not generally associated with bacterial ecological changes such as resistance patterns that 
may result in community harm.63 This trial was designed to fill the evidence gap identified by a 
number of literature reviews concerning the clinical effectiveness of the currently available silver 
alloy-coated catheter. Unfortunately, the findings provide no evidence that this catheter gives any 
benefit to patients or the NHS for general short-term use over the standard option. Individual 
clinicians and NHS organisations will need to consider this lack of evidence of benefit and the 
substantial current cost difference (£7.45 vs £0.91 in 2011 NHS prices4) in deciding whether to 
invest or disinvest in this technology.
As summarised at the start of this chapter, the results for nitrofurazone catheters are more 
difficult to interpret. Most importantly, we found no evidence that these catheters achieved 
our defined minimum clinically important level of effectiveness. The secondary results do 
suggest a modest bacteriological effect, which was statistically significant. The economic 
analysis suggests that this more modest reduction in UTIs could be cost-effective but with 
considerable uncertainty around the model parameter estimates. The health economic analysis 
suggested that, although any improvement in QoL as measured by QALYs is likely to be very 
modest at best and was not significant at the 97.5% level, the use of nitrofurazone catheters is 
likely to reduce net NHS costs (97.5% CI), based on model-based analysis with a reduction of 
£7.07 (–£36.19 to £11.45). Caution is required in interpreting the estimates of cost differences 
obtained from the model, as, despite the attempts to consider more homogeneous groups, 
the patient population within the trial were heterogeneous and differences in infection rates, 
costs and QALYs may be influenced by subtle but unknown imbalance between groups. These 
provisos to our conclusions should result in a cautious approach towards consideration of any 
policy change by clinicians or NHS organisations. Other more generic factors also encourage 
a cautious approach. Indiscriminate use of antimicrobials, particularly in hospitals, is actively 
discouraged because of higher risk of phenotypic changes to both infecting and commensal 
bacteria, resulting in increased virulence and widening of antimicrobial resistance.93 It remains 
unclear whether or not this would be a problem if nitrofurazone-containing catheters were more 
widely used, this not being a chosen outcome to be explored in the present trial. The evidence 
we do have, predominantly for the closely related agent, nitrofurantoin, is somewhat reassuring, 72 Discussion
as surveillance studies show a very low and stable resistant pattern amongst urinary pathogens.55 
The slight, but statistically significant, increase in catheter discomfort during and immediately 
after catheterisation may also influence views of change in practice to their wider use. It is 
unclear whether these observed differences are related to nitrofurazone release or the catheter 
material itself. It may also be the case that patients would be willing to trade off a minor degree of 
increased discomfort during catheterisation against a lower risk of UTI.
In summary, the lack of evidence found in this trial supportive of use of silver alloy catheters 
for short-term catheterisation at their current unit price will influence decisions regarding 
their continued use for this indication. Decisions regarding nitrofurazone catheters are more 
complex. At present, they appear little used in the NHS and this may be due to a number of 
factors including limited evidence, cost (£3.63, 2011 NHS price4), appearance, concerns regarding 
indiscriminate antibiotic use and commercial marketing. Clinicians and managers will have to 
weigh up the lack of improvement in rates of CAUTI shown in the present trial together with 
these wider considerations to plan any change in practice.
Catheter-associated urinary tract infection (CAUTI) remains a problem for the NHS, although 
the results from the present trial are somewhat reassuring that life-threatening consequences are 
very uncommon. There is morbidity, however, which is associated with moderate but significantly 
increased cost to the patient and to the NHS through requirement for antibiotic and further, 
potentially avoidable, use of primary and secondary care services.
Implications for research
This trial has provided evidence that silver alloy-coated catheters are not likely to be cost-effective 
for general short-term use in hospitals but a number of questions remain and there are concerns 
that chance imbalance in subtle confounders may have introduced bias against demonstrating 
potential benefit of the use of silver alloy. There has been much investment in the study of silver 
as an antimicrobial agent with both in vitro experiments and early clinical trials providing 
evidence for its bacteriological effectiveness when used as an adjunct to a number of invasive 
devices such as wound dressings, central venous lines and urinary catheters. The extent of the 
antimicrobial activity, however, does not seem so far to have been translated to pragmatic benefit 
when more clinically based outcome measures are used.94 The reasons for these conflicting 
results remain uncertain. The difference in methodology between smaller explanatory trials and 
larger pragmatic trials embedded in day-to-day clinical practice is likely to be one reason for the 
marked reduction in estimates of effect. Other reasons could be insufficient activity or release 
of the active silver agent and technological design issues concerning the coating or embedding 
of the agent in the carrier device. One solution being explored is the use of silver nanoparticles 
as an alternative drug delivery mechanism. There is no doubt that antiseptics have a number of 
advantages over antibiotics for this use and it is interesting that other well-established agents such 
as triclosan, and emerging agents such as elemental carbon and copper, are under investigation. 
In summary, research priorities regarding silver alloy catheters are to (1) establish why they are 
not effective from a clinical rather than microbiologically point of view and (2) identify newer 
agents or delivery systems/materials that increase clinical effectiveness.
The uptake of antimicrobial-containing devices is necessarily cautious given the higher risks 
of individual sensitivity and encouragement of increased bacterial virulence. Nitrofurazone 
is commonly chosen as an agent because of its wide spectrum of activity and low rates of 
resistance. The widespread use of impregnated catheters in the NHS would raise substantial 
concerns regarding possible detrimental long-term effects related to changes in the virulence 
and resistance patterns of organisms found in hospitals and in the community. Further research © Queen’s Printer and Controller of HMSO 2012. This work was produced by Pickard et al. under the terms of a commissioning contract issued by the Secretary of State for Health. 
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may be beneficial to demonstrate whether or not these concerns are likely to be realised. The 
other main issue raised by this trial is the higher rates of discomfort seen with the nitrofurazone 
catheters. Further work to (1) identify the cause and (2) determine whether or not it could 
be engineered out by further device development may be warranted. We understand that the 
manufacturer of the nitrofurazone catheters used in our study has made progress on this issue 
and the current nitrofurazone-impregnated catheter available to the NHS is considered to have 
less risk of discomfort than that used for the trial (Rochester Medical, personal communication). 
It may also be important to determine the impact of any discomfort for an individual’s overall 
experience during an episode in hospital. It may be that patients would be happy to accept a mild 
degree of increased discomfort in return for a smaller risk reduction for CAUTI than that sought 
in our trial. These aspects could be explored in QoL studies among recipients and potential 
recipients of the different types of catheter.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Pickard et al. under the terms of a commissioning contract issued by the Secretary of State for Health. 
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Chapter 8  
Recommendations and further research
Implications for the NHS and patients
Catheter-associated urinary tract infection remains an important cause of health-care-related 
morbidity worldwide and therefore a target for development of effective preventative strategies. 
This trial examined the clinical effectiveness and cost-effectiveness of the short-term use of two 
widely available antimicrobial catheters and found that neither reached our prestated levels 
of clinical or statistical significance. Our health economics model predicted that the silver 
alloy-coated catheter tested was unlikely to be cost-effective for use in the NHS at its unit price. 
Although the results of the economic analysis for the nitrofurazone-impregnated catheter were 
more favourable there was a high degree of uncertainty. For NHS organisations in which these 
interventions are already in use there may be an opportunity to reallocate resources without loss 
of benefit, whereas those organisations considering implementation may wish to await further 
evidence of benefit or the emergence of alternatives.
At present it seems appropriate for patients, clinicians and the NHS to persist with simple 
strategies to prevent CAUTI, such as avoidance of catheter use, aseptic catheter insertion and 
limitation of duration of catheterisation, as emphasised in recent guidance documents.
Unanswered questions and further research
Minimum clinically important difference
It remains difficult for researchers and trial designers to determine the necessary level of clinical 
effectiveness required as a basis for decisions about policy and practice. Standardisation of 
methods of setting the prestated minimum clinically important difference is required.
Core outcomes
In common with many areas of research, there is a lack of consensus of what outcome measures 
should be used, which leads to difficulty in systematically summarising results of different trials 
and in performing statistical meta-analysis. We suggest that definition of a core outcome set for 
trials of interventions for UTI would be beneficial and the COMET initiative95 would be useful in 
planning such research.
Valuation of benefit
Assessment of both the costs and consequences in terms of health-related QoL of interventions, 
such as urethral catheterisation, which are a subsidiary part of the care of people undergoing a 
more major intervention, such as elective surgery, is problematic. Accurate but feasible methods 
of capturing any changes in well-being specific to the subsidiary intervention and the costs 
associated purely with the benefits and harms of the subsidiary intervention are required.
Further exploration of antimicrobial devices
The concept of antimicrobial catheters as a device to reduce risk of CAUTI remains attractive 
but exploration of different antimicrobial agents and methods of retention in materials used for 
catheter manufacture is required.76 Recommendations and further research
Alternatives to a very short duration catheterisation
Many participants in our trial had catheter duration of less than 2 days but remained at high 
risk of suffering CAUTI. Alternatives to very short periods of indwelling catheterisation should 
be sought.
Other interventions to reduce catheter-associated urinary 
tract infection
Much progress has been made in providing training and monitoring of techniques of 
catheter insertion and catheter care. More recently, monitoring of CAUTI has been mandated 
for Medicare providers in the USA and included as a voluntary option for NHS provider 
organisations. One less researched possibility is to reduce catheter duration. Current guidance 
suggests that duration of < 24 hours should be the norm (USA) or that duration should be 
minimised (UK). Catheter duration is often part of entrenched care pathways and altering these 
requires behavioural change. Research to establish mechanisms to drive behavioural change and 
empower patients would be useful to find out whether or not ‘bottom-up’ approaches are more 
effective than ‘top-down’ initiatives such as guidelines and policy documents.
Alternative uses of antimicrobial catheters
There is no evidence concerning the effectiveness of antimicrobial catheter devices for longer-
term catheterisation, intermittent catheterisation or suprapubic catheterisation. Further early-
phase evidence of efficacy is first required.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Pickard et al. under the terms of a commissioning contract issued by the Secretary of State for Health. 
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Appendix 1  
Critical appraisal of the economic 
studies using a checklist for assessing 
economic evaluations
E
 
conomic studies were appraised as described in Drummond 2005.9688 Appendix 1
Study 1
Plowman R, Graves N, Esquivel J, Roberts JA. An economic model to assess the cost and 
benefits of the routine use of silver alloy coated urinary catheters to reduce the risk of UTIs in 
catheterized patients. J Hosp Infect 2001;48:33–42.
Yes/partly/no/unclear Comments
1.  Was a well-defined question 
posed in an answerable form?
Yes The authors considered both the costs and the effects (number of NUTIs) of silver 
alloy-coated catheters. The viewpoint for the analysis was explicitly stated as that 
of the NHS
2.  Was a comprehensive 
description of the competing 
alternatives given?
No No comparator was used, as the study objective was to assess the number of 
NUTIs occurring in catheterised patients admitted to specialties of interest at one 
or more hospitals; the economic burden those infections impose on the hospital 
sector in terms of number of extra days patients remain in hospital and their 
associated value; and the potential benefits of an intervention that aims to reduce 
the incidence of this type of infection
3.  Was the effectiveness of 
the programmes or services 
established?
Yes  The authors stated that literature on the incidence of NUTIs, risk factors for them, 
their impact on the mortality and the economic burden imposed was reviewed. The 
authors also identified the costs of an additional day in hospital and the cost of the 
intervention
4.  Were all the important 
and relevant cost and 
consequences for each 
alternative identified?
Yes  The relevant costs and consequences were identified
5.  Were costs and consequences 
measured accurately in 
appropriate physical units?
Yes The parameters used to populate the model included the number of admissions to 
the specialties of interest, the number (or proportion) of patients within the group 
of interest, the number of patients catheterised, the estimated incidence of NUTIs 
occurring in catheterised patients, the average number of additional days that 
catheterised patients with a NUTI stayed in hospital, and the cost of an additional 
day in hospital
6.  Were the costs and 
consequences valued credibly?
Yes  Data on number of admissions and specialties were obtained from the Hospital 
Episode Statistics database and number of patients catheterised were obtained 
from an audit carried out in England and Wales. Estimates of costs per bed-day 
were retrieved from the Chartered Institute of Public Finance Accountants health 
service data base. The additional cost of the silver alloy catheter was based on 
personal communication with the manufacturer
7.  Were costs and consequences 
adjusted for differential timing?
No Not relevant
8.  Was incremental analysis 
of costs and consequences 
performed?
No The model was not set up to compare different interventions, although it could be 
adapted to do so, therefore no incremental analysis was performed although the 
results suggest the reduction in incidence of NUTIs that would be required to cover 
the cost of the intervention
9.  Was allowance made for 
uncertainty in the estimates of 
cost and consequences?
Yes One-way sensitivity analysis was performed using the following parameters: 
incidence of NUTI additional bed-days and the value of extra bed-days
10. Did the presentation and 
discussion of study results 
include all issues of concern to 
users?
Partly The author highlighted the issues that the users should consider if they were to 
use results of the analysis. The model was set up to so that it could be adapted to 
the particular needs of the user
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Study 2
Rupp ME, Fitzgerald T, Marion Mario N, Helget V, Puumala S, Anderson JR, et al. Effect of 
silver-coated urinary catheters: efficacy, cost-effectiveness, and antimicrobial resistance. Am J 
Infect Control 2004;32:445–50.
Yes/no/partly/unclear Comments
1.  Was a well-defined question 
posed in an answerable 
form?
Yes The authors have considered both the costs and the effects (UTIs avoided) of two 
comparators. The viewpoint for the analysis has not been explicitly stated, although it 
appears to be that of the health service provider
2.  Was a comprehensive 
description or the competing 
alternatives given?
Partly The competing alternatives have been cited as uncoated catheter and no further 
details have been provided. The information on the types of catheters is included 
under the cost-effectiveness heading and therefore not obvious to the reader
3.  Was the effectiveness of 
the programmes of services 
established?
Yes The rate of infection expressed as UTI/1000 was collected prospectively in 2001 
and 2002 (when coated urinary catheters were in use) and compared with historical 
controls for the same units for 1999 and 2000 (when uncoated urinary catheters 
were used)
4.  Were all the important 
and relevant cost and 
consequences for each 
alternative identified?
Yes The relevant costs and consequences were identified from various sources. The 
number and cost of catheters and costs associated with NUTI were identified
5.  Were costs and 
consequences measured 
accurately in appropriate 
physical units?
Yes The measure of UTI was based on the number of UTI per 1000 catheter-days, which 
appears to be the most widely used method of measuring the rate of infection. The 
number of catheters used was obtained from hospital purchasing department records
6.  Were the costs and 
consequences valued 
credibly?
Yes The purchase cost of the catheters was provided by the manufacturer and the costs 
associated with NUTIs were derived from the medical literature and ranged from 
US$589 to $3805. No details were provided on how the costs associated with NUTI 
were arrived at
7.  Were costs and 
consequences adjusted for 
differential timing?
No The costs and consequences were not adjusted for differential timing. However, 
it was not necessary as the analysis was conducted at one time point in time and 
the analytic horizon, from the beginning of the interventions to the resolutions in 
outcomes of interest, was well inside 1 year
8.  Was incremental analysis 
of costs and consequences 
performed?
Yes The results are presented explicitly in the text as well as the relevant tables. The 
analysis does not provide the cost-effectiveness ratios for the comparator, as it mainly 
focuses on the incremental effectiveness and the cost savings associated with silver 
alloy catheter
9.  Was allowance made for 
uncertainty in the estimates 
of cost and consequences?
No Uncertainty was not explicitly handled, although the authors presented some low 
and high range estimates in the cost analysis. There was also some analysis on the 
percentage reduction break-even efficacy threshold (37–57%)
10. Did the presentation and 
discussion of study results 
include all issues of concern 
to users?
Yes The results are compared with published papers. Although data were also collected 
on the UTI/1000 patient-days the authors did not perform any cost analysis using this 
data, which had lower differences in the overall rates. The authors indicated the need 
for decision-makers to use caution when accepting the cost figures and that they 
should examine the data carefully in the context of their experience
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Saint S, Veenstra DLD, Sullivan SDS, Chenoweth C, Fendrick AM. The potential clinical and 
economic benefits of silver alloy urinary catheters in preventing urinary tract infection. Arch 
Intern Med 2000;160:2670–5.
Yes/no/partly/unclear Comments
1.  Was a well-defined question 
posed in an answerable 
form?
Yes The authors considered both the costs and effects (incidence of symptomatic UTI 
and bacteraemia). The costs and consequences of two types (silver and standard) of 
catheters were compared. The perspective of the analysis was stated as that of the 
health-care payer
2.  Was a comprehensive 
description of the 
competing alternatives 
given?
Yes  The competing alternatives were described
3.  Was the effectiveness of 
the programmes or services 
established?
Yes The authors addressed the clinical evidence using evidence from published studies 
including a meta-analysis they had performed. They used a decision-analytic model 
to inform decision-makers on the clinical and economic impact of using urinary 
catheters coated with silver alloy
4.  Were all the important 
and relevant cost and 
consequences for each 
alternative identified?
Yes  All of the relevant costs and consequences were addressed
5.  Were costs and 
consequences measured 
accurately in appropriate 
physical units?
Yes  The measurement of consequences was derived from several published sources 
and was also based on assumptions that the authors made. The consequences were 
measured in terms of likelihood of clinical events. Details were also provided on how 
the authors arrived at the estimates for the protective effect of systemic antimicrobial 
agents and silver catheters. The measurement of costs of the interventions and the 
consequential resource use costs were straightforward
6.  Were the costs and 
consequences valued 
credibly?
Yes  As the effects are measured in natural units it was not appropriate to value them in 
monetary terms. The reporting of the valuation of costs was handled adequately from 
the stated perspective
7.  Were costs and 
consequences adjusted for 
differential timing?
No Costs and consequences were not discounted to present values as it was 
inappropriate as they all appeared in the present
8.  Was incremental analysis 
of costs and consequences 
performed?
Yes The study could have benefited from a results table as the results were reported in 
the text
9.  Was allowance made for 
uncertainty in the estimates 
of cost and consequences?
Yes The authors performed threshold and sensitivity analysis on several variables as 
reported in tables 1 and 2 to handle the uncertainty in their analysis
10. Did the presentation and 
discussion of study results 
include all issues of concern 
to users?
Partly The analysis does not provide cost-effectiveness ratios for the alternatives. It focuses 
on the percentage relative decrease in the incidence of symptomatic UTI and 
estimated cost saving per patient. The authors highlighted the limitations of their 
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Karchmer TBT, Giannetta ET, Muto CA, Strain BA, Farr BM. A randomized crossover study of 
silver-coated urinary catheters in hospitalized patients. Arch Intern Med 2000;160:3294–8.
Yes/no/partly/unclear Comments
1.  Was a well-defined question 
posed in an answerable 
form?
Yes The authors considered the costs and benefits (reduction in UTIs) of two interventions. 
The viewpoint for the analysis has not been explicitly stated although it appears to be 
that of the health service provider
2.  Was a comprehensive 
description or the 
competing alternatives 
given?
Partly Uncoated catheters were explicitly stated as the comparator although no justification 
was provided for this choice
3.  Was the effectiveness of 
the programmes of services 
established?
Yes The authors collected data over 1 year. During the first 6 months, wards randomised 
to group 1 were stocked with silver-coated catheters, whereas those in group 2 used 
uncoated catheters, and after a 1-month washout period the catheters were changed. 
Hospital-wide surveillance for nosocomial infections was conducted
4.  Were all the important 
and relevant cost and 
consequences for each 
alternative identified?
Yes The authors collected data on costs associated with catheters, type of infection and 
the hospital where the data were collected
5.  Were costs and 
consequences measured 
accurately in appropriate 
physical units?
Yes The costs of the catheters and components used were obtained from the 
manufacturer. The rates of infection were calculated in similar methods used by other 
studies, i.e. number of infections per 100 patients, per 1000 patient-days and per 
100 catheters
6.  Were the costs and 
consequences valued 
credibly?
Yes The costs and consequences were reported separately and adequate details of 
methods of cost estimation were provided but the constituents of the costs were not 
fully reported. It was not clear if the cost data were based on true costs or charges
7.  Were costs and 
consequences adjusted for 
differential timing?
No  The costs and consequences were not adjusted for differential timing. However, 
it was not necessary as the analysis was conducted at one time point in time and 
the analytic horizon, from the beginning of the interventions to the resolutions in 
outcomes of interest, was well inside 1 year
8.  Was incremental analysis 
of costs and consequences 
performed?
Yes Costs and benefits were not combined, as the use of the silver-coated catheters was 
the dominant strategy
9.  Was allowance made for 
uncertainty in the estimates 
of cost and consequences?
No No sensitivity analysis was conducted
10. Did the presentation 
and discussion of study 
results include all issues of 
concern to users?
Partly The results of the study should be interpreted cautiously owing to the limitations of 
the study design, lack of sensitivity analysis and the lack of statistical analysis of the 
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Lai KK, Fontecchio SA. Use of silver-hydrogel urinary catheters on the incidence of catheter-
associated urinary tract infections in hospitalized patients. Am J Infect Control 2002;30:221–5.
Yes/no/partly/unclear Comments
1.  Was a well-defined 
question posed in an 
answerable form?
Yes The authors considered the costs of CAUTI by comparing coated and non-coated 
catheters. The perspective of the study was not explicitly stated but it appears to be 
that of the health service provider
2.  Was a comprehensive 
description of the 
competing alternatives 
given?
Partly  The authors did not provide much detail about the non-coated catheters but stated that 
they were non-coated, standard urinary catheters. More details were provided on the 
type and manufacturer of the coated silver hydrogel catheter
3.  Was the effectiveness 
of the programmes or 
services established?
Yes  The primary clinical outcome was CAUTI rate per 1000 patient-days and was derived 
by dividing the number of UTIs with the patient-days of all hospitalised patients. The 
rate for the non-coated catheters was estimated historically by using the two months’ 
data (January 1996 and January 1997), whereas the rate for the coated catheter was 
estimated in the month of January 1997
4.  Were all the important 
and relevant cost and 
consequences for each 
alternative identified?
Yes Medical records were reviewed closely for resource utilisation, such as laboratory tests 
and antibiotics among others that were related to CAUTI
5.  Were costs and 
consequences measured 
accurately in appropriate 
physical units?
Partly  Although the study reported that all patients with CAUTI were identified along with the 
costs and consequences of CAUTIs, the cost analysis was performed on a randomly 
selected group of patients and no justification was provided for this decision. Also the 
costs were estimated using assumptions on the number of UTI that would be observed 
monthly using different number of data points for the two different groups. It is 
therefore hard to establish how reliable and generalisable the results are
6.  Were the costs and 
consequences valued 
credibly?
Yes  Charges for the resources used for CAUTI were obtained and tallied to obtain the 
average cost of CAUTI at the medical centre
7.  Were costs and 
consequences adjusted for 
differential timing?
No The costs and consequences were not adjusted for differential timing. However it was 
not necessary as the analysis was conducted at one time point in time and the analytic 
horizon, from the beginning of the interventions to the resolutions in outcomes of 
interest, was well inside 1 year
8.  Was incremental 
analysis of costs and 
consequences performed?
Yes Based on the assumptions on the number of catheters per year the centre would have 
216 fewer CAUTI when they used the coated catheters. This translated into a net 
saving of US$142,315 per year as a reduction in the rate of CAUTI 
9.  Was allowance made 
for uncertainty in the 
estimates of cost and 
consequences?
No No sensitivity analysis was conducted
10. Did the presentation 
and discussion of study 
results include all issues of 
concern to users?
Partly The authors indicate that their results were not statistically significantly different 
between the same groups and compared their findings with some of the published 
studies. They also highlighted the limitations of their study that included the fact that 
it was not a randomised controlled study but relied on a historical control and that 
demographic data and risk factor data were not gathered for the two groups of patients 
to see whether or not they were comparable. There were also issues relating to bias 
that had not been addressed and it is therefore difficult to determine how generalisable 
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Bologna RA, Tu LM, Polansky M, Fraimow HD, Gordon DA, Whitmore KE. Hydrogel/silver 
ion-coated urinary catheter reduces nosocomial urinary tract infection rates in intensive care 
unit patients: a multicenter study. Urology 1999;54:982–7.
Yes/no/partly/unclear Comments
1.  Was a well-defined 
question posed in an 
answerable form?
Unclear The authors stated that they investigated the Bardex IC catheter for its ability to reduce 
NUTI
2.  Was a comprehensive 
description of the 
competing alternatives 
given?
Yes Although a description of the coated catheter was provided it was implied that the 
catheters were similar and the difference was that one was coated and the other was 
not. The alternative used in the standard catheter group was the standard type of 
catheter in use
3.  Was the effectiveness 
of the programmes of 
services established?
Yes Five institutions participated in the study. Infections were identified in three ways: 
prospective review of microbiology reports of patients, review of antimicrobial usage 
and through formal chart reviews during daily rounds. CAUTIs were determined by the 
number of infections per 1000 days the patients had an indwelling catheter. A baseline 
period using a standard latex catheter was selected at each hospital during which 
time usage rate and NUTI rate were monitored. A blind switch was made to Bardex IC 
catheter
4.  Were all the important 
and relevant cost and 
consequences for each 
alternative identified?
No Only the cost of the catheters was reported. The authors stated that it was difficult to 
estimate the cost of hospitalisation, extent of patient evaluation and increased duration 
of hospitalisation if any that a NUTI induced
5.  Were costs and 
consequences measured 
accurately in appropriate 
physical units?
Partly The outcome NUTI was measured in a similar to that in other studies. Although the 
study was performed in five hospitals the costs analysis was performed in the only 
centre that reported statistically significantly different results in NUTIs. The cost of the 
catheters was stated as cost per catheter although it was not clear where the costs 
came from
6.  Were the costs and 
consequences valued 
credibly?
Partly See above
7.  Were costs and 
consequences adjusted 
for differential timing?
No The costs and consequences were not adjusted for differential timing. However, it was 
not necessary, as the analysis was conducted at one point in time and the analytic 
horizon, from the beginning of the interventions to the resolutions in outcomes of 
interest, was well inside 1 year
8.  Was incremental 
analysis of costs and 
consequences performed?
Partly Incremental analysis was performed for the NUTI but none was carried out for the costs
9.  Was allowance made 
for uncertainty in the 
estimates of cost and 
consequences
No No sensitivity analysis was performed
10. Did the presentation and 
discussion of study results 
include all issues of 
concern to users?
Partly The authors had some discussion of their results and highlighted two issues that 
needed to be considered. They also compared their findings with those of other studies. 
The authors did not explore how their findings were generalisable beyond the trial but 
identified a need for further research. One of the limitations of the study was that there 
was some variability number of months for which the catheters were used. This was in 
the hospitals themselves, as well as between the hospitals. The adjusted analysis did 
not take into account this variability
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Algorithm to determine primary outcome
C
onsenting participants that reached week 6 of the trial (excluding any deaths within 7 days of 
randomisation) were checked to see if they had a confirmed UTI at 3 days (‘given antibiotics 
for a UTI since removal of the catheter’ from the 3-day urine results form or ‘given antibiotics 
for UTI during catheterisation’ from participant data form). If they had a UTI at 3 days then they 
were logged as having a confirmed UTI during the study.
All participants without a confirmed UTI at 3 days were checked to see if they had a symptom or 
antibiotics reported in any returned diary or 6-week questionnaire. For example, in the diaries 
if the answer was ‘yes’ to any of the following questions ‘In the past 7 days have you had a urine 
infection?’ or ‘Did you see a doctor in relation to a urine infection?’ or ‘Did you see a nurse in 
relation to a urine infection?’ or ‘Did you receive antibiotics for a urine infection?’ or text was 
present in the box ‘If yes to Question 4, which antibiotics did you receive?’ and they had not 
already had a confirmed UTI and their GP had not been previously contacted then a letter would 
be sent requesting GP confirmation of antibiotic prescription between the date of recruitment 
and end date (42 days after randomisation). The same process was repeated for the 2-week diary 
and the 6-week questionnaire.
If a participant had no UTI at 3 days and had not returned any symptom data in the diaries or 
questionnaire then they were followed up by a letter to their GP asking if the participant had 
been diagnosed with a UTI and whether or not antibiotics had been prescribed between the date 
of recruitment and end date (42 days after randomisation).
Participants who had not had a confirmed UTI at 3 days and did not meet the criteria for having 
a letter sent out to GP were recorded as having no UTI during the study.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Pickard et al. under the terms of a commissioning contract issued by the Secretary of State for Health. 
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Full logistic regression model for the 
primary outcome
TABLE 42   Full logistic regression model for the primary outcome (used to estimate adjusted effect sizes)
Covariate OR 95% CI p-value
Nitrofurazone 0.81 0.67 to 0.98 0.031
Silver 0.96 0.80 to 1.16 0.686
Female 2.21 1.83 to 2.67 < 0.001
Age > 60 years 1.39 1.18 to 1.63 < 0.001
Comorbidity 0.97 0.81 to 1.17 0.742
Emergency catheterisation 1.27 0.88 to 1.85 0.207
Antibiotic use last 7 days 0.68 0.56 to 0.82 < 0.001
Antibiotic use at catheterisation 0.91 0.76 to 1.10 0.332© Queen’s Printer and Controller of HMSO 2012. This work was produced by Pickard et al. under the terms of a commissioning contract issued by the Secretary of State for Health. 
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Within-trial cost-effectiveness analysis
Introduction
This appendix describes the results of the prestated within-trial cost-effectiveness analysis. As 
described elsewhere, concerns that imbalances between trial groups could not be adequately 
adjusted for, particularly with respect to length of stay, led to a judgement that the within-trial 
analysis might be potentially misleading. Nevertheless, as this judgement could be questioned, 
this analysis is provided here for completeness. In the main analysis presented, the data are taken 
at face value.
Analysis of resource use and costs
Table 43 (a replication of Table 27) and Table 44 detail the average resource use and the mean 
differences both for the catheters used, and for subsequent use of health services. For the 
comparisons of the PTFE group with nitrofurazone, and PTFE with silver alloy, there was no 
use of health services that was statistically significantly different between the groups. For both 
comparisons the CIs for most areas of resource use were sufficiently narrow to rule out any 
economically important differences (although this is a subjective judgement). The exception 
to this is differences in length of stay, for which the CIs could potentially include economically 
important differences.
TABLE 43  NHS resource use for each trial intervention
Resource type Nitrofurazone (n), mean (SD) Silver alloy (n), mean (SD) PTFE (n), mean (SD)
Intervention
Catheter allocation and no. of catheters used 2153, 1.03 (0.21) 2097, 1.04 (0.29) 2144, 1.03 (0.21)
Secondary care resource use
Length of stay  2104, 7.27 (6.58) 2047, 7.72 (6.87) 2102, 7.57 (7.00)
Outpatient visit 1668, 0.02 (0.28) 1614, 0.02 (0.17) 1671, 0.02 (0.19)
Visit to other providers 1656, 0.02 (0.41) 1605, 0.01 (0.14) 1662, 0.01 (0.20)
Inpatient readmissions 1669, 0.08 (1.26) 1605, 0.01 (0.24) 1673, 0.02 (0.54)
Primary care resource use
GP doctor visit 1661, 0.11 (0.44) 1605, 0.13 (0.47) 1659, 0.12 (0.45)
GP nurse visit 1667, 0.03 (0.27) 1606, 0.04 (0.34) 1669, 0.05 (1.05)
Medications
Antibioticsa 1160, 0.18 (0.38) 1130, 0.18 (0.39) 1154, 0.20 (0.40)
a  As reported on participant-completed questionnaire.152 Appendix 7
Estimation of NHS costs
Tables 45 and 46 are conversions of Tables 43 and 44 into costs to the NHS. As indicated by the 
SD, the cost data were highly skewed to the right; while most of the patients had low costs, some 
of them had very high costs. In terms of NHS costs (see Tables 45 and 46) incurred after the 
patients received the catheters, the mean total cost per patient in the nitrofurazone group was 
£3259 (SD £3152), the mean cost in the silver alloy group was £3438 (SD £3270) and the mean 
cost of the PTFE group was £3390 (SD £3405). There was, however, no evidence of statistically 
significant differences in the total mean costs or other costs, although the CIs are sufficiently 
wide to include economically important differences that may favour any of the catheters. The 
mean difference in costs per patient of catheters for the intervention groups compared with 
PTFE was higher for both: nitrofurazone (£4.19, 97.5% CI 4.11 to 4.26) and silver alloy (£5.39, 
97.5% CI 5.30 to 5.49). Reflecting the findings described above, other costs tended to be lower 
in the nitrofurazone group, particularly differences in length of stay, which was the main driver 
of differences in mean costs between groups. The implications of differences in length of stay are 
explored later as part of the sensitivity analysis.
Quality-adjusted life-years
Table 47 reports the EQ-5D scores for trial groups at baseline, 3 days, 1 and 2 weeks after catheter 
removal and 6 weeks after randomisation. Also reported is the mean difference between the 
groups in EQ-5D score at these time points (Table 48). From these data it was estimated that 
the mean QALYs were 0.081 (SD 0.02) for the nitrofurazone group, 0.079 (SD 0.02) for the 
silver alloy group and 0.081 (SD 0.02) for the PTFE group. The mean difference in QALYs after 
adjusting for minimisation and baseline EQ-5D scores was 0.0002 (97.5% CI –0.002 to 0.002) 
higher QALY value for nitrofurazone group compared with PTFE, which was not statistically 
significant. For the silver alloy group QALYs were, on average, –0.001 (97.5% –0.003 to 0.001) 
lower for the PTFE group, and, again, this difference was not statistically significant. Although it 
is a matter of judgement, the difference in QALYs as described by the CIs is small and may not 
include a meaningful difference.
TABLE 44  Mean differences for NHS resource use for each pair-wise comparison with PTFE
Resource type
Antimicrobial-impregnated (nitrofurazone) vs 
PTFE: mean difference (97.5% CI)
Antiseptic-impregnated (silver alloy) vs PTFE:  
mean difference (97.5% CI)
Intervention
Catheter 0.005 (–0.01 to 0.02) 0.007 (–0.01 to 0.02)
Secondary care resource use
Length of stay –0.30 (–0.77 to 0.17) 0.15 (–0.34 to 0.63)
Outpatient visit –0.003 (–0.02 to 0.02) –0.001 (–0.02 to 0.01)
Visit to other providers 0.008 (–0.02 to 0.03) –0.0002 (–0.01 to 0.01)
Inpatient readmissions 0.06 (–0.01 to 0.14) –0.008 (–0.04 to 0.02)
Primary care resource use
GP doctor visit –0.01 (–0.05 to 0.02) 0.010 (–0.03 to 0.05)
GP nurse visit –0.02 (–0.08 to 0.04) –0.006 (–0.07 to 0.06)
Medications
Antibioticsa –0.02 (–0.06 to 0.01) –0.017 (–0.05 to 0.02)
a  As reported on participant-completed questionnaire.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Pickard et al. under the terms of a commissioning contract issued by the Secretary of State for Health. 
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Estimation of cost-effectiveness
Incremental cost per infection averted
Taking the results of the primary outcome reported in detail in Table 13 in Chapter 5 and 
the differences in cost reported in Table 46, a three-way comparison of the different catheter 
groups was made (Table 49). On average, nitrofurazone was associated with lower costs, with 
a cost reduction of £108, and was more effective, being associated, on average, with 0.021 
UTIs compared with PTFE. An incremental cost per infection avoided is not calculated in this 
circumstance, as, on average, nitrofurazone is less costly and more effective. On average, the care 
of participants in the silver alloy group cost £81 more than PTFE but the patients suffered 0.001 
TABLE 45  NHS costs for each trial intervention
Resource type Nitrofurazone (n), mean £ (SD) Silver alloy (n), mean £ (SD) PTFE (n), mean £ (SD)
Intervention
Catheter 2153, 5.15 (1.19) 2097, 6.34 (1.86) 2144, 0.96 (0.65)
Secondary care resource use
Length of stay 2104, 3302.98 (3107.74) 2047, 3505.72 (3266.80) 2102, 3444.63 (3397.18)
Outpatient visit 1668, 1.63 (26.10) 1614, 1.81 (16.28) 1671, 1.91 (18.30)
Visit to other providers 1661, 0.87 (12.13) 1606, 1.04 (13.05) 1664, 1.16 (18.70)
Inpatient readmissions 1669, 26.53 (412.18) 1605, 3.88 (77.16) 1673, 6.67 (177.44)
Primary care resource use
GP doctor visit 1661, 3.88 (15.80) 1605, 4.67 (17.08) 1659, 4.32 (16.33)
GP nurse visit 1667, 0.35 (2.68) 1606, 0.45 (3.43) 1669, 0.51 (10.49)
Medications
Antibiotics 1160, 0.96 (2.06)  1130, 0.98 (2.09) 1154, 1.07 (2.16)
Total 2153, 3259 (3152) 2097, 3438 (3270) 2144, 3390 (3405)
TABLE 46  NHS cost differences for each pair-wise comparison with PTFE
Resource type Nitrofurazone (A), mean difference (97.5% CI)a Silver alloy (B), mean difference (97.5% CI)a
Intervention
Catheter 4.19 (4.12 to 4.26) 5.39 (5.30 to 5.49)
Secondary care resource use
Length of stay  –127.81 (–338.98 to 83.35) 101.16 (–112.22 to 314.54)
Outpatient visit –0.26 (–2.08 to 1.55) –0.10 (–1.51 to 1.30)
Other health-care providers –0.29 (–1.60 to 1.01) –0.15 (–1.42 to 1.13)
Inpatient readmissions 21.00 (–4.73 to 46.73) –4.03 (–15.34 to 7.27)
Primary care resource use
GP doctor visit –0.44 (–1.75 to 0.87) 0.20 (–1.15 to 1. 56)
GP nurse visit –0.16 (–0.76 to 0.44) –0.08 (–0.71 to 0.54)
Medications
Antibiotics –0.13 (–0.33 to 0.07) –0.12 (–0.33 to 0.08)
Total  –108.49 (–319.09 to 102.10) 81.37 (–131.07 to 293.81)
a  All differences adjusted for sex, age, reason for catheterisation, comorbidities, antibiotic use at 7 days, antibiotic use at catheterisation and CI 
based on bootstrapped data.154 Appendix 7
fewer UTIs. Therefore, the incremental cost per number of infections was £81,370 for silver alloy 
compared with PTFE.
The data presented above do not reflect the statistical imprecision surrounding estimates of 
costs and infections. Therefore, Tables 49 and 50 also show the probability that an intervention 
would be considered cost-effective at different threshold values for society’s willingness to pay 
to avoid an infection. These data show that nitrofurazone had an approximately 90% chance of 
being considered cost-effective at all willingness-to-pay thresholds considered. The main driver 
of these data is the trend towards lower costs in the nitrofurazone group compared with control 
(which, in turn, are driven by the trend towards a shorter length of stay). The probability of either 
silver alloy or PTFE being cost-effective over the range of threshold values considered was low 
(approximately 9% for PTFE and between 1% and 3% for silver alloy).
Sensitivity analysis on the cost and risk reduction differences
Incremental cost-effectiveness ratio results of two-way sensitivity analyses using the 2.5th and 
97.5th percentile values for both costs and absolute risk reduction reported in Table 46 and below 
(see Table 54) for nitrofurazone compared with PTFE ranged from £2431 to £319,090. The ICERS 
for silver alloy compared with PTFE ranged from £5958 to £12,242.
Incremental cost per quality-adjusted life-years gained
The cost-effectiveness results for nitrofurazone indicate that, on average, it is less costly and more 
effective than PTFE (although the CIs surrounding costs in particular are very wide). The results 
TABLE 47  Quality of life for each trial intervention
EQ-5D Nitrofurazone (n), mean (SD) Silver alloy (n), mean (SD) PTFE (n), mean (SD)
Baseline 2126, 0.717 (0.29) 2076, 0.722 (0.29) 2123, 0.722 (0.30)
3 days 1859, 0.592 (0.27)  1801, 0.578 (0.28) 1871, 0.593 (0.27)
1 week 1363, 0.618 (0.27)  1308, 0.601 (0.29) 1366, 0.614 (0.27)
2 weeks 1405, 0.696 (0.26)  1328, 0.686 (0.27) 1398, 0.694 (0.25)
6 weeks 1704, 0.776 (0.24)  1665, 0.782 (0.24) 1721, 0.794 (0.23) 
QALYsa 1116, 0.081 (0.02) 1077, 0.079 (0.02) 1123, 0.081 (0.02)
a  Small value for QALYs is because the trial follow-up is 6 weeks. The maximum QALYs would have been 0.115 over a 6-week period.
TABLE 48  Quality-adjusted life-year differences for each pair-wise comparison with PTFE
EQ-5D Nitrofurazone, mean (97.5% CI) Silver alloy, mean (97.5% CI)
Baseline
3 days –0.001 (–0.021 to 0.019) –0.015 (–0.035 to 0.006)
1 week 0.004 (–0.019 to 0.027) –0.012 (–0.037 to 0.012)
2 weeks 0.002 (–0.020 to 0.023)  –0.008 (–0.030 to 0.014)
6 weeks –0.018 (–0.036 to 0.001) –0.012 (–0.030 to 0.006)
QALYsa 0.0002 (–0.002 to 0.002) –0.001 (–0.003 to 0.001)
a  All differences adjusted for sex, age, reason for catheterisation, comorbidities, antibiotic use at 7 days, antibiotic use at catheterisation and CI 
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for the silver alloy catheter group indicate that, on average, silver alloy is more costly and less 
effective than PTFE (i.e. again CIs surrounding costs in particular are wide). Also included in 
Table 50 are the results of the probabilistic sensitivity analysis (described in more detail below). 
These results show the likelihood for each pair-wise comparison that an intervention would be 
considered cost-effective at different illustrative thresholds for society’s willingness to pay for a 
QALY ranging from £0 to £50,000. When the willingness to pay for a QALY is £0, this means that 
society is not willing to pay for any additional QALYs. However, in the context of this evaluation, 
one interpretation of differences in QALYs reported in Table 48 is that there is no meaningful 
difference in QALYs. In such a circumstance the decision is made on cost alone which is 
equivalent to data presented when the willingness to pay for a QALY is £0.
Figure 22 shows that nitrofurazone catheters have over 85% chance of being cost-effective 
compared with PTFE catheters over the threshold values for willingness to pay for a QALY 
considered. Compared with PTFE, silver alloy has less than a 20% chance of being considered 
cost-effective at the same thresholds.
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FIGURE 22  Cost-effectiveness acceptability curve for nitrofurazone, silver alloy and PTFE.
TABLE 50  Cost-effectiveness results for nitrofurazone vs PTFE and silver alloy vs PTFE
Nitrofurazone vs PTFE: mean (97.5% CI) Silver alloy vs PTFE: mean (97.5% CI)
Difference in mean costs –108.49 (–319.09 to 102.10) 81.37 (–131.07 to 293.81)
Differences in QALYs 0.0002 (–0.002 to 0.002) –0.001 (–0.003 to 0.001)
ICER (£/QALY) Nitrofurazone is dominant PTFE is dominant
Probability (%) intervention is cost-effective at
  £0 per QALY 88 19
  £20,000 per QALY 88 15
  £30,000 per QALY 88 13
  £50,000 per QALY 86 11
ICER, incremental cost-effectiveness ratio.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Pickard et al. under the terms of a commissioning contract issued by the Secretary of State for Health. 
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Figures 23 and 24 show the results of the non-parametric bootstrapping that was undertaken to 
handle the uncertainty around the QALY and cost estimates for both pair-wise comparisons. 
For the comparison of nitrofurazone with PTFE the results of 1000 bootstrap simulations (see 
Figure 23 and 24) indicate that for the majority of the bootstrap estimates the nitrofurazone 
group had lower costs and slightly higher QALYs.
For the comparison of silver alloy with PTFE the results of 1000 bootstrap simulations 
(Figures 25 and 26) show that for the majority of bootstrap estimates the PTFE group had lower 
costs and slightly higher QALYs than the silver alloy catheters. Hence, in Figure 25 the PTFE 
group (control) was much more likely to be considered cost-effective at all threshold values for 
society’s willingness to pay for a QALY considered.
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FIGURE 23  Representation of the uncertainty in differential mean costs and QALYs for nitrofurazone vs PTFE.
FIGURE 24  Cost-effectiveness acceptability curve for nitrofurazone vs PTFE.158 Appendix 7
Subgroup analysis
The results of the subgroup analyses of the primary outcome examining possible effect 
modification of age (< 60 years, ≥ 60 years), sex, comorbidity (pre-existing urological disease, 
diabetes, immunosuppression), duration of catheterisation (< 4 days, ≥ 4 days), indication for 
catheterisation (incontinence, urinary retention and monitoring purpose) and antibiotic use 
prior to enrolment for the nitrofurazone group were similar to those reported in the base-case 
analysis in that none of the differences was statistically significant (Table 51). The subgroup that 
had the highest difference in costs for the comparison of nitrofurazone group with PTFE was 
the subgroup that had a catheter for > 4 days (£–275), followed by that of patients ≥ 65 years 
old (£–222). None of the results of the interaction terms included in the regression model was 
statistically significant. (The product of the variables of interest, e.g. the interaction term for the 
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FIGURE 25  Representation of the uncertainty in differential mean costs and QALYs for silver alloy vs PTFE.
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female group in patients that got nitrofurazone was a product of female and the treatment that 
was received, i.e. nitrofurazone. The presence of an interaction effect implies that the effect of 
sex on costs varies as a function of the type of catheter received). Three of the subgroups (those 
participants who were < 60 years old, had antibiotic use in the last 7 days, and had antibiotics at 
catheterisation) within the nitrofurazone group had higher costs than PTFE but they were not 
statistically significantly different.
The results of the subgroup analysis for silver alloy compared with PTFE followed a similar 
pattern to those of the base-case analysis with the exception of females, those who had no 
comorbidities and those who had catheters for ≥ 4 days. These groups had lower costs for the 
silver alloy catheters than PTFE (Table 52). The highest difference in costs was in the group that 
were catheterised for emergency purposes in which the cost in the silver alloy group was £612 
higher than the PTFE group. However, none of the results was statistically significantly different 
and none of the results of the interaction terms was statistically significant.
TABLE 51  NHS mean cost (£ sterling) for each subgroup analysis for nitrofurazone vs PTFE
Subgroup Mean cost difference (£), (99% CI)
Female –156.07 (–472.67 to 160.53)
Male –84.65 (–488.07 to 318.78)
≥ 60 years –221.88 (–567.41 to 123.64)
< 60 years 0.30 (–358.61 to 359.21)
Comorbidity: no –152.30 (–445.94 to 141.33)
Comorbidity: yes –17.55 (–549.54 to 514.43)
Catheterisation for: monitoring –138.39 (–405.78 to 129.00)
Catheterisation for: emergency –98.26 (–1349.32 to 1152.79)
Antibiotic use last 7 days: no –171.09 (–457.15 to 114.96)
Antibiotic use last 7 days: yes 77.16 (–524.45 to 678.78)
Antibiotic at catheterisation: no –114.41 (–616.04 to 387.21)
Antibiotic at catheterisation: yes 134.46 (–434.59 to 165.67)
Catheter duration ≥ 4 days –275.46 (–897.72 to 346.81)
Catheter duration < 4 days –19.35 (–261.75 to 223.04)
TABLE 52  NHS mean cost (£ sterling) for each subgroup analysis for silver alloy vs PTFE
Subgroup Mean cost difference (£), (99% CI)
Female –11.60 (–334.24 to 311.04)
Male 194.90 (–220.50 to 610.29)
≥ 60 years 64.11 (–287.78 to 416.01)
< 60 years 47.6 (–319.56 to 414.89)
Comorbidity: no –55.87 (–356.68 to 244.93)
Comorbidity: yes 410.27 (–129.35 to 949.89)
Catheterisation for: monitoring 21.67 (–252.10 to 295.43)
Catheterisation for: emergency 612.18 (–662.54 to 1886.91)
Antibiotic use last 7 days: no  52.56 (–239.37 to 344.49)
Antibiotic use last 7 days: yes 75.79 (–547.08 to 698.65)
Antibiotic at catheterisation: no 146.92 (–374.04 to 667.89)
Antibiotic at catheterisation: yes 31.33 (–275.01 to 337.67)
Catheter duration ≥ 4 days –214.96 (–828.55 to 398.63)
Catheter duration < 4 days 78.31 (–170.84 to 327.46)160 Appendix 7
Sensitivity analysis
Sensitivity around cost per day
A sensitivity analysis around length of stay considered the use of alternative unit cost data. In this 
sensitivity analysis, elective inpatient excess bed-days based on Health Resource Group (HRG) 
data from the National Schedule of Reference Costs 2009–10 for NHS Trusts76 were used instead 
of the data from ISD.71 As Table 53 illustrates, the direction of cost results was similar to that of 
the base-case analysis using NHS Scotland ISD data, although the magnitude in the differences 
was lower.
Use of unadjusted differences in costs and quality-adjusted life-years 
instead of the adjusted differences used in the base-case analysis
The base-case analysis was based on differences between different groups that were adjusted 
for age (< 60 years, ≥ 60 years), sex, comorbidity (pre-existing urological disease, diabetes, 
immunosuppression), duration of catheterisation (< 4 days, ≥ 4 days), indication for 
catheterisation (incontinence, urinary retention and monitoring purpose) and antibiotic use 
prior to enrolment. The results of the sensitivity analysis using unadjusted cost and QALY 
differences are presented in Table 54.
The unadjusted results of nitrofurazone compared with PTFE were similar to those obtained 
from the adjusted analysis. The mean difference in QALY was similar to that of the base case and 
again this difference was not statistically significant. Similarly, the cost difference was slightly 
higher than estimated in the base case; again, this difference was not statistically significant. 
TABLE 53  Cost-effectiveness results for nitrofurazone vs PTFE and silver alloy vs PTFE (using NHS reference 
costs data)
Nitrofurazone vs PTFE: mean (97.5% CI) Silver alloy vs PTFE: mean (97.5% CI)
Difference in mean costs –88.00 (–241.98 to 65.97) 41.58 (–113.43 to 196.58)
Differences in QALYs 0.0002 (–0.002 to 0.002) –0.001(–0.003 to 0.001)
ICER (£/QALY) Nitrofurazone is dominant Silver alloy is dominated
Probability (%) intervention is cost-effective at
  £0 per QALY 90 27
  £20,000 per QALY 91 17
  £30,000 per QALY 90 14
  £50,000 per QALY 88 12
TABLE 54  Cost-effectiveness results for nitrofurazone vs PTFE and silver alloy vs PTFE (unadjusted analysis)
Nitrofurazone vs PTFE: mean (97.5% CI) Silver alloy vs PTFE: mean (97.5% CI)
Difference in mean costs –130.78 (–355.20 to 103.87) 48.07 (–180.73 to 276.86)
Differences in QALYs 0.0002 (–0.002 to 0.002) –0.001 (–0.003 to 0.001)
ICER (£/QALY) Nitrofurazone is dominant Silver alloy is dominated
Probability (%) intervention is cost-effective at
  £0 per QALY 91 30
  £20,000 per QALY 91 24
  £30,000 per QALY 91 20
  £50,000 per QALY 90 15© Queen’s Printer and Controller of HMSO 2012. This work was produced by Pickard et al. under the terms of a commissioning contract issued by the Secretary of State for Health. 
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that 
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to NETSCC.
161   Health Technology Assessment 2012; Vol. 16: No. 47 DOI: 10.3310/hta16470
The net effect of this was a small increase in the probability of nitrofurazone being considered 
cost-effective over the threshold values for society’s willingness to pay for an additional QALY 
considered (Figures 27 and 28).
The unadjusted results of the silver alloy group compared with PTFE were similar to those of 
the adjusted analysis as the differences in QALYs and cost were smaller than reported for the 
base-case analysis. As a consequence this slightly increased the probability of silver alloy being 
considered cost-effective at all threshold values for society’s willingness to pay for a QALY 
considered (Figures 29 and 30).
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FIGURE 27  Representation of the uncertainty in differential mean costs and QALYs for nitrofurazone vs PTFE.
FIGURE 28  Cost-effectiveness acceptability curve for nitrofurazone vs PTFE.162 Appendix 7
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FIGURE 29  Representation of the uncertainty in differential mean costs and QALYs for silver alloy vs PTFE.
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Appendix 8  
The CATHETER trial protocol
The CATHETER trial
Types of urethral catheter for reducing symptomatic urinary tract infections in hospitalised 
adults requiring short-term catheterisation.
Protocol
The CATHETER trial
Title of trial: types of urethral catheter for reducing symptomatic urinary tract infections in 
hospitalised adults requiring short-term catheterisation.
This protocol describes a major multicentre UK trial to establish whether using different 
types of urethral catheters, coated with antibiotic or antiseptic, in adults requiring short-term 
catheterisation can reduce symptomatic urinary tract infections. The study is designed to be as 
simple as possible for those participating and those involved in clinical care.
Recruitment officers in each centre will identify and recruit patients who require short-term 
catheterisation and collect patient information and urine samples. Patients will be followed up at 
3 days and 1 and 2 weeks post catheter removal, and at 6 weeks following randomisation.
Trial basics
Full title of study
Types of urethral catheter for reducing symptomatic urinary tract infections in hospitalised 
adults requiring short-term catheterisation: multicentre randomised controlled trial of antibiotic 
and antiseptic impregnated urethral catheters (the CATHETER trial).
(Keywords: short-term urethral catheter, anti-microbial, silver alloy, nitrofurazone, silicone, 
randomised controlled trial, catheter-associated symptomatic urinary tract infection, bacteriuria, 
bacteraemia, cost–benefit analysis)
Acronym
None.164 Appendix 8
Contact trialist
Position Chief Investigator Trial manager
Name  James N’Dow Kath Starr
Address Academic Urology Unit, Health Sciences Building, 
University of Aberdeen, AB25 5ZD
Academic Urology Unit/HSRU, Health Sciences Building,  
University of Aberdeen, AB25 5ZD
Telephone 01224 554963 01224 559644
Fax 01224 554580 01224 554580
email j.ndow@abdn.ac.uk k.starr@abdn.ac.uk
The need for a trial
What is the problem to be addressed?
Development of symptomatic urinary tract infection in adults following short-term urethral 
catheterisation in hospitalised adults.
What are the principal research questions to be addressed?
What is the clinical benefit and cost-effectiveness of using antibiotic- or antiseptic-impregnated 
urethral catheters over standard urethral catheters in hospitalised adults requiring short-term 
catheterisation? Two pragmatic comparisons will be made comparing catheters, as they would be 
used in the NHS:
  ■ antibiotic-impregnated (nitrofurazone) catheter versus ‘standard’ PTFE (PolyTetraFluoro-
Ethylene)-coated latex catheter
  ■ antiseptic-impregnated (silver alloy) catheter versus ‘standard’ PTFE (PolyTetraFluoro-
Ethylene)-coated latex catheter.
The hypothesis being tested is that use of either of the impregnated catheters will reduce the 
incidence of catheter-associated symptomatic urinary tract infection by 40% relative to the 
standard PTFE coated latex catheter (an absolute reduction of around 3%).
Why is a trial required now and what is the available evidence?
25% of patients admitted to hospital will require urethral catheterisation at some stage during 
their stay1, and the risk of developing bacteriuria, the presence of bacteria in the urine, 
in catheterised patients is approximately 5% per day increase1. It has been estimated that 
symptomatic urinary tract infection occurs in approximately 20% of patients with bacteriuria2,3 
whilst bacteraemia, the presence of bacteria in the blood, occurs in up to 4% of these patients4,5. 
Catheter-associated symptomatic urinary tract infections (CASUTI) are the leading cause of 
hospital acquired infections, accounting for between 23% and 40% of all cases6,7, and such 
infections result in additional morbidity3,5 and mortality8 and represent a considerable economic 
burden to the health-care sector, patients and their carers9,10. Consequently, any intervention 
that reduces the incidence of CASUTI may have wide-ranging repercussions. A wide variety of 
preventive approaches have been investigated, including mental care measures, pre-connected 
catheter-collection systems, antiseptic drainage bags, routine bladder irrigation, and prophylactic 
antibiotics, but the evidence in support of these measures is weak at best11. However, coating of 
urinary catheters with antibiotic or antiseptic compounds is thought to be a potentially effective 
preventative measure. Both, however, are more expensive than standard uncoated catheters.
A recent Cochrane review of randomised controlled trials12 concluded that the silver alloy 
impregnated catheter (an antiseptic impregnated catheter) has the most evidence of benefit out © Queen’s Printer and Controller of HMSO 2012. This work was produced by Pickard et al. under the terms of a commissioning contract issued by the Secretary of State for Health. 
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of the antibiotic/antiseptic impregnated urethral catheters available. However, the included trials 
were small and of poor or moderate quality. A reduction in risk of catheter-associated urinary 
tract infections by up to 40% was reported in hospitalised adults having a short-term catheter. 
The evidence for antibiotic-impregnated urethral catheters was even weaker, with only one 
type of catheter (i.e. minocycline and rifampicin impregnated catheter) from one trial being 
considered in the review12. However, minocycline and rifampicin impregnated catheters are no 
longer available (oral communication with Cook Urological, 03/10/05). Another recent small 
trial investigating a different type of antibiotic-impregnated catheter (nitrofurazone impregnated 
urethral catheter, marketed by Rochester Medical) revealed no evidence of a difference in the 
incidence of bacteriuria between the nitrofurazone impregnated and standard silicone catheters 
in patients catheterised for up to 1 week13, although confidence intervals were wide.
In summary, the majority of clinical trials conducted thus far have been small and of poor 
to moderate quality in terms of trial methodology and design, outcome measures (such as 
reporting of bacteriuria rather than symptomatic urinary tract infection) and the lack of a 
comprehensive evaluation.
How will the results of this trial be used?
The trial results will have implications for the management of patients requiring short-term 
urethral catheterisation in hospital and rationalise catheter-purchasing policies for large 
organisations like the NHS. If the use of an antibiotic or antiseptic impregnated urethral catheter 
leads to a significant reduction in CASUTI compared with a standard catheter and proves to be 
cost-effective, it will inform future short-term catheter policies in secondary care. In addition, 
the trial will also explore whether in high-risk sub groups more expensive catheters might be 
more likely to be cost-effective. The trial will clarify amongst currently available catheters, which 
should be used in the NHS.
Research methods (including feasibility study results)
Results of audit of short-term catheter policies
A one week audit was conducted in Aberdeen Royal Infirmary and Freeman Hospital (Newcastle) 
in October 2005. The purpose of the audit was to determine current short-term catheter policies 
across specialities and to identify high volume users. Elements of practice reviewed included the 
number of catheterisations performed, types of catheters used, indication for catheterisation, 
estimated duration of catheterisation, and use of prophylactic and concurrent antibiotic therapy. 
Data from hospital purchasing department records for each individual ward was also reviewed 
to determine general trends in number and type of catheters used over a 12-month period 
and to provide further supporting evidence of high volume users. There were 148 short-term 
urethral catheterisations reported during that week. PTFE-coated latex catheters were most 
commonly used (74%). Antibiotic prophylaxis was used in 39%, and 20% of patients were already 
on concurrent antibiotics at the time of catheterisation. Catheter-related urinary sepsis was 
documented in 29 cases (20%), of which 17 (11%) had culture-positive urinary infections.
Results of feasibility study of short-term catheter in secondary care
Following on from the audit we undertook a feasibility study. The aim of the 2 week feasibility 
study was to devise and test recruitment methods, baseline questionnaires, and to provide 
estimates of numbers likely to be eligible for the trial. The feasibility study aimed to replicate the 
main study protocol including randomisation and was undertaken in Aberdeen Royal Infirmary 
in four different clinical specialities. These specialities were identified as high volume users of 
short-term catheters from the audit (Results of audit of short-term catheter policies above), namely 
General Surgery, Acute Medical Assessment Unit, the Stroke Unit and Gynaecology. The first 166 Appendix 8
week of the two-week feasibility study was dedicated to fine-tuning the practicalities of the study 
in the Urology ward because of the experience of the medical and nursing staff and then rolled 
out to the other specialities towards the end of the first week. A dedicated researcher visited the 
four wards daily. Of 14 patients identified during their hospital admission requiring a short-term 
catheter, nine were approached and five were missed. All nine approached agreed and consented 
to take part in the feasibility study. Thus our estimate of 60% of those approached likely to want 
to participate (Table 1) is conservative, though based on a small sample.
Design
A ten-centre randomised controlled trial testing three short-term urinary catheter policies 
in a range of high-volume clinical settings. Participants will be randomised either by using a 
telephone system or a web-based system. The Centre for Healthcare Randomised Trials (CHaRT), 
Health Services Research Unit, University of Aberdeen, as the Trial Data Centre, will manage 
the randomisation process. As at June 2008, ten centres have agreed to participate: Newcastle 
upon Tyne Hospitals NHS Trust, City Hospitals Sunderland NHS Foundation Trust, Gateshead 
Healthcare NHS Foundation Trust, Aberdeen Royal Infirmary NHS Grampian, Raigmore 
Hospital NHS Highland, Southampton University Hospitals NHS Trust, Northumbria Healthcare 
NHS Foundation Trust, Western General and Royal Infirmary of Edinburgh Hospital NHS 
Lothian, Bristol Royal Infirmary United Bristol Healthcare NHS Trust and Hillingdon Hospital 
NHS Trust.
Setting
Secondary care units with a high volume of short-term catheterisation. In October 2005, an 
audit of catheter use in Newcastle and Aberdeen identified high volume units including: surgical 
specialities, general medical wards, care of the elderly wards, high dependency and intensive care 
units. These are the specialities that will be targeted in the main trial.
Inclusion/exclusion criteria
  ■ Inclusion:
  – Adult patients (≥16 years of age) requiring urethral catheterisation (expected to be 
required for a maximum of 14 days), in pre-selected units with a high volume of 
short-term catheterisation.
  ■ Exclusion:
  – Patients for whom urinary catheterisation is expected to be long-term (i.e. > 14 days).
  – Urological intervention or instrumentation within preceding 7 days (e.g. catheterisation, 
cystoscopy, prostatic biopsy and nephrostomy insertion).
  – Non-urethral catheterisation (e.g. suprapubic catheterisation).
  – Known allergy to any of the following: latex, silver salts, hydrogel, silicone 
or nitrofurazone
  – Any patient who has a microbiologically confirmed symptomatic urinary tract infection, 
at time of randomisation.
  – Unable to give informed consent.
The planned trial interventions
1.  Experimental groups: There will be two experimental groups managed with:
i.  silver alloy impregnated hydrogel urethral catheter (S).
ii.  nitrofurazone impregnated silicone urethral catheter (N).
2.  Control group
There will be one control group managed with a PTFE coated latex urethral catheter – the 
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Participants will be randomised 1:1:1 to the three groups. Size 14 Ch catheters will be used 
for all three arms. The choice of catheter as ‘standard’ control was based on the results of the 
audit of short-term catheter use in all secondary care wards in Newcastle and Aberdeen (see 
Results of audit of short-term catheter policies), which confirmed that the PTFE-coated latex 
urethral catheter was the most commonly used in both hospitals (over 70%); it is also relatively 
inexpensive compared with the coated catheters (at approximately £0.86 each for the PTFE-
coated catheter vs £5.50 for the antiseptic coated and £4.50 for the antibiotic coated, 2007 prices).
Each catheter will have a detachable sticker attached to the outer packaging. This sticker will 
display the ‘CATHETER’ logo and either ‘N’, ‘S’ or ‘P’ to denote catheter type (N, Nitrofurazone; 
S, Silver; P, PTFE). These stickers will then be stuck directly onto Patient Consent Forms so as to 
determine that the patient was given the catheter they were randomised to.
Proposed outcome measures
Primary clinical outcome measure
Incidence of symptomatic urinary tract infection at any time up to 6 weeks post 
randomisation (number of participants with at least one occurrence). This will be defined 
as any symptom reported at 3 days or 1 or 2 weeks post catheter removal or 6 weeks post-
randomisation combined with a prescription of antibiotics, at any of these times, for presumed 
symptomatic UTI.
Subgroup analyses of the primary outcome will examine possible effect modification of age, 
gender, co-morbidity, duration of catheterisation, indication for catheterisation, and antibiotic 
use prior to enrolment.
Secondary clinical outcome measures
Microbiological support of the primary outcome. Defined as those who fulfil the criteria for the 
primary outcome and in addition have any microbiologically positive result where there is ≥ 104 
CFU/mL of no more than two different species of uropathogen.
Tertiary clinical outcomes
Early symptomatic urinary tract infection, defined as any self reported symptom with a 
prescription of antibiotics and a positive microbiological test (≥ 104 CFU/mL of no more than two 
different species of uropathogen) between randomisation and 3 days post catheter removal.
Individually analyse the components of the definition of the primary and secondary outcome:
  ■ Any self-reported symptoms.
  ■ Any antibiotic prescription for presumed symptomatic UTI.
  ■ Any microbiologically positive result (≥ 104 CFU/mL of no more than two different species 
of uropathogen).
Health-related quality of life measured by the EQ-5D up to 6 weeks.
Other significant clinical events: septicaemia and mortality.
Adverse effects of catheterisation apart from symptomatic UTI (e.g. urethral discomfort and pain 
on removal).
Antibiotic use following randomisation and indication.168 Appendix 8
Assessment of the risk of anti-microbial resistance towards silver and nitrofurazone using urine 
specimens from patients, or catheter tips, diagnosed with symptomatic UTI and bacteriuria14.
Secondary economic outcome measures
  ■ Incremental cost per infection averted and QALYs gained.
  ■ Cost to the NHS and patient of the different catheters.
  ■ Quality-adjusted life-years (QALYs) estimated from EQ-5D responses.
Proposed duration of intervention
The mean period of urethral catheterisation is expected to be between 1 and 14 days.
What is the proposed frequency and duration of follow-up and how will 
outcome measures be measured?
Following enrolment in the trial, a mid-stream specimen of urine will be sent for microbiological 
analysis (i.e. microscopy, culture and sensitivity) immediately prior to catheterisation, if one 
has not been sent within the preceding 48 hours (baseline sample). Where this is not possible, 
a specimen of urine will be obtained during catheterisation (i.e. catheter-specimen of urine) 
using standard aseptic techniques. Urine will also be collected again for microbiological analysis 
within, or at, 3 days after catheter removal. If patients are discharged home prior to the third 
post-catheter removal day a sample will be taken as close to the 3 day after removal time point 
as possible. However, patients will also be provided with sterile urine collection bottles to be 
filled and submitted by post, or local NHS courier service, on the third post-catheter removal 
day if the sample taken in hospital is before the 3 day removal time point. If a clinical diagnosis 
of symptomatic UTI is made at any stage, including during the period of catheterisation, either a 
catheter-specimen or mid-stream specimen of urine will be obtained by ward staff or the patient’s 
GP according to normal clinical practice.
Participants will complete the following questionnaires at the specified time points:
  ■ baseline questionnaire (EQ-5D and a urinary symptom questionnaire) around the time 
of recruitment
  ■ a 3 days after catheter removal questionnaire (Urinary Symptoms and EQ-5D)
  ■ patient diary to be completed at 1 and 2 weeks after catheter removal (will contain specific 
UTI questions and EQ-5D)
  ■ final set of questionnaires (i.e. EQ-5D and specific Health Economic questionnaires) 6 weeks 
after randomisation.
The questionnaires will be targeted at identifying symptomatic UTI as well as other catheter-
associated problems (e.g. urethral discomfort), quality of life, and any health economic 
implications such as costs to the patients and the NHS. Questionnaires completed prior to 
hospital discharge will be collected by the Recruitment Co-ordinator. Questionnaires completed 
after hospital discharge will be posted back to the Data Centre (CHaRT, University of Aberdeen); 
patients will be supplied with a discharge pack containing the relevant questionnaires and 
stamped addressed envelopes. The Recruitment Co-ordinator will telephone participants when at 
home to remind and help them to complete Trial questionnaires and submit urine samples. This 
will also provide another opportunity to answer any questions the participants may have about 
the Trial and the associated paperwork. This phone call system will not be standard practice and 
will only be used when participants fail to send back questionnaires or urine samples once they 
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Collection of information to describe UTIs
Information will be collected in five phases to contribute data to identify UTIs.
1. During catheterisation Ward-based diagnosis from symptoms, observations and microbiology or clinician directed use of antibiotics for UTI 
– data recorded by trial co-ordinator
2. 3 days post catheter 
removal
Urine specimen and symptoms will give symptomatic UTI, asymptomatic UTI and symptomatic sterile urine – data 
recorded by participant
3. 1 and 2 weeks post 
catheter removal
Patient diary will record symptoms and clinician contact together with antibiotic usage – data recorded by patient; 
this will give evidence of symptoms, clinician diagnosis but no microbiology unless patient/GP requests urine sample
4. 6 weeks post 
randomisation
Clinician contact, antibiotic usage and hospital readmissions will be gathered
Proposed sample size
Based on the Cochrane review and other data12,15,16, the anticipated incidence of UTI in the 
standard control group is 7%. Given that this trial is assessing patient reported outcomes rather 
than microbiology or clinician reported symptoms, the predicted incidence rate of UTIs is 11% 
and it is reasonable to hypothesise that the impregnated catheters will reduce this to about 8%. 
The increased cost associated with use of the silver alloy and nitrofurazone catheters is further 
justification for aiming to identify an effect of this size. With 90% power and alpha set at 2.5% 
rather than 5% (to adjust for the two comparisons of antibiotic impregnated catheter and control 
catheter, and antiseptic impregnated catheter and control catheter), and using chi-square tests of 
association to compare the incidence of CASUTI in an intervention group and the control group, 
the trial would require an estimated 1970 fully followed up participants per group, inflated to 
2362 per group to allow for an observed loss to follow up of 17%, giving a total of 7086.
Statistical analysis
All primary analyses will be according to the intention-to-treat principle, and will be governed 
by a Statistical Analysis Plan, which will be agreed by the Trial Steering Committee (TSC). The 
outcomes listed in Proposed outcome measures will be compared with (a) antibiotic impregnated 
and control and (b) antiseptic impregnated and control using generalised linear models (for 
example, for the primary outcome of proportion of participants with symptomatic catheter 
associated infection, a logistic regression model will be used, adjusting for any covariates felt to 
be of prognostic importance). Nominal 95% confidence intervals will be calculated. Subgroup 
analyses will examine possible effect modification of age, gender, co-morbidity, duration of 
catheterisation, indication for catheterisation, and antibiotic use prior to enrolment using tests 
for interaction (all at stricter levels of significance P< 0.01). We will also explore the comparison 
of antibiotic and antiseptic groups. A single main analysis will be performed at the end of the trial 
when all follow up has been completed. An independent Data Monitoring Committee (DMC, 
see below) will review confidential interim analyses as frequently as requested (see Independent 
supervision) of accumulating data but at least annually.
TABLE 1  Proposed size of the trial
Participants with a short-term catheter
Participants needed per arm (minimum) 1970
Allowing for 17% dropout 2362
Total number of participants needed in 3 arms 7086170 Appendix 8
Economic evaluation
The economic evaluation will be integrated into the trial. Outcomes and costs will be assessed 
from the perspective of the NHS and patients for a 6-week time horizon. The alternatives 
compared are described in The planned trial interventions.
Effectiveness will be measured in terms of number of symptomatic urinary tract infections up to 
6 weeks after randomisation and quality-adjusted life-years (QALYs) at six weeks. QALYs will be 
derived using data from EQ-5D administered at baseline, 3 days, 1 week, 2 weeks and at 6 weeks 
post randomisation as part of the main study questionnaires. These responses will be converted 
into health state utilities using UK population tariffs. The estimation of QALYs will take account 
of the mortality of study participants. Participants who die within the study follow-up will be 
assigned a zero utility weight from their death until the end of the study follow up. QALYs will 
be estimated using linear extrapolation between the QALY scores at baseline and all available 
EQ-5D.
Costs for the six week follow-up will be assessed from the trial. The number of infections 
will be collected using the baseline questionnaire, the UTI questionnaire completed 3 days 
after catheter removal, the patient diary at 1 and 2 weeks after catheter removal and from 
the final questionnaire at 6 weeks. Other cost generating events of the interventions such as 
the use of primary care services including contacts with primary care practitioners (e.g. GPs 
and practice nurses) and prescription medications, will be collected using the health-care 
utilisation questionnaires administered at 1, 2 and 6 weeks follow-up. Use of secondary care 
services following the period of catheterisation will be collected using the 6 week follow up 
questionnaire. If patients are identified as having been re-admitted following their discharge, 
within the 6 weeks post randomisation, they will be further investigated using the NHS Patient 
Administration System (PAS). This will record information on non-protocol outpatient visits, 
readmissions relating to the use and consequences of urinary catheters. This approach will 
ensure that information on the use of secondary care services that could be main determinants of 
incremental costs can be identified without overburdening the participants.
Estimates of resource utilisation will be combined with unit costs to derive total costs. Unit costs 
will be based on study-specific estimates and data from standard sources. Participant costs will 
be based on self-purchased health care (e.g. prescription costs, over the counter medications), 
will be collected as part of the health-care utilisation questions (see above). The results of 
these analyses will be presented as point estimates of mean incremental costs, QALYs and cost 
per QALY. Measures of variance for these outcomes will be derived using bootstrapping and 
deterministic sensitivity analysis will be used to explore other forms of uncertainty (e.g. the 
exploration of the implication of extrapolating outcomes beyond the 6 weeks time horizon). 
Similar sub-group analysis to that described in Statistical analysis will also be undertaken.
A simple decision model will be developed to compare the different catheters in terms of the 
loss of quality of life (based on the responses to the EQ-5D collected as part of the trial) and 
change in cost caused by a symptomatic catheter-associated infection. In this analysis it will be 
assumed that the only loss of quality of life will be caused by a symptomatic catheter-associated 
infection and that the type of catheter does not affect quality of life except by changing the risk 
of a symptomatic catheter-associated infection occurring. Regression methods will be used to 
estimate the loss of quality of life for those with a symptomatic catheter-associated infection 
compared with those without a symptomatic catheter-associated infection. A similar approach 
will be used to estimate costs associated with developing a symptomatic catheter-associated 
infection compared with costs for those without a symptomatic catheter-associated infection. 
Estimates of cost for each arm of the decision model (i.e. each type of catheter) will be adjusted 
to reflect the cost of using the catheter. Probabilistic sensitivity analysis will be performed along 
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Practical arrangements for identifying and allocating participants to 
trial groups
(a) Identifying potentially eligible participants: A potentially eligible participant will be identified 
by either ward staff, operating theatre staff, or by the local recruitment co-ordinator. The 
recruitment co-ordinator will visit the wards daily to check on possible activity that day and by 
doing so, also promote the trial. Laminated recruitment sheets will be placed prominently at 
the nurses station/doctors room on the wards. Participants will be identified according to the 
pre-stated inclusion and exclusion criteria from pre-determined high volume units. The local 
recruitment co-ordinator will obtain informed consent (see below) and ensure completion of 
in-hospital questionnaires and other data collection.
(b) Informed consent: Participants will be provided with written information and will sign a 
consent form once they have had enough time to understand the implications and requirements 
of the trial. The only exception to this will be for adults in an emergency situation.
In emergency situations common reasons for short-term catheterisation are acute urinary 
retention or for monitoring purposes in an unwell patient. These patients will be provisionally 
included in the trial according to a protocol which will respect both their right to best quality 
care and the ethical requirement of informed consent. As the decision to catheterise is based 
solely on clinical need by the caring physician, we propose that a randomised catheter is used 
in an emergency situation. Once the patient’s condition has settled, they will be provided with 
an information sheet and an opportunity to opt out of the trial if they wish, with assurances 
that such a decision will not affect the level of care they receive. As the antiseptic/antibiotic-
impregnated catheters are reported to lessen the risk of infection compared with the usual 
standard catheter, we feel this proposed protocol for including adults in emergency situations 
is justified. Ethics Committee approval was secured from the all Research Ethics Committees 
involved in the trial to include such patients in the study using the above arrangements for post-
procedure consent or withdrawal.
Although unlikely, we have anticipated a situation whereby a patient may have been randomised 
and is discharged before the recruitment co-ordinator can obtain informed consent (e.g. if 
over the weekend). Therefore, we propose to send a letter to any patient that may have been 
randomised to the trial and ‘missed’ by the recruiter. This letter will describe the trial, a patient 
information sheet will also be sent, and will invite them to participate in the trial. They will be 
asked to contact the recruitment co-ordinator if they are interested in taking part in the trial. A 
copy of the letter that will be sent to the patient is enclosed.
(c) Recruitment: The feasibility study and audit indicated that although the ‘office hours’ are 
busy periods for the flow of potentially eligible participants, it will be necessary to be able to 
recruit throughout the 24 hour period. The telephone randomisation system is the easiest way to 
effectively recruit throughout this period.
(d) Randomisation: Eligible participants will be randomised centrally by simple randomisation 
to the three groups using either by telephone to the automated IVR telephone randomisation 
application at CHaRT in Aberdeen.
(e) Data Management. The recruitment co-ordinator, during the daily round, will input the last 
session’s data via the study web portal to the Study Data Centre in Aberdeen on a daily basis.
(f) Use of Posters. The inclusion of posters to be displayed in the treatment rooms of wards taking 
part in the trial as reminders of:172 Appendix 8
  ■ the trial and
  ■ the catheters to be used in the trial.
Posters are also to be included in admission lounges and ward areas to highlight the trial 
to eligible patients. It is hoped that this will alert patients to the trial so that when they are 
approached to take part, they have some familiarity with the research. Each site will have posters 
than contain site specific contact details.
(g) Withdrawal: Any patient who is withdrawn from the study for personal or medical reasons 
will be recorded appropriately using a specific Withdrawal Form. The form will record what the 
patient has withdrawn from e.g. questionnaires being sent, their hospital and GP records being 
accessed (for the results of medically indicated urine samples and antibiotics prescribed for UTIs) 
and contact by the CATHETER team.
Some patients will be classed as post-randomisation exclusions as opposed to withdrawals. 
Patients who will be categorised as post-randomisation exclusions are as follows:
  ■ emergency patients who retrospectively refuse consent
  ■ those patients who are randomised due to medical intention to catheterise but are 
never catheterised
  ■ those patients who are randomised but receive a suprapubic catheter in theatre.
In line with this a notice (a CATHETER compliments slip, see enclosed) documenting that the 
patient was never catheterised or received a suprapubic catheter will be placed in the patients 
notes. The recruiter will explain to the patient that they are no longer in the trial.
Methods for protecting against other sources of bias
As indicated, the study will be open, with at least the antibiotic catheter easily identifiable by 
its unavoidably bright yellow colour. The concern about ‘open’ use of catheters is that knowing 
which catheter has been used might influence clinical decisions, such as about sending a urine 
specimen for culture or removing a catheter. To guard against bias introduced in this way, we 
shall standardise clinical policies in these respects. Further protection comes from the fact that 
the person inserting the catheter is unlikely to be the same person making later clinical decisions 
specifically regarding timing of catheter removal. All urine samples will be tested ‘blind’ to the 
catheter allocation. Outcome assessment in terms of symptoms of UTI will be made by patient 
self-completed questionnaires. Participants will not be told until the end of the study which 
catheter has been used to protect against the influence of preconceptions on the participants’ side 
in respect of self-reported outcomes. While researchers will be blinded to type of catheter, clinical 
staff performing the catheterisation will not be.
To attempt to standardise catheter insertion technique, catheter care, catheter urine sampling 
and catheter removal policies, a protocol has been developed and tested in the feasibility study 
and will be implemented in all centres involved in the trial. This protocol incorporates principles 
of ‘Best Practice’ based on published guidelines17. In addition, the protocol also advocates 
that patients with asymptomatic bacteriuria should not routinely be treated with antibiotics18. 
Catheter care violations, such as inappropriate collection of urine (e.g. from catheter bag rather 
than from the sampling port or accidental disconnection of the closed-drainage system) will be 
recorded to attempt to explain false-positive diagnosis of bacteriuria12. Every attempt will also be 
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Ethical arrangements
This project has been approved by the Grampian MREC. We believe this is a very low risk study, 
with a correspondingly favourable risk: benefit ratio, since both patients and society (through 
efficient allocation of resources within NHS) will benefit from the results of the research. We do 
not anticipate that there will be risks to participants, and they may benefit from participation in 
the trial. Society will benefit from the conclusions of the research, which will be used to inform 
future short-term catheter policies in secondary care. An information leaflet will be given to 
each potential participant to inform them of the benefits and known drawbacks that may apply. 
Informed signed consent will be obtained from the participants in all centres. Participants who 
cannot give informed consent (e.g. due to their mental state) will be excluded. The trial will 
be co-ordinated from a centre with considerable experience of multicentre trials (CHaRT), 
cognisant of the implications of research governance and other legal frameworks for the conduct 
of trials. This is not classed as a trial of any investigational medicinal products or Medical 
Devices, and so does not come under the EU Clinical Trials Directive. Nevertheless we will 
conduct the study to the standards required by ICH GCP, and the NHS and Universities Research 
Governance as well as all other applicable legal, ethical and regulatory requirements.
The risk of adverse events associated with catheterisation is minimal. Please see appendix 1 for 
further information on SAE reporting.
Arrangements for independent supervision are described below.
Independent supervision
A Trial Steering Committee that will include an independent Chairperson and other independent 
members and a consumer representative will oversee the trial. The Steering Committee will 
meet at least three times over the course of the study, and at least annually. The DMC will meet 
early in the trial to agree its terms of reference and other procedures. While its deliberations will 
take into account the full implications of any recommendations it may choose to make (such 
as whether or not any interim findings are sufficiently convincing to change clinical practice), 
the statistical guidelines adopted are likely to be those suggested by Peto19 based on a difference 
in a main outcome measure of at least three standard deviations. The DMC will report any 
recommendations to the Chairperson of the TSC.
Source of funding for study
The study is funded by the UK NHS Health Technology Assessment Programme.
Participating centres
The following centres have agreed in principle to take part in the trial:
Aberdeen Royal Infirmary NHS Grampian
Newcastle upon Tyne Hospitals NHS Trust
City Hospitals Sunderland NHS Foundation Trust
Gateshead Healthcare NHS Foundation Trust
Raigmore Hospital NHS Highland
Southampton University Hospitals NHS Trust
Northumbria Healthcare NHS Foundation Trust174 Appendix 8
Royal Infirmary of Edinburgh NHS Lothian
Bristol Royal Infirmary United Bristol Healthcare NHS Trust.
Project timetable and milestones
Duration 33 months
1–6 months: set up office, assemble team, secure ethical approval
7–12 months: establish eight centres
7–24 months: identify and recruit 5700 participants requiring short-term catheterisation 
(an average of 720 is feasible in each of the eight centres based on the Newcastle and 
Aberdeen audits)
10–25.5 months: follow up at 6 weeks
25.5–33 months: complete data collection, analysis and dissemination.
Figure 1 shows the projected recruitment of centres and participants, and projected number who 
would be approached. Our plan is to establish two centres relatively early in the project (by seven 
months) and to roll out to the others over the subsequent five months. We recognise that this will 
need prior preparation. An application to MREC will be submitted between funding decision and 
the start date.
The participant recruitment graph in Figure 1 has been modelled to take into account: the 
rollout to the centres over the first 5 months and that there are likely to be slightly fewer 
short-term catheters inserted around August and over Christmas due to a reduction in elective 
surgical throughput.
Milestones
Based on the groundwork that has already been done, particularly the feasibility study and 
audit of short-term catheter policies, we believe that we are ready to mount the full trial. 
However, specific, time-related milestones have been listed in Table 2, to allow close monitoring 
of progress.
Expertise
The applicants are a multidisciplinary team that includes clinical experts, a consumer 
representative, experienced trialists, statisticians and health economists. They will form a Trial 
Management Group. James N’Dow (the Lead Applicant), Rob Pickard and Thomas Lam are 
academic urologists with a special interest in incontinence and members of the Cochrane 
Incontinence Group. James N’Dow and Cathryn Glazener are editors of the Cochrane 
Incontinence Group responsible for delivering the Cochrane review that prompted the call for 
this trial. Adrian Grant is the Co-Chairperson of the Cochrane Collaboration and has many years 
experience of multicentre trials. John Norrie is an experienced trialist and medical statistician 
and is Director of the Aberdeen Centre for Healthcare Randomised Trials (CHaRT). Luke Vale 
is Professor in Health Technology Assessment with a joint appointment between the Health 
Economics Research Unit and the Health Services Research Unit in Aberdeen. All have extensive 
experience in the design, conduct, analysis and reporting of multicentre trials. Brian Buckley has 
an academic interest in patient/carer representation, and is the current chairperson of Incontact, 
a charitable organisation advocating consumer issues in incontinence. Kathy Orr is a consultant 
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FIGURE 1  Projected recruitment chart. 
Month
3
Month
5
Month
7
2 4 6 8
Month
9
Month
11
Month
13
Projected recruitment
Month
15
Month
17
Month
19
Month
21
Month
23
10000
9000
8000
7000
6000
5000
4000
3000
2000
1000
0
Sites recruiting
Short-term
catheterisations
approached
Recruited
TABLE 2  Milestones
Year one
By month 2 MREC approval
By month 7 Set up office and administrative base 
Construct access database, including randomisation program
Establish first two centres
(LREC approval, R&D negotiations, appoint local recruitment co-ordinator)
By month 9 First Steering Committee Meeting
Establish third and fourth centres
By month 12 First Data Monitoring Committee meeting. Roll out to further four centres
1285 participants recruited
Year two
By month 18 3595 participants recruited
By month 24 Second Steering Committee meeting. Second Data Monitoring Committee meeting
5700 participants recruited
Year three
By month 25.5 Follow up of participants at 6 weeks after randomisation completed
By month 32 Data analysis completed
By month 33 Final Steering Committee meeting
Submit Final Report and main papers describing the trials
Economics. Graeme MacLennan is an experienced statistician in the Health Services Research 
Unit in Aberdeen. Kathy Getliffe brings expertise from a nursing perspective.
Consumers
One of the applicants, Brian Buckley, is chairperson of Incontact, a consumer group for people 
with continence problems. Dr Buckley will be a member of both the Trial Management Group 
and Trial Steering Committee. He has contributed to the development of the design of the 
proposed study and to this application. We have sought, and will continue to seek, Dr Buckley’s 
advice (and through him, the advice of other members of Incontact) to ensuring that we take into 
account patient and carer views of the acceptability and relevance of the trial. We shall (through 
Brian Buckley) involve Incontact in the dissemination of the study findings.176 Appendix 8
Appendix 1: Reporting of serious adverse events
The CATHETER trial involves conservative interventions which are well established in clinical 
practice, we do not anticipate any adverse effects which are related to the catheter. However, due 
to the nature of the trial (e.g. hospital setting, patients undergoing surgery) some patients are 
at risk of any of the events listed below. We will monitor all of these events but will only report 
those which are believed to have a causal relationship to the intervention which the patient was 
randomised to.
Collaborators and participants may contact the chairperson of the Steering Committee through 
the Study Office about any concerns they may have about the study. If concerns arise about 
procedures, participants or clinical or research staff (including risks to staff) these will be relayed 
to the Chairperson of the Data Monitoring Committee.
All of the following are defined as serious adverse events
  ■ Resulted in death.
  ■ Life-threatening.
  ■ Required inpatient hospitalisation or prolongation of existing hospitalisation.
  ■ Septicaemia.
  ■ Persistent or significant disability/incapacity.
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Appendix 9  
Details of methods used to estimate 
distributions for model parameters
TABLE 55  Details of values and/or the distributions attached to them (base-case analysis)
Variable name Parameters/information
Cost of no UTI Log normal, u (mean of logs) = ln(2359), sigma (SD of logs) = sqrt[ln(3375.42/2359) × 2]; expected value: 3375.42
Cost difference Normal, mean = 547.6296, SD = 425.6165; expected value: 547.6296
PTFE risk Beta, real-numbered parameters, alpha = 271, beta = 1873; expected value: 0.126399254
Cost difference Normal, mean = –0.021, SD = 0.01; expected value: –0.021
QALY difference Normal, mean = 0.001, SD = 0.01; expected value: 0.001
No UTI QALY Beta, real-numbered parameters, alpha = [(0.07536942) × (1-0.0753694)/(0.02454172)],  
beta = [0.0753694 × (1 – 0.0753694)/(0.02454172)] – [(0.07536942) × (1 – 0.0753694)/(0.02454172)];  
expected value: 0753694
Nitrofurazone risk 
reduction
Normal, mean = –0.021, SD = 0.01; expected value: –0.021
Silver alloy risk 
reduction
Normal, mean = 0.001, SD = 0.01; expected value: 0.001
TABLE 56  Patients admitted to obstetrics and gynaecology specialty
Variable name Parameters/information
Cost no UTI Log normal, u (mean of logs) = ln(1383), sigma (SD of logs) = sqrt[ln(1805.411/1383) × 2]; expected value: 1805.411
PTFE risk Beta, real-numbered parameters, alpha = 271, beta = 1873; expected value: 0.126399254
QALY difference  Normal, mean = 0.0069204, SD = 0.0015331; expected value: 0.0069204
Cost difference Normal, mean = 127.93, SD = 116.55; expected value: 127.93
Nitrofurazone risk 
reduction
Normal, mean = –0.021, SD = 0.01; expected value: –0.021
Silver risk reduction Normal, mean = 0.001, SD = 0.01; expected value: 0.001
QALY with a UTI Beta, real-numbered parameters, alpha = [(0.07961892) × (1 – 0. 0796189)/(0.02061812)], 
beta = [0.0796189 × (1 – 0.0796189)/(0.02061812)] – [(0.07961892) × (1 – 0.0796189)/(0.02061812)];  
expected value: 0.0796189186 Appendix 9
TABLE 57   European Quality of Life-5 Dimensions score = 1 (full health)
Variable name Parameters/information
Cost no UTI Log normal, u (mean of logs) = ln(1844), sigma (SD of logs) = sqrt[ln(2452.314/1844) × 2]; expected value: 2452.314
PTFE risk Beta, real-numbered parameters, alpha = 271, beta = 1873; expected value: 0.126399254
QALY difference  Normal, mean = 0.0024116, SD = 0.0050177; expected value: 0.0024116
Cost difference Normal, mean = 988.7469, SD = 471.9682; expected value: 988.7469
Nitrofurazone risk 
reduction
Normal, mean = –0.021, SD = 0.01; expected value: –0.021
Silver alloy risk 
reduction
Normal, mean = 0.001, SD = 0.01; expected value: 0.001
QALY with a UTI Beta, real-numbered parameters, alpha = [(0.09909562) × (1 – 0.0990956)/(0.01904892)], 
beta = [0.0990956 × (1 – 0.0990956)/(0.01904892)] – [(0.09909562) × (1 – 0.0990956)/(0.01904892)];  
expected value: 0.0990956
TABLE 58  Three-day infection outcome analysis
Variable name Parameters/information
Cost no UTI Log normal, u (mean of logs) = ln(2317), sigma (SD of logs) = sqrt[ln(3331.245/2317) × 2]; expected value: 3331.245
PTFE risk Beta, real-numbered parameters, alpha = 271, beta = 1873; expected value: 0.126399254
QALY difference  Normal, mean = 0.0044876, SD = 0.0020633; expected value: 0.0044876
Cost difference Normal, mean = 1417.482, SD = 209.0975; expected value: 1417.482
Nitrofurazone risk 
reduction
Normal, mean = –0.021, SD = 0.01; expected value: –0.021
Silver risk reduction Normal, mean = 0.001, SD = 0.01; expected value: 0.001
QALY with a UTI Beta, real-numbered parameters, alpha = [(0.07553412) × (1 – 0.075534)/(0.02553342)], 
beta = [0.075534 × (1 – 0.075534)/(0.02553342)] – [(0. 0755342) × (1 – 0.075534)/(0.02553342)]; expected value: 
0.075534
TABLE 59  Excluding inpatient analysis
Variable name Parameters/information
Cost no UTI Log normal, u (mean of logs) = ln(5.29), sigma (SD of logs) = sqrt[ln(13.29876/5.29) × 2]; expected value: 13.29876
PTFE risk Beta, real-numbered parameters, alpha = 271, beta = 1873; expected value: 0.126399254
QALY difference  Normal, mean = 0.0063294, SD = 0.0013823; expected value: 0.0063294
Cost difference Normal, mean = 67.94424, SD = 20.29843; expected value: 67.94424
Nitrofurazone risk 
reduction
Normal, mean = –0.021, SD = 0.01; expected value: –0.021
Silver risk reduction Normal, mean = 0.001, SD = 0.01; expected value: 0.001
QALY with a UTI Beta, real-numbered parameters, alpha = [(0.07665482) × (1 – 0.0766548)/(0.02561182)], 
beta = [0.0766548 × (1 – 0.0766548)/(0.02561182)] – [(0.07665482) × (1 – 0.0766548)/(0.02561182)];  
expected value: 0.0766548© Queen’s Printer and Controller of HMSO 2012. This work was produced by Pickard et al. under the terms of a commissioning contract issued by the Secretary of State for Health. 
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Appendix 10  
Cost/quality-adjusted life-year plots and 
cost-effectiveness acceptability curves for 
the base-case and sensitivity analyses
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FIGURE 31  Representation of the uncertainty in differential mean costs and QALYs for nitrofurazone, PTFE and silver 
alloy for base-case analysis.
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FIGURE 32  Cost-effectiveness acceptability curve for nitrofurazone, PTFE and silver alloy for base-case analysis.188 Appendix 10
FIGURE 33  Representation of the uncertainty in differential mean costs and QALYs for nitrofurazone, PTFE and silver 
alloy for analysis on patients admitted to maternity specialty.
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FIGURE 34  Cost-effectiveness acceptability curve for nitrofurazone, PTFE and silver alloy for patients admitted into 
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FIGURE 35  Representation of the uncertainty in differential mean costs and QALYs for nitrofurazone, PTFE and silver 
alloy for EQ-5D = 1 (full health) score analysis.
FIGURE 36  Cost-effectiveness acceptability curve for nitrofurazone, PTFE and silver alloy for EQ-5D = 1 (full health) 
score.190 Appendix 10
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FIGURE 37  Representation of the uncertainty in differential mean costs and QALYs for nitrofurazone, PTFE and silver 
alloy for 3 days’ outcome analysis.
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FIGURE 39  Representation of the uncertainty in differential mean costs and QALYs for nitrofurazone, PTFE and silver 
alloy for analysis excluding inpatient cost data.
FIGURE 40  Cost-effectiveness acceptability curve for nitrofurazone, PTFE and silver alloy for analysis excluding 
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